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Abstract 
 
We have synthesized several self-assembled multivalent (SAMul) systems based on two 
parts; a hydrophobic part as the driving force for self-assembly, and a cationic hydrophilic 
part as the binding site for polyanions. A number of modified ligand displays were 
synthesized in order to investigate structure-activity relationship and their effects on self-
assembly of such systems as well as their selectivities towards binding different 
polyanions (heparin and DNA).  
The first three systems were synthesized using unsaturated fatty acids (containing alkene 
groups), this resulted in different self-assembly abilities, in addition to different 
selectivities towards the biological polyanions (heparin and DNA). In an attempt to 
stabilize those systems, we cross-linked the alkene groups – however the binding did not 
improve. We modified the ligand binding sites, using different amines. This also resulted 
in different self-assembly preferences in addition to selectivities for binding heparin and 
DNA. Alternative approaches to stabilizing displays of heparin-binding ligands were 
tested using a branched scaffold with a high density of positive charges on the surface 
groups, gold nanoparticles and a ligand-polymer conjugate approach.  Finally, a 
multicomponent approach was employed in this work. PEG-lipid additives, were 
introduced to our SAMul systems to test their impact on binding heparin and DNA. 
Adding PEG-lipids to our SAMul demonstrated that a simple uncharged species can have 
an influence on binding strength in the clinically relevant serum medium. In addition, the 
multicomponent approach was also performed on two compounds using a multi 
component MalB assay. This showed that this approach may in the future help rapidly 
identify mixtures of self-assembling components which have positive synergistic effects. 
In each study we have learned more about the structural impact of ligand designed display 
in polyanion binding – information which should prove useful in the future design of 
systems with clinical relevance. 
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1 Introduction 
 
1.1 Nanomedicine  
 
Biological systems – proteins, nucleic acids, membranes etc. – all have nanoscale 
dimensions. This has increasingly driven the attention of chemists towards working in the 
1-100 nanometre length scale in order to intervene in new ways in biomedical processes. 
This has led to the development of nanoscale interactions which are widely investigated 
and used in all aspects of science. Indeed, the prediction of the famed Richard Feynman1 
"There is plenty of room at the bottom"2, has been proven as scientists have designed 
systems which inhabit the nanoscale world in order to develop new technologies.  
In the last two decades, there has been a revolution in nanotechnology; the science of 
engineering particles 1-100 nanometre in diameter. This revolution is rapidly having 
increasing impact in the pharmaceutical industry. Nowadays, drugs can be designed on 
the nanoscale level in order to achieve the best results, accomplish improved delivery of 
poorly soluble materials and facilitate them to reach specific targets.3 Pharmaceutical 
nanotechnology has two basic types; nanomaterials and nanodevices (Fig. 1-1). 
Nanodevices such as microelectromechanical (MEMS) and nanoelectromechanical 
(NEMS) systems can integrate electrical and mechanical functionality on the micro and 
nanoscale, respectively.4 Nanomaterials such as polymer nanostructures; nanoparticles, 
micelles, dendrimers and drug conjugates, have great potential importance for biomedical 
use.5   
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Fig. 1-1 Schematic diagram of nanotechnology types of pharmaceutical nano systems, reproduced from 
reference.5 
 
So far, there are few nanomedicines that have been approved by the U.S. Food and Drug 
Administration (FDA).6-8 The first nano-drug to be approved by FDA in 1995 was Doxil®; 
a liposomal doxorubicin product (Fig. 1-2) in which hydrophobic doxorubicin is 
incorporated within a liposome (vesicle).9,10 It targeted tumours and its doxorubicin is 
released and becomes available to kill tumour cells. It is reasoned that the nanoscale size 
led to tumour targeting through the enhanced penetration and retention effect which 
means tumour tissue is more accessible to drugs in this size range – hence limiting off-
target toxicity effects associated with the drug.10  
 
Fig. 1-2 Doxorubicin structure (Doxil®). 
 
 Some other nanoscale drugs have been tested in mice and showed good results but are 
awaiting testing in human trials.5 For example, gold nanoshells; are proposed for use to 
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diagnose and cure cancer.11 Sokolov et al.12 demonstrated the use of gold colloids, as 
scattering contrast agents, conjugated to antibodies to the epidermal growth factor 
receptor (EGFR) and used for biomolecular optical imaging in vivo of cervical cancer 
cells and tissues. They showed that gold bio-conjugates can be delivered topically in order 
to image the whole epithelium.11,12 Also, liposomes were used as vaccine adjuvants as 
well as vehicles for drug transport.5,13,14 Liposome formulations were used for reducing 
toxicity as well as increasing accumulation at targeted sites.15 Preparation methods of 
liposomes were based on lipid drug interactions and the mechanism of disposition 
liposome which was achieved by controlling particle size charge and surface hydration, 
hence inhibiting the rapid clearance of the liposome.16 
 Biodegradable polymers are still under investigation as drug nano-carriers.17 They 
attracted researchers because of their non-toxicity and complete elimination from the 
body18,19 as well as low side effects.20,21 For example, poly(lactic-co-glycolic acid), 
poly(lactic acid) and poly(glycolic acid) have been approved by FDA for specific medical 
applications, such as treatment of neurodegenerative diseases22 and to diagnose and treat 
cardiovascular disease.23 These polymers can be degraded and eliminated from the body 
as carbon dioxide and water.24  
Another class of nano-drugs is dendrimers, which offer a new approach compared with 
traditional linear polymer architecture classes. Dendrimers are based on repetitive 
branched structures.25 Synthetic dendrimers offer the chance to generate monodisperse 
nanoscale structures, similar to those observed in biological systems such as proteins.26,27 
Over one hundred families of different dendrimer have been synthesized as well as >1000 
reported significant chemical surface modifications.26,28,29 In general, the design of 
dendrimers is based on three parts; inner scaffold, terminal groups and linkers5,29 (Fig. 1-
3).5 Increasing the generation, molecular size and terminal groups of a dendrimer 
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increases the potential for varies of interactions, as such, the dendrimer would be 
considered as highly functional.30  
 
 
 
Fig. 1-3 Schematic representation of a dendrimer showing core, branches, and surface. Figure adapted from 
reference.5 
 
 
Overall, novel functional nanomaterials with special physical properties are being 
designed to deliver significant improvements to current medicines. They have been 
developed with the intention to avoid significant side effects to patients (toxicity). 
However, many nanomaterials, in preclinical assessment, face problems by either having 
high toxicities during in vitro or in vivo testing, or failing to have the minimum 
bioavailability according to their adsorption, distribution, metabolism, and excretion 
(ADME) profile. These challenges created a need to develop alternative methods for 
producing such systems.31  
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1.2 Self-Assembled Multivalent (SAMul) Nanostructures   
 
1.2.1 Multivalency 
 
Multivalency is the concept of a molecule having multiple binding groups/sites. Although 
the term ‘multivalency’ is most used by macromolecular chemists, it is widely applied 
across a range of scientific disciplines.32-34 An effective way of binding nanoscale 
biopolymers is to use multivalent interactions where multiple ligands cooperate in the 
binding process.35,36 On the molecular level, multivalent interactions should be defined 
with care. For instance, a multivalent host, that has two or more binding sites, interacting 
with two or more monomeric guest molecules does not count as a multivalent interaction, 
because each individual guest will only form a single interaction with the host. However, 
these interactions can be described as multivalent when the guest become larger – when 
interactions are occurring between the guest, at multiple binding sites, and different 
receptor groups on the same molecule (host).33 
 
Multivalent ligands can have enhanced binding through a number of different 
mechanisms as shown in Figure 1-4.  In general, after the binding of the first ligand an 
entropic effect will allow subsequent binding events to occur more easily, for example at; 
an additional binding site (a) or a sub binding site (b). In addition, multiple ligands can 
enhance binding by clustering the receptors together facilitating the binding (c) – this type 
of effect frequently occurs in biological membranes. There can also be an effect of local 
concentration, in which rebinding of a ligand has a greater chance once it has dissociated 
from a receptor due to a high local concentration (d).37 some, or all, of these mechanisms 
can be operating in a multivalent binding event.   
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Fig. 1-4 Different binding modes displayed by multivalent ligands; additional binding site (a), sub binding 
site (b), clustering of multiple ligands (c) and high local concentration (d). cartoon reproduced from 
reference.37 
 
The calculation of the free energy of multivalent interactions (ΔGmulti) can be achieved in 
a similar way to calculating monovalent interactions.38 Such calculations were done in a 
study by Whitesides et al.32  to determine the degree of cooperativity associated with a 
multivalent interaction. This study provided a comparison between the changes in the free 
energy of multivalent interactions and monovalent interactions in order to determine the 
binding enhancement factor, α, which is described as the degree of cooperativity (Eq. 
1.1), where N is the number of ligand-receptor pairs, ΔGmulti is the free energy associated 
with the interaction between N receptors and N ligands, ΔGmono is the free energy change 
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from the corresponding monovalent interaction and Kmulti and Kmono are the affinities 
resulting from multivalent and monovalent binding events, respectively.  
 
Eq. 1-1 Calculation of changes in the free energy of a multivalent interaction, by Whitesides.32 
 
In general, the α value can be employed to define three types of multivalent interaction. 
The first is when α > 1, which means that for binding events, the second binding is more 
favourable than the first, which can be defined as positive cooperativity or a synergistic 
interaction. When α = 1, the binding events are non-cooperative; each subsequent binding 
event has the same affinity as the previous one. The final type, when α < 1 indicates that 
the interaction of the second ligand with the receptor is inhibited due to the presence of 
the first one; this means the interaction can be described as negatively cooperative.39,40  
However, it is worth noting that it is not strictly necessary that a multivalent interaction 
requires a positively cooperative synergistic effect. Simply it requires a higher affinity for 
the whole system towards the target than when it is just a monovalent system.40 In this 
way, binding affinity can be boosted – a particularly valuable effect for useful interactions 
in highly competitive biological media.  
Multivalent binding can be employed across a wide range of biological and chemical 
systems. Examples of such processes in nature32 can be found when a virus is attached to 
a cell surface wall (Fig. 1-5).  The attachment of a virus on a host cell is mediated by 
several surface components, with the virion protein(s) binding either to specific host 
surface molecule(s) such as membrane proteins, lipids, or to the carbohydrate moieties 
present either on glycoproteins or glycolipids.41  An example for such processes is when 
virus membrane glycoproteins attach to a target cell surface by binding to heparan sulfate 
proteoglycans.42 These first interactions between a target cell surface and a virus are 
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usually electrostatic and facilitate virus attachment to  a specific receptor.43 There are two 
types of cell receptors; adhesion and entry receptors. The adhesion receptors attach to a 
virus in a reversible manner to target cells or organ but do not trigger entry. However, the 
adhesion receptors facilitate more concentration of the virus in the vicinity of the entry 
receptors. Once a virus is attached to the entry receptors, the receptors trigger virus entry 
by endocytosis or by inducing fusion (penetration), which is an irreversible process.44  
 
Fig. 1-5 Schematic cartoon of virus binding to cell surface adhesion receptor. 
 
Another example of multivalent binding in nature is when a dendritic polymer interacts 
with DNA as shown in Figure 1-6. Polyamidoamine (PAMAM) dendrimers can achieve 
targeted gene delivery,45,46 and have multivalent binding to DNA.  PAMAM dendrimers 
have a well-defined spherical cationic structure consisting of primary amines on the 
surface and tertiary amines in the interior (Fig. 1-6) this allows them to bind 
electrostatically to DNA.47 In particular, for effective gene delivery, highly multivalent 
larger fifth generation PAMAM dendrimers are required.48   
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Fig. 1-6 Schematic cartoon of a dendritic polymer, such as PAMAM, multivalent binding to DNA through 
surface electrostatic interactions. 
 
Supramolecular chemists have studied many varieties of multivalent binding system, 
from systems designed for biological applications to templates for assisting covalent 
synthesis. For example, synthetic multivalent inhibitors were designed for inhibiting 
viruses,49-52 bacterial toxins,53-55 and for promoting required cellular responses.37,56,57 
Multivalency can also be used for controlling recognition events at surfaces.34,58 
Understanding the multivalent attachment processes of viruses on cell surfaces, led 
medicinal approaches to develop viral inhibitors that are capable of multivalent 
interactions. Haag59 and co-workers developed a range of multivalent antiviral ligands by 
focusing on the use of synthetic dendritic polyglycerol sulphates (dPGS) (Fig. 1-7). dPGS 
operates via a multivalent binding mechanism mimicking naturally occurring ligands and 
proved to inhibit both leukocytic L-selectin and endothelial P-selectin with high 
efficacy.59   
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Fig. 1-7 Dendritic polyglycerol sulphate structure, by Haag.59 
 
Other synthetic multivalent inhibitors were reported by Whitesides and co-workers. They 
synthesized polymers of sialic acid in multiple copies; which are approximately 109-fold 
stronger than monovalent sialic acid when blocking the adhesion of influenza virus 
particles to erythrocytes.60 Also, Kitov et al.61 designed oligo-valent inhibitors of Shiga-
like toxin 1 which were 1–10 million-fold more active than the monovalent ligands. 
As a further example, Gestwicki56 and co-workers synthesized multivalent derivatives of 
the chemo-attractant galactose (Fig. 1-8a) in order to create reagents that stabilize the cell 
inter-receptor interactions.  They investigated the impact of ligand multivalency on 
bacterial behaviour especially Escherichia coli (E. coli). They observed that E. coli 
mutants and wild-type E. coli, after pre-treatment by monovalent ligand were unaffected 
when adding serine.  However, when they were pre-treated by multivalent ligands, they 
showed more stabilized inter-receptor contact, when adding serine; the response to serine 
was amplified by at least 100-fold from motion analysis results (Fig. 1-8b).56  
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Fig. 1-8 Structure of the galactose monomer 1 and the multivalent arrays displaying galactose 2–3 (a) and 
motion analysis showing a plot of average angular velocity versus time for E. coli AW405 treated with 
chemoattractant (galactose or ligands 1-3) (b). Figure adapted from reference.56 
  
1.2.2 Ligand Display 
 
1.2.2.1 Cationic Lipids 
 
Generally, cationic lipids consist of three parts; a head group (cationic), a tail 
(hydrophobic) and a linker between the two parts. Modification of each of these parts 
have developed a wide range of vectors for gene delivery in addition to many studies of 
structure-activity relationships. Cationic lipids were used for gene transfection in 
pioneering work by Felgner et al.,62 who developed the lipid N-[1(2,3-dioleyloxy)propyl]-
N,N,N-trimethylammonium chloride (DOTMA) (Fig. 1-9).62-64 After that, they performed 
another study to uncover more details of structure-activity relationships in order to 
enhance the performance of their systems. This initial effort was followed by several 
attempts to develop other cationic lipids such as 1,2-dioleyloxypropyl-3-dimethyl-
hydroxyethyl ammonium bromide (DORIE) and 1,2-dimyristyloxypropyl-3-dimethyl-
hydroxyethyl ammonium bromide (DMRIE) (Fig. 1-9)65 which have later been employed 
by other research groups.   
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Fig. 1-9 Structure of cationic lipids DOTMA, DORIE and DMRIE.by Felgner.62 
 
Several developments followed that initial effort by Felgner and co-workers in which the 
ligand or linker were modified to produce commercially available cationic lipids 
including DOTMA, sold under the name LipofectinTM.62 A derivative product from 
DOTMA known as 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1 
propanaminiumtrifluoroacetate (DOSPA), is sold under the name Lipofectamine 
2000TM.66 In addition, two more products were developed; 1,2-dioleoyl-3-
trimethylammoniumpropane (DOTAP)67 and dioctadecylamido-glycylspermine (DOGS) 
or Transfectam®68 (Figure 1-10).  
 
Fig. 1-10 Structure of cationic lipids DOTAP, DOGS and DOSPA, all of which are commercially available 
as transfection agents.  
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1.2.2.2 Gold Nanoparticles (AuNPs) 
 
Gold Nanoparticles (AuNPs) have attracted the attention of researchers due to their 
unique properties and multi-applications.69,70 AuNPs are used as biomarkers and bio-
delivery vehicles in medicine and pharmacy.71,72 The unique optical properties of AuNPs, 
their size dependent properties and their high chemical stability have made them an ideal 
system for exploring many aspects including self-assembly, bio-labelling, catalysis, etc., 
These nanoparticles when stabilized or protected by a shell of thiolate ligands,70 display 
good stability toward aggregation and other modes of decay.73 
There are two methods to synthesise such thiolate-protected nanoparticles; the top-down 
approach and the bottom-up technique. The second method is more common and 
effective. Gold ions are reduced, from their salt, by a reducing reagent. They then start to 
nucleate to form nanoparticles while in the presence of protective ligands which prevent 
uncontrolled growth of gold metal.70 “Brust synthesis” 74,75 has been thoroughly explored 
(Fig. 1-11). This method has enabled the synthesis of a great variety of functionalized 
noble metal nanoparticles over the years.75,76,77 Their high stability is due to the 
passivation property that alkanethiols cause, which form a strong bond with the particle 
surface.75,78 
 
Fig. 1-11 Scheme for gold nanoparticle synthesis by Brust Two-Phase Approach, cartoon adapted from 
reference.75  
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Another method was introduced by Turkevich et al.79-81 as a single phase synthesis. This 
method is water based reduction of a gold salt by citrate. Later, Frens81,82 improved this 
method to produce almost spherical particles with controllable range of sizes.83 These 
nanoparticles, when stabilized or protected by a shell of thiolate ligands,70  display good 
stability toward aggregation and other modes of decay.73  
In the development of therapeutics, Melander84 and co-workers constructed a platform 
for their multivalent therapeutic by employing 2.0 nm diameter, mercaptobenzoic acid 
modified gold nanoparticles. These mercaptobenzoic acid coated gold nanoparticles were 
conjugated to SDC-1721, a derivative of TAK-779, a known CCR5 antagonist (Fig. 1- 
12).84 They demonstrated that when gold nanoparticles are conjugated to a weakly 
binding and biologically inactive small molecule they transform it into a multivalent array 
that has the ability to inhibit HIV-1 fusion to human T cells (Fig. 1-13).84 
 
Fig. 1-12 TAK-779 and SDC-1721.84 
 
Fig. 1-13 Synthesis of a multivalent gold nanoparticle therapeutic; multivalent presentation of small 
molecules on gold nanoparticle surfaces can convert inactive drugs into potent therapeutics. Adapted from 
reference.84  
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Gold nanoparticles have been employed in many studies to mimic the multivalent 
presentation of cell surface carbohydrates and have been used in applications such as drug 
delivery systems, sensors, bioimaging reagents and affinity probes.85-88 In recent work 
from Okada and co-workers,89 they developed multivalent carbohydrate photoaffinity 
probes based on gold nanoparticles as an approach for the identification of carbohydrate-
binding proteins. They designed their systems to be capable of removing non-specific 
proteins by covalent cross-linking as well as promoting affinity enhancement to achieve 
efficiency and selectivity of capturing specific carbohydrate-binding proteins. This work 
presented novel bifunctional chemical tools, which can perform a one-pot photoaffinity 
labelling and affinity purification (Fig. 1-14).89 
 
Fig. 1-14 A streamlined photoaffinity labelling approach toward identification of carbohydrate-binding 
proteins by using AuNP-based multivalent carbohydrate probes by Okada and co-workers. Figure adapted 
from reference.89 
 
1.2.2.3 Drug-Polymer Conjugates 
 
In the 1960s, initial work on employing polymers, as pharmaceutical drugs, was using 
them as blood plasma expanders, for wound bandages and as injectable depots.90,91 In 
1975, Helmut Ringsdorf92 proposed the first coherent model for pharmacologically active 
polymers (Fig. 1-15). The concept he proposed, of covalently bound polymer-drug 
conjugates, is still employed for most of the performed work in this area to date. This 
model attracted drug delivery scientists, as it offered a practical way of achieving the 
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specific delivery of therapeutic agents to their desired site as well as improving efficacy 
and decreasing toxicity.  
 
Fig. 1-15  The first proposed model for pharmacologically active polymers, Ringsdorf, 1975, figure adapted 
from reference.93  
 
Cell–cell recognition and the initiation of signal transduction processes often depend on 
the formation of the multiple receptor-ligand complexes at cell surfaces. These complex 
events of cell surface-binding could benefit from a multivalent ligand approach.94 Ligand 
architectures have effects on inhibitory activity and specificity, these effects were 
explored by Reuter et al. with series of polymeric synthetic inhibitors of 
hemagglutination.95 They generated a number of ligands, with distinct structures such as 
sialic acid (SA) residues conjugated to be tested in vitro for their ability to inhibit 
hemagglutinin binding and viral infection (Fig. 1- 16). The polymer-conjugates were 
shown to be more effective than monomeric SA after testing on four viruses; influenza A 
H2N2 (selectively propagated two ways), X-31 influenza A H3N2, and sendai.95   
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Fig. 1-16 Structure of sialic-acid-conjugated polymeric inhibitor subunits. Adapted from reference.95 
 
Schaffer96 and co-workers designed multivalent conjugates with the ability to organize 
stem cell receptors into nanoscale clusters in addition to controlling behaviour of stem 
cells in vitro and in vivo. They conjugated an integral membrane protein ligand, 
ectodomain of ephrin-B2, to a soluble biopolymer (Fig. 1-17). The results were 
multivalent nanoscale conjugates that have the potential to induce signals in the neural 
stem cells as well as promoting neuronal differentiation; both in culture and within the 
brain.  
 
Fig.1-17 Synthesis of multivalent ephrin-B2. Scheme adapted from reference.96  
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1.2.3 Self-Assembly 
 
The spontaneous aggregation of molecules into well-defined structures held together by 
non-covalent interactions is known as self-assembly. One example of self-assembly is 
provided by surfactants which contain both hydrophobic and hydrophilic regions.97 For 
simple amphiphilic molecules, when the concentration of a monomer molecules increases 
(in solution), the hydrophobic groups aggregate to minimize contact with water and 
surface groups (hydrophilic) are displayed on the periphery.98 This process is reversible 
and there are a number of factors that affect the overall aggregate’s structure, such as, the 
monomer concentration and its morphology.99 
Israelachvili et al. published a discussion in 1976 of the monomer geometry effects and 
the degree to which hydrophobicity influences the subsequent self-assembly mode.100 
They introduced a definition of a critical packing parameter, P, which allowed a 
prediction of the morphology of such aggregate. This P value was based on the volumes 
of both hydrophobic and hydrophilic groups within the assembly. As shown in Figure 1-
18, the relative sizes of hydrophilic and hydrophobic groups of a monomer affect the 
overall shape of the nanoscale assembly. As the hydrophobic group size increases 
compared to the hydrophilic surface group, the morphology changes so that more 
geometric space is provided to incorporate it. At low P values, spheres are favoured (a) – 
maximizing surface area but as P increases cylindrical morphologies occur, reducing 
unfavourable interactions with the aqueous solvent (b). With an increase in 
hydrophobicity (e.g. presence of a second aliphatic tail) vesicles or liposomes become the 
preferred mode of self-assembly (c). When hydrophilic and hydrophobic groups are of 
similar size, a planar bilayer structure will form (d). Once the hydrophobicity is 
significantly increased and becomes much bigger than the hydrophilic surface group, an 
inversion will occur and the micelle non-polar groups will be at the surface and the 
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hydrophilic groups in the core (e). Such systems form these reverse micelles in organic 
media.  
 
Fig. 1-18 Critical packing parameter (P); prediction of aggregate morphology in aqueous solution by 
Israelachvili.100  
 
In the early 1990s, Whitesides97 and co-workers presented an example of self-assembly. 
The strategy that they outlined proved to be a successful one. This strategy was based on 
reversible, noncovalent interactions to assemble nanostructures aggregates. They 
achieved that by synthesizing nanostructures (solid 1:1) complex formed by mixing 
melamine (M) and cyanuric acid (CA) in aqueous solution to form CA-M lattice; each 
CA and M units were connected by benzene ring, as a linker (Fig. 1-19), to minimize the 
entropic cost of self-assembly and to control the assembled nanostructure shape.   
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Fig. 1-19 Melamine cyanuric acid synthesized self-assembled nanostructures (CA-M lattice), by 
Whistsides.97 
 
1.2.4 Self-Assembled Multivalent (SAMul) Approaches  
 
Self-assembly has significant power in the solution-phase and readily allows multiple 
monovalent non-assembled ligands to potentially cooperate in binding to a target. This 
can allow high-affinity multivalent binding (Fig. 1-20).101 This area was first 
conceptualized as a distinct approach in a key review by Barnard and Smith.101 The ease 
of synthesis (assembly) and tunability of nanostructure morphology and ligands, in 
addition to the potential to incorporate multiple active units as well as the responsive 
nature of self-assembly, mean this is a powerful and general tool for generating synthetic 
multivalent nanoscale binding arrays with potential biomolecular applications.101 
 
Fig. 1-20 Self-assembly enables high-affinity multivalent binding.  
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The biological and medicinal applications of self-assembled multivalent (SAMul) 
nanostructures are currently being developed.102 DNA has been a target for several 
research groups who have employed self-assembled binding approaches for develop 
potential medicinal drugs of genetic diseases103 as well as cancer treatments.104 Yadav105 
and co-workers synthesized a conjugated system of branched hydrophilic oligosaccharide 
structure neomycin with a hydrophobic modified dipeptide to result an amphiphilic self-
assembled nanostructure (Pep–Neo conjugate) (Fig. 1-21). This system has cationic 
charges on the surface that would facilitate entry into the cells after interaction with 
negatively charged DNA. 
 
Fig. 1-21 Structure of Pep–Neo conjugate, by Yadav.105 
 
The naturally occurring DNA-binding ligand spermine is one of the most employed 
surface groups in SAMul systems and was featured in notable work from both Cheng106 
and Smith107 group. Cheng and co-workers used two oleyl hydrophobes to directly 
functionalize spermine (Fig. 1-22). Whereas Smith used Newkome108,109 low-generation 
amphiphilic dendron (cholesterol) and decorated its surface with spermine107 (Fig. 1-23), 
then reasoned that more lipidic character better promoted self-assembly.  
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Fig. 1-22 Schematic representation of the supramolecular self-assembly of individual vector components 
with plasmid DNA, by Cheng. Figure adapted from reference.106 
 
Fig. 1-23 Structure of cholesterol functionalised Newkome dendrons with spermine ligands on their 
surface.107,110  
 
Smith and co-workers have investigated their systems through several structural 
modifications; on the monomer surface,39 within the scaffolds of the dendritic 
branches110,111 and modifications to the hydrophobic part.112 Also, they examined the 
effects of co-assembling PEG-additives into the self-assembled DNA-binding 
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nanostructures.113 Overall, the potential gene delivery vehicle they worked to develop, 
contained a DAPMA binding group, a degradable scaffold (polyester) and a cholesterol 
hydrophobe as well as a cleavable disulphide-containing linker to enable breakdown of 
the SAMul array. They developed this system to bind DNA, then release it from the 
complex as the self-assembled system degraded into small components, that individually 
have low affinity towards binding DNA.112 In collaboration with the Haag group, they 
also synthesized low-molecular-weight dendritic polyglycerol-based amphiphiles with 
N,N-di-(3-aminopropyl)-N-(methyl)amine (DAPMA) on their surfaces (Fig. 1-24).114 
They suggested that these structures have a prospective application in vivo as new 
promising alternatives for nonviral siRNA delivery systems in addition of great potential 
for further synthetic modifications.114 It was demonstrated that such self-assembled 
vehicles did not induce any immune response in an animal model.  
 
Fig. 1-24 Synthetic low-molecular-weight dendritic amphiphiles, reported by Haag and Smith.114  
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Stupp and co-workers employed self-assembly using isoleucine-lysine-valine-alanine-
valine (IKVAV). IKVAV, is a vital pentapeptide sequence for cell attachment, migration, 
and neurite outgrowth.115,116 They used it  to synthesize nanofiber peptides117 as bioactive 
sequence for neural applications.118-120 They designed these IKVAV-containing peptide 
amphiphiles to contain four regions; hydrophobic tail, beta-sheet forming segment, 
charged groups and bioactive epitope (Fig. 1-25).  
 
Fig. 1-25 IKVAV-containing peptide amphiphile molecule and its self-assembly into nanofibers, by 
Stupp.117 
 
Another study was performed by Ravoo and co-workers121 to develop switchable SAMul 
DNA binders. Their work was based on using an azobenzene moiety to functionalize 
spermine, this moiety has the ability to be encapsulated within cyclodextrins (CD) α and 
β (α-CD and β-CD) at the surface of CD-vesicles (Fig. 1-26). They found that this self-
assembled multivalent approach enhanced DNA binding, and could be switched by light 
as the azobenzene unit converted from trans to cis.  
 
 
Fig. 1-26 Ravoo and co-workers self-assmbled systems; functionalized spermine by azobenzene at CD-
vesicles surface. Structures adapted from reference.121  
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1.3 Heparin 
 
1.3.1 Heparin Therapy  
  
 
Heparin (Fig. 1-27), from mast cells, is an anionic sulphated polysaccharide that is 
considered the most highly charged anionic biological polymer.122-124 It has a 
heterogeneous chain consisting of different repeating monomers (copolymers).123,125  The 
molecular weight of heparin varies between 3,000 and 30,000 kDa, the mean being 
around 15,000, which represents 45 saccharide units (Fig. 1-27).126 In practical terms, 
only about one third of those units consist of the functional active pentasaccharide that 
binds specifically to its target-antithrombin.127,128,123  
 
Fig. 1-27 Major heparin disaccharide repeated unit and the active antithrombin III binding pentasaccharide, 
reproduced from reference.126 
 
In nature, heparin exists as part of the heparans in the inner walls of the microvascular 
system.129 Heparin is extracted from animals as a heterogeneous drug, and injected into 
the blood stream to circulate during surgical procedures.130,131 It is considered the only 
choice to treat and prevent thromboembolic disease.129 It acts as, and can be considered 
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as, the only anticoagulant drug during surgery by binding to antithrombin and has been 
in use since 1935.132-134  There are two major forms of heparin in current use; 
unfractionated heparin (UFH) and the fractionated heparin; low-molecular-weight-
heparin (LMWH), which mainly consists of polysaccharides with Mr typically between 
4000 – 6000 Da. Both work as indirect anti-coagulants, where plasma cofactors play a 
mediation role.135 However, LMWH has a metabolism half-life of 3-6 hours, whereas 
UFH is removed rapidly in ca. 30 minutes.136 The normal concentration of heparin, during 
clinical procedures, is between 1.2 and 48 μg/ml (0.2–8 international unit (IU) /ml).137 
For estimation of heparin in vivo, a method of activated clotting time is commonly 
used.137,138  
Despite the fact that heparin is widely used in open heart surgery and other major 
operations, heparin sodium causes a low platelet count in patients 
(thrombocytopenia).125,135 Therefore, complications such as severe bleeding can lead to 
postoperative mortality.139 As such, it is necessary to reverse the effects of heparin once 
surgery is complete (see below).  
 
 
1.3.2 Heparin Replacements 
 
Heparin alternatives such as Warfarin (Fig. 1-28); a synthetic derivative of coumarin have 
been used as anticoagulants by reducing all four dependent coagulation factors of vitamin 
K. Warfarin produces its anticoagulant effect by interfering with the vitamin K 
interconversion cycle and its epoxide (2,3 epoxide).140 It blocks the formation of vitamin 
K1 and vitamin KH2 by inhibiting vitamin KO reductase, which stops the carboxylation 
of glutamate residues of vitamin K–dependent proteins (Fig. 1-29).141  Nonetheless, its 
function in blood is slower than heparin. In addition, it causes bleeding, headache, 
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dizziness and difficulty breathing.142  Typically, it is used as a long-term blood-thinner in 
patients as risk of stroke, rather than in critical care and during surgical intervention.   
 
Fig. 1-28 Warfarin Structure.  
 
 
 
Fig. 1-29 Warfarin inhibition of the vitamin K interconversion cycle and its epoxides. Adapted from 
reference.141 
 
Ancrod143 from the venom of the Malayan pit viper, was another candidate to replace 
heparin, but it causes skin reactions, pain at the injection site, splenomegaly, and some 
systemic bleeding.143,144 Lepirudin145 which was extracted from yeast cells (in the past, 
saliva of leeches), also has major side effects such as numbness, weakness, headache, 
confusion, problems with vision and speech, and bleeding (haemorrhage). In addition, 
when excreted through the renal system (90%) it affects kidney function.145,146 Another 
example of a heparin replacement is Fondaparinux147 a synthetic pentasaccharide factor 
Xa inhibitor but this has no antidote, is expensive, causes skin rashes and has renal 
excretion problems which prevent its use in patients with renal dysfunction. Overall, all 
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of these alternative compounds have more critical side effects than heparin147 and as such, 
heparin remains the only clinically used anticoagulant during major surgery.  
 
1.3.3 Protamine  
 
The removal of excess heparin from the blood system after surgery is essential in order 
to rapidly limit excess bleeding during patient recovery. Protamine, an arginine-rich 
protein123,128  (Fig. 1-30),148 derived from salmon sperm,147 has been used for heparin 
removal after surgical intervention for decades.149 Protamine is used in its sulphate form: 
it is a polyarginine polypeptide (positively charged) and can reverse heparin anticoagulant 
effects. After it is injected through the intravenous route, protamine (cationic) binds with 
heparin (anionic) to produce a salt (neutral).149,150 The complex is excreted, and hence, 
protamine eliminates heparin’s anticoagulation effects.151 Although the mechanism of 
protamine appears to be a straight-forward cation-anion binding interaction, it is not well 
defined as both components are polydisperse.152 
 
Fig. 1-30 An example of protamine (e.g. Arg4 = Arg-Arg-Arg-Arg), adapted from reference.148   
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Protamine also inhibits the inactivation of thrombin by antithrombin III (AT III).152,153 
Moreover, clotting assays showed that the inhibition of thrombin by converting 
fibrinogen to fibrin depends on concentration. Although this conversion is partial and 
reversible,154,155 protamine has complications by inhibiting factor V activation which 
leads to “hidden hemorrhage”.153,156 
In addition, studies of cardiac contractility showed that injection of protamine sulphate is 
followed by systemic pulmonary hypotension in patients.157,158 Other major side effects 
such as allergy and anaphylaxis were also reported.149  The demand for a simple non-
toxic protamine replacement has therefore increased.  
 
1.3.4 Protamine Replacements 
 
 There have been a number of attempts to replace protamine in order to prevent the toxic 
side effects in 10% of the treated patients.152,158 However; none of those attempts were 
successful due to their critical side effects or lack of efficiency.159 Polybrene; polycationic 
hexadimethrine bromide; a positively charged polymer160,161 (Fig. 1-31), was investigated 
as early as 1950s. It was 70% effective at removing heparin by producing non-specific 
agglutination of red blood cells, to neutralize the negative charge of the red blood cells 
caused by heparin.160,162,163 However, it has side effects such as hemodynamic, 
hematologic, and renal problems.164 
 
Fig. 1-31. Polybrene structure; rich positively charged molecule.  
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Another compound tested as a protamine replacement was toluidine blue (tolunium 
chloride,160,165 (tolunium chloride).166 Although it has a reversal effect on heparin, it 
caused disagreeable side-effects; methemoglobinemia and hypoxia were seen after the 
treatment of 23 heparinized dogs.160 Heparinase 1 enzyme167 is a naturally occurring 
enzyme which can degrade heparin into less active fragments to neutralize the 
anticoagulant effects. It was tested clinically, but was not applied directly and has been 
used via dialysis through a blood filter containing immobilized heparinase. This method 
required a blood transfusion and was time consuming.168  
The most recent clinical attempt was Delparantag,169 initially reported as PMX 60056.170 
This is a chiral peptide consisting of salicylamide units and lysine groups (Fig. 1-32).  
 
Fig. 1-32. Delparantag structure; lysine group with aromatic core. 
 
Although the mechanism of action of Delparantag was not reported in the literature, from 
its structure it is obvious that it is positively charged (5 +ve) and can bind with heparin, 
with the aromatic part possibly enhancing stability or providing structural organization.  
However, this compound has failed to replace protamine due to “funding problems”.169 
The search for a heparin binder through the development of protamine replacement(s) is 
now a hot topic in the field of nanomedicine. A self-assembling mimetic for the protamine 
structure was reported by Smith et al. This was a spherical self-assembled protamine 
mimic formed from C22-G1 (Fig. 1-33). The focal hydrophobic chain provided the driving 
Chapter 1 – Introduction  
58 
force for the assembly of this supermolecule. The positively charged amines were the 
cationic part that binds heparin.171 
 
Fig. 1-33 Self-assembling ligand C22-G1.171 
 
Although the binding of this system along the heparin polymer chains was successful and 
has been proven by electron microscopy and a solution phase binding assay, 
unfortunately, it was relatively unstable in blood serum.171,172 
 
1.4 Project Aims 
 
The aim of this project is to gain a fundamental insight into structure-activity relationships 
in self-assembled multivalent polyanion binding. This will be achieved by building a self-
assembling supramolecular system consisting of an amine as the positively charged 
binding site and a hydrophobic part that has the force to drive the assembly. Importantly, 
we then aim to stabilize the self-assembled structure by stabilization of the hydrophobic 
part of the molecule; for example, by cross-linking. In addition, several modifications 
will be made to the hydrophobic tail and/or the hydrophilic binding site to test the effect 
of such modifications on binding affinities towards different polyanions such as heparin 
and DNA. In addition, multi-component systems will be used to test their effects on the 
binding affinities.  
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2 Effect of Alkene Modified Hydrophobic Units on SAMul 
Binding of Biological Polyanions 
  
2.1 Introduction  
 
The search for a heparin binder through the development of protamine replacement(s) is 
now a hot topic in the field of nanomedicine as illustrated in detail in the previous chapter 
(1. 3. 4). A self-assembling mimetic for the protamine structure was reported by Smith et 
al.171 This was a spherical self-assembled protamine mimic formed from C22G1 (Fig. 1-
33). The hydrophobic chain at the focal point provided the driving force for the assembly 
of this supermolecule. The positively charged amines were the cationic part that binds 
heparin.171 Although the binding to heparin polymer chains was successful and has been 
proven by electron microscopy and a solution phase binding assay, unfortunately, these 
self-assemblies were relatively unstable in human blood serum.171,173  
Furthermore, there was significant interest in gaining further fundamental understanding 
of the binding process which underpin this kind of nanoscale recognition event. In 
addition, we wanted to understand the features that governed the binding of different 
polyanions, such as DNA and heparin. Little attention has been given to attempts to 
explore selectivity in binding between such highly charged polyanion targets.  Therefore, 
we decided to continue the work of finding a biocompatible nanostructured heparin binder 
with potentially greater serum stability by building a self-assembling supramolecule(s) 
consisting of amine, with two positive charges, as the positively charged binding site and 
a naturally occurring fatty acid as the hydrophobic focal point that will drive the assembly 
(Fig. 2-1). We proposed that geometric differences in the nanostructures should impact 
directly on the heparin and DNA binding abilities of self-assembled multivalent systems 
(SAMul). In this part of our work, we therefore decided to modify the hydrophobic tail 
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of the micelles, in an attempt to impact on their assembly, structural characterization and 
binding ability.  
 
Fig. 2-1 Target compounds; consisting of amine, with two positive charges, as the positively charged 
binding site and a naturally occurring fatty acid as the hydrophobic focal point that will drive the assembly. 
 
Importantly, we then hoped to stabilize the self-assembled structures by modification of 
the hydrophobic part of the molecule. It is known that micelles are unstable at lower 
concentrations than their critical micelle concentration (CMC), and in different solvents 
particularly competitive media such as human serum.174 In an attempt to mimic natural 
ways of stabilizing self-assembled structures which is often achieved by covalent cross-
links, we proposed to perform a polymerization reaction175 to cross-link the alkene groups 
within the micelles. Such covalent cross-linking (C-L) should help to ‘capture’ and 
stabilize the self-assembled micelles in more competitive media. In recent years the 
researchers interest has been focused on cross-linking few polymer molecules within self-
assembled structures.176-178 Thurmond et al., had reported the stabilization of polymer 
micelles by cross-linking.174,179 They demonstrated that incorporation of cross-linkable 
functional groups within the exterior of micelles allows polymerization to take place and 
gives stability to the micellar assembly.179,180 
There are several locations for C-L within the micelle’s domain; it could occur in the core 
chains or it could happen on the surface of the micelle, the shell. The location of C-L has 
a dramatic effect on the physical and chemical properties of the resultant products. In 
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addition, the extent of C-L could impact on the level of the stability and also the structure, 
hence modifying the binding abilities of such compounds.174 
 
2.2 Alkene-Modified SAMul Nanostructures 
 
The initial aim was to study the effect of alkene groups on self-assembly as well as 
binding affinities to heparin and DNA. We therefore started by building a self-assembled 
supramolecular system consisting of a positively charged binding site (amine) and 
hydrophobic focal point (naturally occurring unsaturated fatty acid). The unsaturated fatty 
acids were varied from mono-unsaturated to di- and tri-unsaturated fatty acid (Fig. 2-1).   
 
2.3 Synthesis of Unsaturated-C18-DAPMA 
 
Three unsaturated-C18-DAPMA compounds were synthesized with different alkene 
groups in the hydrophobic chain. Each of these were based on a naturally occurring 
unsaturated lipid. The synthesis of each of these compounds consisted of three key steps; 
the first step was the protection of N,N-di-(3-aminopropyl)-N-methylamine (DAPMA). 
The protection was a selective protection, as DAPMA contains relatively unreactive 
tertiary amine in addition to two primary amines. The mono-protection was achieved by 
using di-tert-butyl dicarbonate (Boc2O) to produce mono-Boc-DAPMA or compound 1
171 
(Scheme 2-1). This was achieved by using an excess of DAPMA in the reaction; 
unreacted DAPMA could then be easily removed. This limited the formation of di-Boc-
protected DAPMA, and the small amounts which did form could also easily be removed 
by washing. Although this step was straightforward, the yield was relatively low (39%).   
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Scheme  2-1 Protection of DAPMA by using Boc2O (compound 1). 
 
Peptide coupling reaction was then performed between mono-Boc-protected DAPMA 
and the target hydrophobic units, each of which contained a different number of alkene 
groups.  Firstly, to test the method, we synthesized potential binder (di-unsaturated C18-
DAPMA, Binder 2), corresponding to two alkene groups within the hydrophobic tail. 
The protected N,N-di-(3-aminopropyl)-N-methylamine (Boc-DAPMA, 1) was reacted 
with naturally occurring linoleic acid (di-unsaturated fatty acid). The reaction was 
performed in the presence of O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
tetrafluoroborate (TBTU) (Fig. 2-2) as coupling agent (Scheme 2-2).181  
 
 
Fig. 2-2 O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU).  
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Scheme  2-2 TBTU coupling reaction mechanism.181 
 
The product (di-unsaturated-C18-Boc-DAPMA) was purified by using gel permeation 
chromatography (GPC) column (Bio-beads SX-1, 100% DCM) and gave 33% yield.  The 
identity of the product was demonstrated using all key analytical techniques including 
mass spectrometry (MS); HRMS: Calc. [M+H] + (C30H58N3O3) m/z = 508.4473 Found 
[M+H] + = 508.4456. The third step was to remove the Boc group and hence produce 
Binder 2. To achieve that, the compound resulting from the previous step was dissolved 
in methanol and HCl gas was applied for 15-20 seconds then the mixture left to stir for 3 
hours (Scheme 2-3). The solvent and excess HCl was then removed by evaporation to 
produce a product of 80% yield. The removal of the Boc group was demonstrated by the 
loss of the CH3 protons at ca. 1.4 ppm in the 
1H NMR (Fig. 2-3). The shifts in other peak 
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positions are due to the different solvents that we have used; for the protected compound 
we used chloroform and due to solubility issues with the deprotected compound (Binder 
2) we had to use methanol as the solvent.  
 
 
Scheme  2-3 Synthesis of di-unsaturated-C18-Boc-DAPMA by coupling of compound 1 and the fatty acid 
(linoleic acid), then removing the Boc group to produce Binder 2. 
 
 
 
Fig. 2-3 NMR spectra for Binder 2 before removing the Boc group (top) showing CH3 protons around 1.35 
ppm and (bottom) the spectra showing the loss of the peak after the deprotection reaction.   
Chapter 2 – Effect of Alkene Modified Hydrophobic Units on SAMul Binding of Biological Polyanions 
65 
In addition, coupling reactions were performed between the other fatty acids and 
compound 1 to synthesize new potential heparin binders with different numbers of alkene 
groups. This was achieved using the same method described above for the synthesis of 
Binder 2. Oleic acid which has one alkene group (Fig. 2-4a) was used to synthesize 
mono-unsaturated-C18-DAPMA or Binder 1 with overall yield of 91% (Fig. 2-5a) and 
linolenic acid (Fig. 2-4b) which has three alkene groups was used to synthesize tri-
unsaturated C18-DAPMA or Binder 3 (77%) (Fig. 2-5b). For simplicity, the binders were 
named according to the number of double bond(s) they have within the hydrophobic tail. 
 
Fig. 2-4 (a) Oleic acid (one double bond) and (b) Linolenic acid (three double bonds). 
 
 
Fig. 2-5 (a) Binder 1 (one double bond) and (b) Binder 3 (three double bonds). 
 
All three binders, in the Boc protected form, were purified by size-exclusion method; gel 
permeation chromatography (GPC) column (Bio-beads, 100% DCM) then fully 
characterized by all analytical methods including mass spectrometry (MS) and NMR. 
Final binders were also fully characterized after the simple HCl-mediated deprotection 
step.   
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2.4 Self-Assembly Studies 
 
2.4.1 Nile Red Assay  
In order to determine the critical aggregation concentration (CAC) for the synthesized 
compounds, a Nile Red assay was performed. Nile Red dye (9-diethylamino-5-
benzo[a]phenoxazinone)182 (Fig. 2-6) is a hydrophobic compound that has a high 
fluorescence emission which is quenched when in the presence of water.182,183 Nile Red 
has demonstrated its efﬁciency to measure the aggregation183,184 of compounds that 
contain both hydrophilic and hydrophobic parts (i.e., amphiphiles). It begins to fluoresce 
(Fig. 2-7) when it is encapsulated within the hydrophobic interior of a self-assembled 
structure, as a result of its increased solubility and a decrease in quenching.182,183 In this 
assay, Nile Red ﬂuorescence excitation was achieved at 550 nm and its emission intensity 
was measured at 635 nm.171 The ability of Nile Red to fluoresce is determined as a 
function of the concentration of the amphiphile. Once the critical aggregation 
concentration (CAC) is reached, Nile Red fluorescence gets switched on. Monitoring the 
emission intensity as a function of concentration therefore allows critical concentration 
to be determined.    
 
 
Fig. 2-6 9-Diethylamino-5-benzo[a]phenoxazinone (Nile Red).  
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Fig. 2-7 Nile Red confined in the micelle’s core at and above CAC provides evidence of self-assembly and 
allows quantification of the CAC.  
 
The compounds stock solutions were prepared at a variety of concentrations starting from 
(200 µM) and less in disposable cuvettes. Samples of the stock solution were diluted by 
phosphate-buffered saline (PBS) to the required concentration in a 1 mL assay volume. 
Nile red (1 µL) was applied to each sample to give concentration of (2.5 µM). 
The CAC for Binder 2 was found to be around 82 (± 1.7) µM (log10 Concentration = 
1.96) (Table. 2-1). This was calculated from Figure 2-8. This value indicates that this 
compound will only self-assemble at concentrations above 82 µM. This is a relatively 
high value compared to the previously reported heparin binder; C22-G1 (Fig. 1-33).  
which had a CAC of 4 µM. However, Binder 2 is only a very simple self-assembling unit 
with two positive charges and the goal of the study here was not to form the best self-
assembly but rather to determine the effect of changing the number of alkene groups on 
self-assembly and consequently on polyanion binding. Therefore, the CACs of the other 
two compounds (Binders 1 and Binder 3) were also measured.   
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Fig. 2-8 Critical aggregation concentration (CAC) for Binder 2 determined by Nile Red assay. 
 
CACs for Binder 1 and Binder 3 were 42 (± 3.1) μM and 78 (± 9.8) μM respectively 
(Table 2-1), (Fig. 2-9 and 2-10). Clearly if only one alkene is present, the CAC is lower, 
whereas if 2 or 3 alkenes are present in the hydrophobic chain the CAC is elevated.  This 
would suggest that the presence of alkene groups hinders self-assembly by distorting the 
extended conformation of the alkene chain. Fewer double bonds give more freedom for 
the compound (Binder 1) to self-assemble as the compound practically still has a linear 
shape. Double bonds enforce a geometric preference onto the hydrophobic group – in 
particular the cis alkenes found in these three examples. More than one double bond in a 
compound begins to enforce strongly nonlinear geometric onto the tail and can even cause 
a bend in the compound’s structure to produce a semi-ring shaped tail185 (Fig. 2-11). 
Similar disruption effects of alkenes on lipid self-assembly have been reported elsewhere 
and are known for example to introduce fluidity into cell membranes.186,187 A double bond 
results in a bend of approximately 30 degrees in a chain of carbons,188 therefore, it causes 
a space within the molecule. This space gives unsaturated fatty acids (lipids), on the 
molecular level, more fluidity than saturated lipids as they are unable to pack together as 
effectively.189 
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Binder 1   2   3  
CAC (μM) 42 ± 3.1 82 ± 1.7 78 ± 9.8 
Table 2-1 Critical aggregation concentration (CAC) for binders (1 – 3), in PBS buffer (pH = 7.4). 
 
Fig. 2-9 Critical aggregation concentration (CAC) for Binder 1 determined by Nile Red assay. 
 
Fig. 2-10 Critical aggregation concentration (CAC) for Binder 3 determined by Nile Red assay.  
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It is also worth noting that above the CAC, the emission intensity of Nile Red is greatest 
with Binder 1 than for Binder 2 and Binder 3. This would suggest the less-ordered 
hydrophobic domains formed by these more bent systems are less-able to protect the Nile 
Red from quenching by the surrounding water – indicative of ‘looser’ and more open self-
assembled nanostructures.  
 
 
Fig. 2-11 Binder 3 possible semi-ring shapes of the hydrophobic unsaturated tail. 
 
We were also interested in using mixtures of different compounds in the hope of 
combining (e. g.) the lower CAC of Binder 1 with the greater alkene density of Binder 
3. As such, a mixture of Binder 1 and Binder 3 (1:1) was prepared. The CAC for this 
mixture was measured and it was 88 (± 5) µM (Fig. 2-12). This CAC was closer to the 
CAC value of Binder 3 than that of Binder 1 and this demonstrated that the disruption 
effect of the other alkene groups on self-assembly dominates in the mixed system.   
 
Fig. 2-12 Critical aggregation concentration (CAC) for Binders 1 and Binder 3 mixture (1:1).  
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2.4.2 Dynamic Light Scattering (DLS)   
 
The synthesized binders were then characterized in terms of aggregate size in solution by 
dynamic light scattering (DLS). This provides a quantitative insight into the self-
assembled nanostructures present in solution which is of key importance for 
understanding their preferences in (e. g.) heparin binding assays. The DLS technique uses 
a laser light beam and when the light shines onto a solution with spherical particles (in 
Brownian motion) the light hits the moving particle causing a change (scatter) in the 
wavelength of that incoming light.190 This scattered light is related to the size of the 
particles and the sphere size distribution.191 Particle size was calculated by the 
instrument’s software in accordance with the Stokes-Einstein formula192 (Eq. 2-1), which 
relates particle size to the diffusion coefficient and viscosity. Where NA is the Avogadro 
number, T is the temperature and η is the viscosity of the solution, ru is the solute radius 
assuming the solute has a spherical geometry (a reasonable assumption for these systems). 
 
Eq. 2-1 Stokes-Einstein formula.  
 
The self-assembly of the binders was measured under similar conditions to the heparin 
binding assay reported later (i.e., in buffer; 150 mM NaCl / 10 mM Tris HCl). In addition, 
the samples were prepared at concentrations above the CAC to guarantee the 
measurement of the self-assembled micelles. Diameters can either be calculated using a 
volume distribution (which reflects the amount of self-assembled volume) or an intensity 
distribution (which reflects the intensity of the scattered light).  
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Converting from intensity distribution to volume distribution lowers the contribution of 
larger aggregates which scatter light more significantly even at lower concentrations and 
emphasizes the contribution of the species which are present as the majority is solution.  
As such, larger aggregates are often not observed in the volume distribution and all peaks 
are shifted to smaller diameters as the larger components have their larger contributions 
re-weighted (this is similar to the difference between Mw and Mn in polymers molecular 
mass distributions).193 We therefore use volume distribution to characterize and report the 
size of the dominant species in solution. However, it is important not to ignore the 
contribution/presence of larger aggregates as minor component in solution and for this 
reason we also present intensity distribution data.   
 
The results (Table 2-2) showed that the binders are dispersed in a moderate level; the 
poly-dispersity index (PDI) values were higher than 0.1-0.2, for a perfectly uniform 
sample the PDI would be 0.0.194 This is a consequence of the intensity distribution data 
which indicates the presence of a larger aggregate (>100) (Fig. 2-13). It is noteworthy 
that going from Binder 1 to 2 to 3, the intensity distribution indicates that the relative 
amount of light scattered from larger aggregates increases. This would suggest that the 
controlled assembly into smaller micelles is most favoured by 1 > 2 > 3. This would be 
in agreement with the CAC values described earlier and may suggest that Binder 2 and 
Binder 3 have a greater propensity to assemble into less well-defined, larger aggregates 
in addition to well-defined smaller micelles. This would support the view that the more 
alkene groups are present, the more the self-assembly of these systems is disrupted owing 
to the distorted structures of the hydrophobic chains limiting effective packing.   
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Fig. 2-13 Size distribution by intensity from DLS analysis of Binder 2 in buffer (150 mM NaCl / 10 mM 
Tris HCl) showing the contribution of larger aggregates which scatter light more significantly even at low 
concentrations. 
 
Sample in NaCl 
(150 mM) / Tris 
HCl (10 mM) 
Diameter (Intensity 
distribution) / nm 
Diameter (Volume 
distribution) / nm 
PDI 
Binder 1 
Pk1:   10.5 (38%)               
Pk2:         167.4 (62%) 
5.2 ± 0.51 0.344 ± 0.004 
Binder 2 
Pk1:    9.6 (27%)         
Pk2:         156.3 (73%) 
6.4 ± 0.41 0.365 ± 0.002 
Binder 3 
Pk1:     10.6 (45%)    
Pk2:        203.1 (55%) 
7.6 ± 0.27 0.697 ± 0.012 
Table 2-2 Size Analysis by DLS for the three synthesized binders in NaCl (150 mM) / Tris HCl (10 mM). 
 
When considering the volume distribution to focus on the major species presence (Fig. 2-
14), the average diameter for Binder 1 micelles was around 5.2 (± 0.5) nm. Comparing 
with the other two compounds (Binder 2 and Binder 3), Binder 1’s micelles are smaller. 
The average diameter for Binder 2 micelles was around 6.4 ± (0.41) nm and for Binder 
3 was 7.6 (± 0.27) nm (Table 2-2). We suggest that these size differences reflect the 
number of the double bonds in the hydrophobic tail. Binder 1, which has one double 
bond, has a linear hydrophobic tail that packs effectively and allows relatively small 
micelles to assemble. Conversely, Binder 2 and Binder 3, which have two and three 
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double bonds, respectively, form larger micelles. We suggest that more double bonds 
adversely affect the shape of the molecules and the self-assembly gives larger and looser 
micelles. This supports the Nile Red assay (2. 4. 1), when the CAC values for Binders 2 
and Binders 3 were higher than Binder 1, and the observed emission intensities were 
lower.   
 
Fig. 2-14 Size distribution by volume from DLS analysis of Binder 1 in buffer (150 mM NaCl / 10 mM 
Tris HCl) showing that larger aggregates not observed and all peaks are shifted to smaller diameters as the 
larger components have their larger contributions re-weighted. 
 
In addition, DLS data showed that the self-assembled nanostructures were highly 
positively charged. Zeta potentials for Binders 1-3, which reflect surface charge density, 
were between 64 and 73 mV (Table 2-3). These high positive charges assure that the 
potential binders are suitable to bind heparin as it is known that binding to heparin, which 
is a highly negatively charged anion, will occur through electrostatic interactions.195,196  
Sample in Buffer  Zeta potential (mV) 
Binder 1 64.1 ± 0.6  
Binder 2 72.9 ± 3.7 
Binder 3 72.9 ± 2.5 
Table 2-3 Zeta potential for binders 1-3 in buffer; NaCl (150 mM) / Tris HCl (10 mM), showing that they 
are highly positively charged.  
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2.4.3 TEM Images  
Transmission electron microscopy (TEM) images were recorded for the three binders. 
The images were recorded both in the absence and the presence of heparin in order to 
characterize both the self-assembled nanostructures and the impact of heparin on them. 
The binder solutions were prepared in ultra-pure water at concentrations (200 µM), above 
the CAC values calculated from the Nile Red assay, in an effort to ensure that there would 
be self-assembled prior to sample preparation. The samples were then placed on a formvar 
grid, stained with uranyl acetate then left to dry for about 20 minutes prior to imaging. 
Electron microscopy is particularly subject to artifacts, and can be unable to differentiate 
between ‘real’ agglomerates and those formed upon deposition and drying.197 However, 
the images showed approximate size and shape of the micelles, in particular in the 
presence of heparin (see below). This allows us to estimate a rough size of the micelles 
as well as visualizing them when bound to their polyanion targets.  
In the absence of heparin, Binder 1 showed some aggregates (Fig. 2-15a) but these were 
not particularly well-defined. This might suggest that the micelles, characterized by DLS, 
are not particularly stable when dried down on a TEM grid and imaged under the electron 
beam. Conversely, in the presence of heparin, micellar objects are clearly seen. We 
suggest that heparin binding plays a role in stabilizing the aggregates under imaging 
conditions. Furthermore, the micelles are organized into an effective (lattice-like) 
arrangements. A similar effect was previously reported by Smith and co-workers171 for 
the binding of C22-G1 to heparin (Fig. 2-16), showing their self-assembled binder in the 
presence of heparin. We suggest that interactions between the polyanionic rods of heparin 
and the polycationic sphere of the binder leads to this degree of hierarchical assembled 
nanostructure within the overall aggregate. This organizational effect may play a role in 
enabling the better imaging of the micelles as they are more effectively immobilized on 
the grid. Comparing Binder 1’s image (Fig. 2-15b) to the reported TEM images by Smith 
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et. al, Binder 1 was found to have similarity of forming organized nanostructured 
aggregates on the surface of heparin. Figure 20b shows the spherical micelles of Binder 
1 deposited in organized linear arrays on the surface of heparin. The individual spherical 
structures of Binder 1 appeared to be less than 10 nm in diameter.  
 
 
Fig. 2-15 TEM images of Binder 1, dried from aqueous solution (200 µM), in the absence of heparin (a); 
a spherical self-assembled nanostructure and in the presence of heparin (b), showing the organized linear 
nanostructured arrays, scale bar = 100 nm.    
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Fig. 2-16 TEM image of self-assembled spherical C22-G1 nanostructures in the presence of heparin, leading 
to linear organization of the nanostructures.171 
 
A previous binder Mallard Blue (MalB), that has been synthesized by Smith group for 
heparin sensing showed that MalB does not form these notable aggregations by itself. In 
addition, when imaging heparin by itself (Fig. 2-17a), we found that it does not aggregate. 
Furthermore, on mixing MalB and heparin (Fig. 17b), MalB does not self-assemble and 
does not show hierarchical structure or patterning. As such, we are confident in assigning 
the hierarchical nanostructures to Binder 1:heparin assemblies.  
 
Fig. 2-17 TEM images dried from aqueous solution of: (a) MalB (25 µM) in the presence of heparin 
showing the less defined organized nanostructured on the surface of heparin and (b) heparin by itself in 
similar assay conditions (27 µM), scale bar = 100 nm.    
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In addition, TEM images of Binder 2 and Binder 3 showed similar characteristics (Fig. 
2-18 and 2-19). Some self-assembly was observed in the absence of heparin but on 
binding of the nanostructures to heparin, these micelles could be much more clearly 
observed and furthermore the micelle-heparin aggregates had a degree of internal 
nanostructuring with effective close packing of cationic nanospheres presumably being 
meditated by interactions with the polyanionic heparin chain.  
 
Fig. 2-18 TEM image of Binder 2 dried from aqueous solution (200 µM), showing spherical self-assembled 
nanostructures; (a) before binding to heparin, (b) in the presence of heparin, scale bar = 100 nm.  
 
Fig. 2-19 TEM image of Binder 3 dried from aqueous solution (200 µM), showing spherical self-assembled 
nanostructures; (a) before binding to heparin, (b) in the presence of heparin, scale bar = 100 nm.  
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Nevertheless, all binders’ aggregates in TEM images showed that the micelles were 
aligned in an organized style. This nanoscale organization was induced by heparin, as it 
is considered to be a relatively rigid polymer, which led the micelles to be organized along 
its backbone. This way of binding, known as “beads on a string”  has been observed when 
spherical cationic systems bind to DNA.198    
 
2.5 Binding Data  
 
2.5.1 Heparin Binding  
2.5.1.1 Mallard Blue  
 
The detection of heparin binding in serum has recently been achieved by the Smith 
group199 through the development of a novel cationic dye “Mallard Blue” (MalB); an 
arginine-functionalized thionine (Fig. 2-20), which has a high affinity for heparin and 
works as a sensor for the anionic polysaccharide.  
 
Fig. 2-20 Mallard Blue (MalB); a dye with five positive charges designed to bind to polyanionic heparin.14 
 
Monitoring heparin binding with this dye was performed by UV-Vis spectroscopy.199 The 
dye showed a high efficiency as the binding was detectable at low concentrations of 
heparin in serum; as low as 1 IU/mL in 100% human serum.123,199 Mallard Blue showed 
much better detection levels for heparin compared with other heparin sensing dyes such 
as Azure A.200 Currently, in the research group, a MalB competition assay, as discussed 
below, is used to screen new potential therapeutic candidates for non-toxic protamine 
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replacements to bind with heparin in order to remove it from patients’ blood after 
surgeries.123  
Heparin binding affinities for the synthesized compounds were tested in competitive 
conditions such as buffer (pH 7.4), salt and human serum. The maximum UV-Vis 
absorbance at 615 nm for MalB was recorded. When initially dissolved in buffer at room 
temperature (20 -22 ºC) the color develops when the solution is incubated at 50 °C for 24 
hours (Fig. 2-21). This incubation process is essential to prevent the aggregation or to un-
stack the tri-cyclic aromatic cores of this dye. In addition, the binding of this dye to 
heparin has proven to be more efficient after the incubation process. The incubation is 
done prior to any binding assay, the flasks were wrapped with foil to ensure that the dye 
was not exposed to direct light as it has been reported to be light-sensitive.123     
 
Fig. 2-21 MalB (25µM) before incubation (a) and after the incubation for 24 h at 50 °C (b). 
 
On binding to heparin, the MalB absorbance peak at 615 nm dropped in intensity (Fig. 2-
22), also, the solution color changed to a darker shade of blue. On the addition of any 
compound’s (binder’s) stock solution, the binder then replaced MalB gradually (Fig. 2-
23) in the competition assay and as a result the intensity increases. This demonstrates that 
these compounds (binders) can effectively bind heparin under these assay conditions.   
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Fig. 2-22 UV-Vis spectra showing mallard blue (MalB) maximum absorbance at 615 nm binding to heparin 
(blue line) and after binding to heparin (red line). 
 
 
Fig. 2-23 UV-Vis spectra showing a binder replacing mallard blue (MalB) in the titration competition 
experiment. 
 
  
Chapter 2 – Effect of Alkene Modified Hydrophobic Units on SAMul Binding of Biological Polyanions 
82 
a. MalB Assay in Buffer 
 
The MalB competition assay, in buffer, was performed for each binder individually. The 
assay was carried out under optimized conditions of 25 µM MalB, 27 µM heparin, 150 
mM NaCl and 10 mM Tris HCl. Each titration was carried out in triplicate and the results, 
are presented below (Fig. 2-24, Table 2-4).  For each compound, the charge ratio in the 
cuvette was calculated after every addition and was plotted against the normalized 
absorbance value at 615 nm for each reading. The charge ratio at the point when 
normalized absorbance = 0.5 was estimated by plotting a linear graph of the data around 
this value. The effective concentration at 50% binding (EC50) and the charge excess at 
50% binding (CE50) were calculated from the plotted graph as well as the required dose 
in mg/100 IU of heparin (Table 2-4). 
 
Fig.  2-24 Charge ratio against normalized absorbance at 615 nm of Binders 1 - 3 and a mixture of Binder 
1 and Binder 3 (1:1), in buffer, showing the effect of alkene variation on binding to heparin, ‘open’ markers 
represent points in the titration affected by aggregation and light scattering.   
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The charge excess is a useful tool to consider the binding ability normalized per charge 
of the binder, a lower charge excess means more binding.  Therefore, CE50 values are 
used to indicate the efficiency of a binder to bind heparin. Also, these values are used in 
comparison terms between different binders especially where theses binders have 
different number of charges, such as the drug; protamine. Protamine’s CE50 has been 
reported to be 0.52 using this assay.123,126,128  
 
Table 4 also shows the effect of alkene groups on heparin binding ability. Clearly the 
system with most alkenes (Binder 3) is least able to bind to heparin with a CE50 of 2.3 (± 
0.18). whereas that with the fewest (Binder 1) is the most effective heparin binder with 
a much lower CE50 of 0.8 (± 0.05). Binder 2 is intermediate in value with CE50 of 1.8 (± 
0.1). This would suggest that the alkenes, which hinder the self-assembly of these 
nanostructures as discussed above, also limit their ability to bind to polyanionic heparin. 
These differences are significant and are well beyond errors associated with this assay.  
 
We also monitored the ability of co-assembled Binder 1 and Binder 3 to bind heparin 
and found that the CE50 value of 2.0 (± 0.3) was more similar to the performance of 
Binder 3 than the performance of Binder 1. This agrees with our previous hypothesis 
that the presence of Binder 3, and the multiple alkene groups within it, significantly 
disrupt the self-assembly process, and hence the ability of the SAMul nanostructures to 
bind to heparin. 
Compound Binder 1 Binder 2 Binder 3 
Binder 1 + 
Binder 3 (1:1) 
CE50 0.8 ± 0.05 1.8 ± 0.1 2.3 ± 0.18 2.0 ± 0.3 
EC50 (μM) 45 ± 3.0 76 ± 7.0 125 ± 9.9 107 ± 16.2 
Dose (mg) / 
100 IU 
0.6 ± 0.04 1.1 ± 0.01 1.7 ± 0.13 1.5 ± 0.22 
Table 2-4 Calculated CE50, EC50, required dose (in buffer) and the CAC of the synthesized binders showing 
the effect of the alkene group(s) on self-assembly and binding abilities comparing to compounds with 
saturated hydrophobic tails.  
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It should be noted that in some cases the final normalized absorbance is > 1.0, Figure 2.25 
demonstrates this effect. As can be seen, on titration, the absorbance at 615 nm becomes 
higher than that of Mallard Blue alone. However, looking at intensity at 500 nm also 
shows that in the later part of the titration intensity begins to increase at this wavelength. 
For this reason, we assign the increase of intensity > 1.0 as due to light scattering 
associated with aggregates between heparin and the SAMul binder which impacts across 
the whole spectrum. We Note that in early stages of the titration, light scattering effects 
are not seen significantly at 500 nm and we therefore reason that the determination of the 
CE50, which lies in the early part of the titration is sound. As a result, we did not attempt 
to correct data for this aggregation effect. We also note that for Binders 1-3, the largest 
absorbance are observed for Binder 3 > Binder 2 > Binder 1. This is in agreement with 
DLS studies on the binders above which suggested that aggregation was less controlled 
for Binder 3 because of the alkene units inserted in the structure. As such, the observation 
of uncontrolled aggregation in the MalB titration would seem to match the preference of 
the binder.   
 
Fig. 2-25 UV spectra for the MalB assay of Binder 3 showing the aggregation effect that increase 
absorbance at higher charge ratios towards the end of the titration.  
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b.  MalB Assay in Human Serum  
 
Human serum has an extraordinary binding ability for a wide range of ligands; 
endogenous and exogenous. This binding ability makes it significant to determine the 
pharmacokinetic behavior of many drugs.201-203 Human serum does not contain white or 
red blood cells nor a clotting factor; it is basically plasma without fibrinogens.201,204,205 
However, human serum albumin (HSA), a spherical protein that consists of 585 amino 
acids, constitutes 60% of the total protein in blood serum.202,205 It is known that HSA can 
interact with a wide range of different molecular species – in particular those with 
significant hydrophobic surfaces.206 Therefore, testing the synthesized compounds, in 
such conditions, was the next step in this work.   
After testing the synthesized binders’ abilities to bind heparin in 150 mM NaCl and 10 
mM Tris HCl, we decided to investigate the stability of these systems in more challenging 
conditions. Biologically relevant media, such as human serum is  recognized as suitable 
and challenging biological conditions. This type of testing will allow more insight to the 
binding behavior of these compounds and allow them to be considered as potential 
candidates for future trials in even more challenging conditions, such as blood plasma.  
The ability of the synthesized compounds (Binders 1-3) to bind heparin in human serum 
was therefore tested. Binding data were recorded by measuring MalB absorbance by UV-
Vis spectroscopy at 615 nm as described in the buffer procedure above. Binders (1-3) 
showed binding to heparin and the charge ratio at the point when normalized absorbance 
= 0.5 was estimated by plotting a graph of the data around this value. EC50 and CE50 
values as well as the required dose were calculated from the plotted graphs in a similar 
method to that described above. While the binders showed stable binding to heparin in 
human serum, the binding abilities were relatively rather weaker than those in buffer; less 
competitive conditions. The Binder 1 CE50 value in human serum (Fig. 2-26) was high 
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(2.5 ± 0.2) (Table 2-5), compared to the value in buffer (0.8 ± 0.05) suggesting significant 
disruption of the binding.  
 
 
Fig. 2-26 Charge ratio against normalized absorbance at 615 nm of Binder 1 in human serum, showing 
high values of CE50 which indicates less binding to heparin, ‘open’ markers represent points in the titration 
affected by aggregation and light scattering.  
 
Binder 1 in Human Serum 
CE50 2.5 ± 0.2 
EC50 (μM) 133.5    ± 10.0 
Dose (mg) / 100 IU 1.86    ± 0.13 
 
Table 2-5 Calculated CE50, EC50 and required dose (in human serum) of Binder 1, showing the weaker 
binding abilities than in buffer.  
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Binder 2 (Fig. 2-27 and Table. 2-6) showed some binding to heparin in human serum, 
but again this binding ability was weaker than its ability to perform in buffer, with a CE50 
value in serum (3.4 ± 0.1) higher than that in buffer (1.8 ± 0.1).  
 
Figure 2-27 Charge ratio against normalized absorbance at 615 nm of Binder 2 in human serum, showing 
high values of CE50 suggesting significant disruption of the binding, ‘open’ markers represent points in the 
titration affected by aggregation and light scattering.  
 
Binder 2 in Human Serum  
CE50 3.4 ± 0.1 
EC50 (μM) 182 ± 14 
Dose (mg) / 100 IU 2.5 ± 0.2 
Table 2-6 Calculated CE50, EC50 and required dose (in human serum) of Binder 2, showing the weaker 
binding abilities than in buffer. 
 
Binder 3 (Fig. 2-28 and Table 2-7) was also adversely affected by human serum although 
less so than Binder 1 and Binder 2 as the binding was already relatively weak even in 
buffer. The CE50 rises from 2.3 (± 0.18) in buffer to 3.1 (± 0.1) in serum. Interestingly, 
this might suggest that human serum is less-able to adversely affect the self-assembly of 
Binder 3 than it does to Binder 1 and Binder 2. It is known that HSA has a preference 
for binding long chain aliphatic compounds which would lead to disruption of self-
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assembly and hence SAMul binding. However, for Binder 3, which has the most distorted 
chain (Fig. 2-11), perhaps this binds less effectively to HSA and hence the relative degree 
of disruption is less.  
It is worth noting that the binding of MalB (the competitive species) to heparin is 
relatively un influenced by the presence of human serum, presumably because it does not 
have a hydrophobic unit capable of interaction with (and competition from) HSA.  
 
Fig. 2-28 Charge ratio against normalized absorbance at 615 nm of Binder 3 in human serum, showing no 
significant differences in CE50 values in buffer, ‘open’ markers represent points in the titration affected by 
aggregation and light scattering.  
 
Binder 3 in Human Serum  
CE50 3.1 ± 0.1 
EC50 (μM) 166 ± 1.9 
Dose (mg) / 100 IU 2.3 ± 0.01 
Table 2-7 Calculated CE50, EC50 and required dose (in human serum) of Binder 3, showing no significant 
differences in those values in buffer.  
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2.5.2 DNA Binding  
We were then interested in the relative ability of these compounds to bind to different 
polyanionic targets. As such, we went on to study the binding of these compounds to 
DNA. We were interested to know the impact of modifying the hydrophobic group on 
selectivity between different biological polyanions. The biological world is highly rich in 
polyanions and understanding theses selectivities in this process is of key importance, yet 
surprisingly selective binding of such species is rarely addressed. We discussed DNA 
binding207 to self-assembled amphiphilic peptides in the introduction chapter (1. 2. 4). In 
order to perform such a study, we also selected a competition assay. Calf-thymus DNA 
was mixed with a known concentration of ethidium bromide (EthBr). EthBr (Fig. 2-29); 
a well-known DNA stain,208,209 is a flat molecule that fits between adjacent base pairs 
(intercalates) in the DNA double helix.210,211 On the addition of  increasing amounts of 
binder, the EthBr is displaced from the DNA causing a reduction in fluorescence. The 
fluorescence of EthBr is significantly higher when intercalated than it is in aqueous 
solution.211,212 Competitive displacement studies with EthBr showed that complexes 
compete for the DNA binding sites with EthBr and displaces the molecule.211,212 This 
method can be used to quantify interactions between DNA and different binding 
molecules and is a very useful comparative technique, although it does not give any data 
on the binding mode.  
 
Fig. 2-29 8-Diamino-5-ethyl-6-phenylphenanthridinium bromide (EthBr).  
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The studies of the synthesized binders were carried out in HEPES buffer at pH 7.4 and at 
physiological salt concentrations, 150 mM NaCl. At this pH value the amine groups 
(binding site) on the binder are protonated and can thus form interactions with the 
negatively charged phosphate backbone of the DNA via electrostatic binding. The 
concentration of calf-thymus DNA was 4.0 μM with respect to an individual nucleotide 
base, with a molecular weight assumed to be 330 gmol-1. The concentration of EthBr in 
solution was 5.07 μM. The maximum EthBr emission was measured at 595 nm. The 
fluorescence measurements were normalized to a value of 0.0, with respect to a solution 
of EthBr alone, and to a value of 1.0 for the starting solution containing both EthBr and 
DNA. 
EthBr displacement assays were performed on all the binders (Binders 1-3) to assess their 
relative binding abilities to DNA.213 In addition, a DNA assay was performed on a 
mixture of Binders 1 and Binders 3 (1:1). The assay results, for each binder, indicated 
different DNA binding affinities (Fig. 2-30, Table 2-8). Interestingly, in this case, there 
was an apparent decrease of CE50 values with an increasing number of alkene groups on 
the hydrophobic tail. This decrease was from = 5.0 ± 0.7, in the case of Binder 1, to 4.3 
± 0.5 and 3.5 ± 0.4 for Binder 2 and Binder 3, respectively (Table 2-8). It should be 
noted that these differences are somewhat smaller than observed for heparin binding and 
Binder 1 and Binder 2 have DNA affinities within error of one another, but most 
remarkably, and contrary to our initial expectations Binder 1, with the smallest number 
of alkenes and the best ability to self-assemble, was no longer the most effective binder, 
and appeared to be the least able to bind DNA. 
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Fig. 2-30 Charge ratio against normalized emission at 595 nm from EthBr assay for all the synthesized 
binders. 
. 
 
 
 
Table 2-8 CE50 of the binders 1-3 (in buffer) after binding to DNA and heparin showing the binding 
selectivity caused by differences in alkene groups density.  
 
In other words, Binder 3 is better for binding DNA than Binder 1. This is clearly in 
contrast to the CE50 values for binding to heparin which were much better for Binder 1 
than Binder 3 (Table 2-8). This would suggest that DNA and heparin, at least in the 
assays performed here, have different requirements in terms of compounds which will 
exhibit optimal binding profiles towards them. We suggest that the looser aggregates 
formed by Binder 3 may be more effective for DNA binding as the ligands may be more 
freely able to insert into the minor groove and bind to the phosphate groups, whereas for 
heparin binding we suggest that the most densely packed best organized charged 
assemblies are optimal – more for a pure charge-charge interaction with less influence of 
Binder 1 2 3 
 
1 + 3 
(1:1) 
CE50 in DNA 
 
5.0 ± 0.7 
 
4.3 ± 0.5 3.5 ± 0.4  3.2 ± 0.2 
CE50 in Heparin 
 
0.8 ± 0.1 
 
1.8 ± 0.2 2.3 ± 0.2 2.0 ± 0.3 
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ligand organization. We come back to this concept in a later chapter (Chapter 3) dealing 
with the impact of ligand structure on polyanion binding process.   
The mixture of Binders 1 and Binder 3 (1:1) was closer to Binder 3’s values, for DNA 
binding, which indicated that, once again, Binder 3 dominates the self-assembly and also 
indicates that the loosening effect on the self-assembly of incorporating the lipid with 
these double bonds is significant and is the key factor influencing polyanion 
recognition.214 
The observation of different binding preferences for heparin and DNA induced by a 
simple change in the hydrophobic unit is a very significant observation. In both cases, 
cation-anion interactions are responsible for binding and it might be expected that simple 
change density will dominate and control the binding interaction. The fact that heparin 
and DNA show different responses indicates that the morphology of the nanostructure 
can significantly influence the binding event. This result overthrows many 
preconceptions about electrostatic ion-ion interactions which are usually considered to be 
difficult to have control, and demonstrates that by modulating the self-assembly of 
multivalent systems, we can have direct influence on the preferences of the SAMul array 
(Fig. 2-31). This shows how versatile this approach to biological binding really is.   
 
Fig. 2-31 CE50 values showing binding selectivity of Binders 1-3 between different biological polyanions; 
heparin and DNA.  
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2.6 Alkene Groups Cross-linking (C-L)  
 
The goal of this step was to enhance the stability of the self-assembled micelles of each 
binder in serum as micelle stability has been previously reported to be improved after 
cross-linking.174,215 We tested the cross-linking of Binders 1-3 using 2,2-azo-
bis(isobutyronitrile) (AIBN)175 (Fig. 2-32) as a radical polymerization initiator (Fig. 2-
33); each binder was cross-linked individually. Polymerization of the alkene groups 
should act to link each binder together covalently and within the confined environment 
of the micelle interior might be expected to hence covalently ‘capture’ the self-assembled 
nanostructure. The mechanism of AIBN initiation and alkene polymerization is shown in 
Scheme 2-4.  
 
Fig. 2-32 2,2-azo-bis(isobutyronitrile) (AIBN) as the radical initiator in the polymerization reaction of the 
alkene groups or cross-linking (C-L) reaction. 
 
 
Scheme  2-4 Proposed mechanism of AIBN initiation and the alkene polymerization (cross-linking).   
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Water was used as the reaction medium of choice in order to enable the binders to form 
a self-assembled nanostructure. Tetrahydrofuran (THF) was then used as a co-solvent to 
ensure the total solubility of AIBN which should partition inside the self-assembled 
nanostructures prior to thermal activation. The self-assembled nanostructures should be 
stable at these elevated temperatures as the entropically driven hydrophobic effect is 
usually favoured as temperature increases (ΔG = ΔH – TΔS). It is well-known, for 
example, that detergent micelles, used in cleaning applications have greater stability at 
elevated temperatures. 
 
 
Fig. 2-33 Cross-linking the reactive alkene groups of binders using AIBN as a radical polymerization 
initiator. The red dotted red line indicates the proposed cross-linking within the nanostructures. 
 
It is clear that the number of alkenes may impact on the potential for cross-linking. 
Furthermore, it is possible that either intramolecular reaction (undesired) or 
intermolecular cross-linking (desired) may occur for the systems which have more than 
one alkene group. After the cross-linking reaction of Binder 1, there was still a presence 
of the alkene groups at 5.10-5.24 ppm in the 1H NMR (Fig. 2-34). The integral had 
decreased by 20% relative to other peaks. This would suggest that some reaction is 
occurring but that any polymerization is incomplete.    
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Fig. 2-34 NMR spectra of Binder 1 before cross-linking alkene groups (left) and (right) after the cross-
linking reaction, showing the presence of the alkene protons multi peaks at 5.10-5.24 ppm.  
 
In addition, mass spectrometry (MS) of Binder 1 after polymerization showed the clear 
presence of the monomer (Fig. 2-35), HRMS: Calc. [M+H]+ (C25H52N3O) m/z = 410.4105 
Found [M+H]+ = 410.4097. This supports the NMR data to indicate that the cross-linking 
was not complete. We suggest that with just one alkene self-assembled within the micelle 
interior, these groups are unable to effectively come into contact with one another and 
hence polymerization is relatively ineffective.  
 
Fig. 2-35 MS spectra showing the presence of Binder 1’s monomer, indicating the unsuccessful C-L.  
 
In contrast, after the cross-linking reaction of Binder 2 the alkene groups multiplet peak 
at 5.10-5.24 ppm in the 1H NMR had a significantly lower intensity (Fig. 2-36); a decrease 
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of 76% was recorded.  Further, the alkene group multiplet peak for Binder 3 was 
negligible after cross-linking (Fig. 2-37), decreasing to just 19%. This would suggest 
when more alkenes are present a greater degree of alkene cross-linking can occur. This 
may be a result of enhanced intermolecular cross-linking as a result of the greater density 
of alkenes in the micelle interior, or may result from intramolecular alkene-alkene 
reactions.   
 
Fig. 2-36 NMR spectra of Binder 2 before cross-linking alkene groups (left) showing the presence of the 
alkene protons multi peaks at 5.10-5.24 ppm and (right) after the cross-linking reaction the peaks had a 
lower intensity. 
 
Fig. 2-37 NMR spectra of Binder 3 before cross-linking alkene groups (left) showing the presence of the 
alkene protons multi peaks at 5.10-5.24 ppm and (right) after the cross-linking reaction the peaks are 
negligible.  
 
In order to determine whether the reaction between alkenes was intra or inter molecular, 
we employed mass spectrometric analysis of the products from these cross-linking 
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reactions. The mass spectra for Binder 2 and Binder 3 (Fig. 2-38 and Fig. 2-39) 
supported the NMR results by showing a distribution of several peaks at higher masses 
than that expected for the monomer (m/z = 408 and 406 for Binder 2 and Binder 3 
respectively). We suggest that these peaks represent multiply charged ions resulting from 
oligomerization of the binders induced by the AIBN cross-linking conditions, although 
they were difficult to fully assign.   
 
Fig. 2-38 MS spectra of Binder 2 after C-L showing distribution of the polycation ions. 
 
 
Fig. 2-39 MS spectra of Binder 3 after C-L showing distribution of the polycation ions. 
 
The differences in alkene reactivity between Binders 1,2 and 3 lead us to suggest that the 
higher density of alkenes in self-assembled nanostructures formed by Binder 3 leads to 
far more effective intermolecular cross-linking (C-L) and capture. On the other hand, the 
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relatively low density of alkenes in Binder 1 means that the alkenes are more difficult to 
react with one another within the self-assembled nanostructure and, as such, we suggest 
that cross-linking does not occur successfully. We then went on to test the performance 
of these cross-linked systems.    
2.6.1 Characterization of the Cross-linked Systems 
2.6.1.1 Nile Red Assay  
 
The Nile Red assay was used to determine CAC for the cross-linked systems. This assay 
was performed as described above (2. 4. 1). CACs for Binder 1 before and after C-L (Fig. 
2-40, Table 2-9) were similar (42 µM). The stability of the CAC values is a result of the 
presence of the alkene groups after the C-L reaction indicating unsuccessful C-L and/or 
capture of the nanostructure in this case. 
Compound  
Binder 1  
Before C-L 
Binder 1  
After C-L  
Binder 2 
Before C-L  
Binder 2 
After C-L 
Binder 3 
Before C-L 
Binder 3 
After C-L 
CAC (μM) 42 ± 3.1 42 ± 1.8 82 ± 1.7 90 ± 2.7 78 ± 9.8 151 ± 10 
Table 2-9 Critical aggregation concentration (CAC) for Binders (1 – 3) before and after C-L.  
 
Fig. 2-40 Critical aggregation concentration (CAC) for Binder 1 before C-L (a) and after C-L (b); Binder 
1 micelles showed similar aggregation behavior before and after C-L.    
Chapter 2 – Effect of Alkene Modified Hydrophobic Units on SAMul Binding of Biological Polyanions 
99 
The CAC value (Table 2-9) of Binder 2 after the C-L reaction was determined as 90 ± 
2.7µM, similar to the value before C-L (82 ± 1.7 µM). This would suggest that the 
reaction of the alkenes is not significantly impacting on the concentration at which Nile 
Red is fluorescing which would suggest that self-assembly is similar both before and after 
our C-L reaction.    It was, however, noted that there was some difference in the line-
shape for Binder 2 after C-L compared with before (Fig. 2-41) with more Nile Red being 
solubilized at lower concentrations (i.e. the grey line is less horizontal). This may suggest 
some more nanostructure stabilization after C-L allowing Nile Red to be solubilized 
below the CAC of the binder alone.  
 
Fig. 2-41 Critical aggregation concentration (CAC) for Binder 2 before C-L (a) and after C-L (b) showing 
the difference in the grey line shape which might indicate some stabilization. 
 
Binder 3’s CAC values, however, had changed (151 µM) after the C-L reaction (Fig. 2-
42b) comparing to the values before the C-L reaction (78.0 µM) (Fig. 2-42a). It was, 
somewhat, surprising that the CAC had increased (Table 2-9) as we had been hoping to 
stabilize the nanostructure, which should mean it forms at lower concentrations. We 
discuss this further below.   
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Fig. 2-42 Critical aggregation concentration (CAC) for Binder 3 before C-L (a) and after C-L (b). 
 
2.6.1.2 Dynamic Light Scattering (DLS)  
 
The cross-linked systems of Binder 2 and Binder 3 were characterized by DLS in order 
to obtain an insight into the micelle size after the C-L reaction. The samples were prepared 
as described above (2. 4. 2). After the C-L reaction, Binder 2 (Table 2-10) maintained 
the same size average (around 7 nm). However, Binder 3 average diameter by volume 
distribution before C-L was around 7 nm (Table 2-10), while after C-L the average was 
bigger; around 9 nm. An explanation to the size increase after C-L is that only parts of 
the structure are cross-linked which then still need to self-assemble, a process which gives 
an even less well-defined aggregate. Interestingly, the data support our hypothesis that 
Binder 3 assembles into a large and looser nanostructure than Binder 2, presumably as 
a consequence of the additional alkene group which for geometric reasons prevents 
effective packing of the hydrophobic tails (Fig 2-11). 
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Sample in NaCl (150 
mM) / Tris HCl (10 
mM) 
Diameter 
(Intensity 
distribution) / nm 
Diameter (Volume 
distribution) / nm 
PDI 
Binder 2 
Pk1: 7.80 (75%)           
Pk2:   143.8 (25%) 
6.36 ± 0.41 0.365 ± 0.002 
Cross-linked Binder 2 
Pk1: 8.20 (25%)   
Pk2:   168.6 (75%) 
7.08 ± 0.05 0.981 ± 0.032 
Binder 3 
Pk1: 10.69 (45%)   
Pk2:   203.1 (55%) 
7.58 ± 0.27 0.697 ± 0.012 
Cross-linked Binder 3 
Pk1: 17.21 (66%) 
Pk2:   159.8 (34%) 
8.87 ± 0.09 0.438 ± 0.011 
Table 2-10 Size Analysis by DLS for Binder 2 and Binder 3 (before and after C-L), in NaCl (150 mM) / 
Tris HCl (10 mM).  
 
It is also important to note that zeta potential values for Binder 2 and Binder 3 after C-L 
were similar to the values before C-L (Table 2-11); this is an indication that performing 
the C-L reaction has not affected the surface charges of those two compounds.  
 
Sample in Buffer  Zeta potential (mV) 
Cross-linked Binder 2 69.4 ± 1.0 
Cross-linked Binder 3 75.6 ± 2.7 
Table 2-11 Zeta potential values of Binder 2 and Binder 3 in buffer; NaCl (150 mM) / Tris HCl (10 mM), 
showing that the cross-linked systems were highly positively charged.  
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2.6.1.3 TEM Images  
 
Transmission electron microscopy (TEM) images were recorded for the cross-linked 
systems of Binder 2 and Binder 3 in a similar method to that described above (2. 4. 3). 
TEM images of Binder 2 after C-L (Fig. 2-43), showed that, in the presence of heparin 
after C-L the micelles have similar shape yet smaller in size than those before C-L (Fig. 
18). Furthermore, TEM images of Binder 3 after C-L (Fig. 2-44) gave smaller aggregates 
than before C-L (Fig. 2-19). This might be reflective of less organized system being 
present after C-L has taken place.   
 
 
Fig. 2-43 TEM images of Binder 2 dried from aqueous solution (200 µM), showing spherical self-
assembled nanostructures in the presence of heparin; after C-L, scale bar = 100 nm.  
Chapter 2 – Effect of Alkene Modified Hydrophobic Units on SAMul Binding of Biological Polyanions 
103 
 
Fig. 2-44 TEM images of Binder 3 dried from aqueous solution (200 µM), showing spherical self-
assembled nanostructures in the presence of heparin; after C-L, scale bar = 100 nm.   
 
2.6.2 Heparin Binding 
2.6.2.1 Mallard Blue  
 
a. MalB Assay in Buffer 
Binding abilities of the cross-linked systems were tested using MalB assay; Binder 2 and 
Binder 3 were tested individually. The assay was performed as described above. After 
C-L the alkene groups in Binder 2, the binding ability has improved slightly. This 
improvement was shown in the values of EC50 and CE50 (Table 2-12), which was 
calculated from the graph below (Fig. 2-45). The CE50 was 1.5 ± 0.19 which is lower than 
the value before C-L (1.8 ± 0.1) and may suggest that C-L has tightened the self-assembly 
and strengthened its binding ability. However, it should be noted that differences are very 
close to error range. We now needed to test this system in serum, where competition was 
stronger. However, although the C-L reaction appeared to be more successful in the case 
of Binder 3, CE50 values were higher after C-L; 2.6 (Table 2-12). By looking at the graph 
below (Fig. 2-46), we could see a clear difference between these values.  
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Compound 
in buffer  
Binder 2 
Before C-L 
Binder 2 
After C-L 
Binder 3 
Before C-L 
Binder 3 
After C-L 
CE50 1.8 ± 0.1 1.5 ± 0.19 2.3 ± 0.18 2.6 ± 0.03 
EC50 (μM) 76 ± 7.0 64 ± 10.7 125 ± 9.9 142 ± 5.8 
Dose (mg) / 100 IU 1.1 ± 0.01 0.9 ± 0.14 1.7 ± 0.13 1.9 ± 0.01 
Table 2-12 Calculated CE50, EC50 and required dose (in buffer) of synthesized binders, before and after C-
L, showing the effect of the density of alkene groups on self-assembly and binding abilities.  
 
Fig. 2-45 Charge ratio against normalized absorbance at 615 nm of Binder 2, in buffer, before and after C-
L, showing a slight improvement in CE50 values, ‘open’ markers represent points in the titration affected 
by aggregation and light scattering.   
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Fig. 2-46 Charge ratio against normalized absorbance at 615 nm of Binder 3, in buffer, before and after C-
L, showing a slight difference in CE50 values, ‘open’ markers represent points in the titration affected by 
aggregation and light scattering.  
 
On cross-linking, there is no significant improvement in heparin binding. This suggests 
that cross-linking is either incomplete or does not significantly change the ability of these 
compounds to bind under these conditions. We considered that in serum, which is much 
more competitive, the advantages of cross-linking should become more apparent and we 
therefore went on to study the heparin binding event in serum.  
 
b. MalB Assay in Human Serum  
 
After testing the cross-linked systems, abilities to bind heparin in 150 mM NaCl and 10 
mM Tris HCl, we decided to investigate the stability of these systems in more challenging 
conditions; human serum. The assay was carried out as described above. Binder 2 CE50 
values in serum (3.4 ± 0.1) were higher than the values in buffer (1.8 ± 0.1). After C-L 
(Fig. 2-47) Binder 2 showed some improvement but not significantly more than error 
(3.1 ± 0.3).  
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Fig. 2-47 Charge ratio against normalized absorbance at 615 nm of Binder 2 before and after C-L, in human 
serum, showing no significant differences in CE50 values more than error might suggest, ‘open’ markers 
represent points in the titration affected by aggregation and light scattering.  
 
Considering the data from the table below (Table 2-13), it was clear that Binder 3’s 
binding ability to bind heparin in human serum after C-L did not change significantly 
CE50 values before and after C-L were about 3.0 (± 0.1) (Fig. 2-48). We believe that 
overall, the reaction of the alkenes is not significantly enhancing the polyanion binding 
performance of these nanostructures.  
 
Fig. 2-48 Charge ratio against normalized absorbance at 615 nm of Binder 3 before and after C-L, in human 
serum, showing total similarity of binding behavior; no significant differences in CE50 values, ‘open’ 
markers represent points in the titration affected by aggregation and light scattering.   
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Compound  
Binder 2 
Before C-L 
Binder 2 
After C-L 
Binder 3 
Before C-L 
Binder 3 
After C-L 
 in Buffer  
CE50 1.8 ± 0.1  1.50 ± 0.19 2.30 ± 0.18 2.60 ± 0.03 
EC50 (μM) 76.0 ± 7.0 64.0 ± 10.7 125.0 ± 9.9 142.0 ± 5.8  
Dose (mg) / 100 IU 1.10 ± 0.01 0.90 ± 0.14 1.70 ± 0.13 1.90 ± 0.01 
  in Human Serum   
CE50 3.4 ± 0.1  3.0 ± 0.3 3.1 ± 0.1 3.2 ± 0.1 
EC50 (μM) 182.0 ± 14.0  150.0 ± 12.0 166.0 ± 1.9.0  168.0 ± 0.7 
Dose (mg) / 100 IU 2.5 ± 0.2 2.0 ± 0.4 2.30 ± 0.01 2.40 ± 0.02 
Table 2-13 Calculated CE50, EC50 and required dose (in buffer and human serum) of Binder 2 and Binder 
3, before and after C-L. 
 
2.7 Comparison Study 
 
Finally, we compared the results collected here with those for two analogue compounds 
synthesized by Vieira, Smith et al. These two compounds’ hydrophobic tails were 
modified using saturated fatty acids with different lengths; palmitic acid to produce (C16-
DAPMA) and stearic acid to produce (C18-DAPMA) (Fig. 2-49).  
 
Fig. 2-49 C16-DAPMA and C18-DAPMA; saturated hydrophobic tails.  
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The saturated hydrophobic tails yield assemblies which had lower CE50, and EC50 values 
indicating the adverse effect of the alkene group(s) on nanostructures packing and on the 
binding abilities. A slight solubility problem occurred with C18-DAPMA, due to the chain 
length, this hydrophobic behavior resulted in high aggregation values, CAC at 75 µM. it 
is interesting to note that the alkene-containing analogues studied in this chapter do not 
suffer from this solubility problem – mainly because the hydrophobic chains are distorted 
and pack less well. Furthermore, the low CACs of those compounds with saturated 
hydrophobic chains, supported the effect the alkene group have on self-assembly and 
hence heparin binding. It is clear from our proposal that the lower CE50 values of the 
saturated systems, that they had better binding to heparin (0.6 and 0.7).  
 
Compound 
(in buffer) 
Binder 1 Binder 2 Binder 3 
C16-
DAPMA  
C18-
DAPMA  
Fatty Acid    
Oleic 
(C18H34O2) 
Linoleic 
(C18H32O2) 
Linolenic 
(C18H30O2) 
Palmitic 
(C16H32O2) 
Stearic 
(C18H36O2) 
CE50 0.8 1.8 2.3 0.6 0.7 
EC50 (μM) 45.0 76.0 125.0 35.0 37.0 
Dose (mg) / 
100 IU 
0.6 1.1 1.7 0.5 0.5 
CAC (μM) 41.0 82.0 77.0 38.0 75.0 
Table 2-14 Calculated CE50, EC50, required dose (in buffer) and the CAC of the synthesized binders 
showing the effect of the alkene group(s) on self-assembly and binding abilities comparing to compounds 
with saturated hydrophobic tails.  
Chapter 2 – Effect of Alkene Modified Hydrophobic Units on SAMul Binding of Biological Polyanions 
109 
2.8 Conclusions and Future Work 
 
This project continues the investigations of a biocompatible nanostructured heparin 
binders with by building a self-assembling supramolecule consisting of an amine group 
as the positively charged binding site and a naturally occurring fatty acid as the 
hydrophobic focal point that will drive the assembly. The synthesis of these compounds 
was relatively straightforward and the target compounds were fully characterized. The 
amphiphilic synthesized compounds were successfully self-assembled into micelles and 
bonded to large polyanionic targets (heparin and DNA) electrostatically (Fig. 2-50). The 
binding was monitored using Mallard Blue dye as a sensor which allowed us to determine 
heparin binding affinities and the ability to bind in competitive media, such as human 
serum. Ethidium bromide displacement was used to monitor DNA binding. We found that 
human serum disrupted self-assembly and heparin binding. Moreover, the binders showed 
intriguing different binding affinity to heparin and DNA which we believe are controlled 
by the alkene modified self-assembly and nanostructured morphology of the SAMul 
systems. We suggested that the more organized nanostructures are better able to bind to 
heparin while the looser ones are preferentially bound by DNA. 
 
Fig. 2-50 Amphiphilic micelles bind to large polyanionic targets (heparin and DNA) electrostatically.
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The alkene group cross-linking reaction which was performed for all three binders went 
to highest conversion for Binder 3 with the most alkene groups and was unsuccessful for 
Binder 1.  Cross-linking proved not to significantly enhance binding affinity. In addition, 
the cross-linking reaction appeared to increase the size of the binder micelles suggesting 
that cross-linking may be only partial and that some reorganization may occur during self-
assembly. Nonetheless, this size enhancement means an increase of the core size; this 
may be a useful tool to load a greater amount of (e. g) drug inside such systems.    
 
 In future work, other compounds (binders) could be synthesized to be tested for both 
heparin and DNA binding. These compounds could consist of the same hydrophobic tail 
bonded to different ligands or similar ligands bonded to a different hydrophobic tail. Also, 
using two hydrophobic tails could be considered to enhance the self-assembly which 
would lead to a better binding. By tuning these head groups and tails, we can modify the 
binding abilities of the SAMul nanostructures to heparin and DNA; nanoscale biological 
polyanions. Ion-ion binding is often considered as non-directional and as such only 
depends on the charge density of the species involved – however, this study clearly 
demonstrates that under competitive biological conditions, the choice of hydrophobic 
group and its capacity to display and orientate the ligands has a major role in tuning the 
binding affinity (such effects will be discussed in further detail in the following chapter). 
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3 Effects of Modifying Ligands of Polycationic SAMul 
Nanostructures on Binding Affinities to Different 
Polyanions  
Some of the results in this chapter have been reported in: L. E. Fechner, B. Albanyan, V. 
M. P. Vieira, E. Laurini, P. Posocco, S. Pricl and D. K. Smith, Chem. Sci., 2016, 7, 4653-
4659. 
3.1 Introduction 
The selectivity between different polyanions, in terms of electrostatic binding, that we 
observed in the previous chapter led us to be more curious to understand the factors 
behind the preferences of self-assembled displays of receptors to bind to one polyanion 
over another. In addition, we wanted to address a genuine challenge in supramolecular 
design by developing systems that would be able to intervene more precisely in 
biomedical processes and would be better optimised for specific clinical 
applications.126,216 Self-assembled multivalent (SAMul) ligands are small molecules with 
a highly tunable strategy due to their simple synthesis. Therefore, it is easy to vary their 
structures and hence explore structure–activity relationships.217  
It is known that to bind polyanions such as DNA or heparin, cationic ligands are required 
and that binding is established via multiple electrostatic ion–ion 
interactions.102,107,110,114,218-220 Recently, Smith and co-workers, have reported that ligand 
chirality could have an influence on heparin/DNA binding selectivity,221 but selective 
polyanion binding induced by structural ligand differences is rarely explored, and hence 
a challenging target. Although charge density has the major role in binding, other 
interactions can have an influence on selectivity, however, there are relatively few 
examples of such experimental studies.222-224 In this chapter we determine the effect of 
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ligand modifications in our SAMul nanostructures on observed selectivities of different 
biological polyanions; DNA and heparin. In addition, we used multiscale modelling 
methods in collaboration with Pricl group (Trieste) in order to provide further insight into 
such complexes, and the interdependent, hierarchical self-assembly and nanoscale 
binding processes. 
We selected palmitic acid (C16), as the hydrophobic unit, coupled with different amines 
as ligands to study this structure–activity effect. The synthesised compounds had nominal 
ligand charges of +1, +2, +2 and +3 (Fig. 3-1). This work was carried out by visiting 
undergraduate student Loryn E. Fechner; under my guidance she performed the synthesis 
and some of the analytical studies and I completed the analytical work ready for 
publication.  
 
Fig. 3-1 C16-ligands; compounds investigated in this chapter.  
 
3.2 Synthesis of C16-Ligands 
Four binders containing a hydrophobic tail and a positively charged polyamine head 
group were synthesized to investigate the influence of structural differences on the self-
assembly and binding affinities to heparin and DNA. The hydrophobic tail used for this 
work was palmitic acid (C16H32O2), a C16 saturated chain.
217 The synthesized C16-ligands 
were designed to have different positively charged head groups (Fig. 3-1). The first 
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compound was synthesized using 1,3-propanediamine (DAP) which after coupling 
contains one primary amine group. It was synthesized using a TBTU-mediated coupling 
strategy with Boc protecting groups (Scheme 3-1). All the compounds in each step, 
including the final product, were characterized by 1H and 13C NMR, MS and IR.  
 
 
Scheme  3-1 Synthesis of C16-DAP. 
  
DAPMA and spermidine (SPD), both contain, after coupling, two free amine groups 
which can be positively charged, and were used to synthesized two more compounds; 
C16-DAPMA and C16-SPD (Fig. 3-1). C16-SPD possesses a secondary amine in the 
middle whereas C16-DAPMA contains a tertiary amine.  
C16-DAPMA was simply synthesized using TBTU-mediated coupling of compound 1 
(reported in chapter 2) with palmitic acid to produce Boc-C16-DAPMA in 90% yield, 
followed by deprotection with HCl gas (Scheme 3-2). The final product structure was 
confirmed by 1H- and 13C-NMR, MS and IR.   
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Scheme  3-2 Synthesis of C16-DAPMA. 
 
For the Synthesis of C16-SPM, due to the asymmetry of the polyamine spermidine (Figure 
3-1), the selective Boc-protection required a different approach. Instead of using 
spermidine as a starting material for selective protection, an alternative pathway starting 
from diamino butane (DAB) was employed.225 This allowed stepwise construction of the 
protected spermidine. Similar reactions to form selectively protected spermidines and 
spermidine homologues have been described by Andruszkiewicz et al. in 2005.226 
The first reaction was the mono-Boc-protection of DAB (Scheme 3-3) analogous to the 
protection of DAP in Scheme 3-1. The di-protected water-insoluble side product was 
separated by filtration and the product was extracted from the filtrate with DCM. The di-
protected product was also isolated in 13% yield. Both structures were confirmed by 1H- 
and 13C-NMR, MS and IR. A Michael reaction between mono-Boc DAB and acrylonitrile 
then yielded compound cyanoethyl mono-Boc-DAB. This reaction proceded with simple 
heating in THF. After drying in vacuum, cyanoethyl mono-Boc-DAB was received as 
yellow oil in 84 % yield (Scheme 3-3). The secondary amine was then Boc-protected in 
a similar manner as the first protection (Scheme 3-3) to give compound cyanoethyl di-
Boc-DAP in 92% yield. All structures were confirmed by 1H and 13C NMR, MS and IR. 
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Finally, the selectively – protected N1,N2-Bis-Boc-spermidine (Boc-SPD) was yielded by 
reduction of the cyano group to an amine with lithium aluminium hydride (LAH). The 
reaction conditions were chosen according to the description of Andruszkiewicz et al.226 
The product was extracted with ether, then with water in acidic conditions (pH = 3-4) 
then with DCM. After drying, the product was obtained as a slightly yellow oil in 62% 
yield (Scheme 3-3). The structure was confirmed by 1H and 13C NMR, MS and IR.  
 
Scheme  3-3 Synthesis of Boc-SPD. 
  
N1,N2-Bis-Boc-spermidine (Boc-SPD) was then coupled with palmitic acid by a standard 
TBTU-mediated coupling (Scheme 3-4) to yield 76%, and the product was deprotected 
by HCl gas to produce C16-SPD as a white powder (81%). The structure was confirmed 
by 1H and 13C NMR, MS and IR.   
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Scheme  3-4 Synthesis of C16-SPD. 
 
The final compound C16-SPM was synthesized from spermine (SPM) (Fig. 3-1). The 
selective Boc-protection should be carried out in a way such that both of the secondary 
and one of the primary amine groups are protected. Due to the symmetry of the molecule, 
this can be achieved by doing firstly a mono-protection of one of the primary amines with 
an orthogonal protecting group to the Boc-groups, i.e., the protecting group used should 
be stable in acidic media and cleavable under basic conditions. In 1998, Blagbrough and 
Geall227 described a one-pot procedure using trifluoroacetic acid as the orthogonal 
protection group (Scheme 3-5). Spermine was dissolved in MeOH and cooled to -78 °C. 
Ethyl trifluoroacetate was added slowly and the mixture was stirred for 1 h at -78 °C and 
for 75 minutes at 0 °C. Afterwards the remaining amines were all protected with Boc-
groups by adding Boc2O in excess. Finally, the trifluoroacetyl was removed by adding 
conc. NH3(aq) until the pH was higher than 10. The crude product was a very sticky 
yellow oil (34%). Mass spectra indicated the desired product contaminated with tetra-
Boc-spermine as side product. The tetra-Boc-spermine a side product should not react in 
the coupling reaction with palmitic acid due the lack of free amine groups, and as such 
the crude product was used in the following coupling reaction without further 
purification.   
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Scheme  3-5 Synthesis of protected spermine (Boc-SPM). 
 
Boc-SPM was coupled with palmitic acid by standard TBTU-mediated coupling and after 
the solvent was evaporated the product was purified first by silica column 
chromatography in DCM/MeOH (1:0 to 9:1) then by a second column in Hex/EtOAc 2:1 
to give a colourless oil (75%).  The final step was deprotection of Boc groups by HCl gas 
to produce C16-SPM in 97% yield as a white solid (Scheme 3-6). The structures were 
confirmed by 1H and 13C NMR, MS and IR.  
 
Scheme  3-6 Synthesis of C16-SPM. 
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3.3 Self-Assembly Studies  
3.3.1 Nile Red Assay  
The Nile Red assay was performed on all four C16-ligands, individually, in order to 
quantify their self-assembly and determine CAC values (Table 3-1).  
 
 
 
 
Table 3-1 CACs values for the synthesized binders from Nile red assay. 
 
The standard assay procedure is usually to dissolve (dilute) the binders with phosphate-
buffered saline (PBS) to the required concentrations – however, C16-ligands had solubility 
difficulties, therefore, they were dissolved (diluted) in Tris HCl (10 mM) in the presence 
of NaCl (150 mM). It is worth noting that different solubilities in different buffers can 
results as a consequence of interactions between (e. g.) the cationic self-assembled 
structures and the anionic phosphate ions present in PBS. Even still, C16-DAP (single 
charged) was largely insoluble in water/buffer – we reasoned that its +1 charge is 
insufficient to counterbalance the hydrophobicity, and it was not studied further.217 
Compound C16-DAPMA (+2) was well-soluble in water/buffer, C16-SPD (+2) was 
slightly less soluble, and C16-SPM (+3) was more difficult to dissolve and heating was 
required to encourage solubility under the assay conditions. We suggest that the +3 charge 
of C16-SPM hinders assembly, and hence solubility, the cation–cation repulsions on the 
micellar surface are not fully balanced by the hydrophobic driving force for assembly.228 
From the results shown in Table 3-1; C16-DAPMA had the lowest CAC (40.0 ± 1.0) and 
C16-SPM the highest. The latter also required heating to encourage solubility – this was 
in agreement with entropically-driven hydrophobic self-assembly. As ΔG = ΔH – TΔS, 
Compound   C16-DAPMA C16-SPD C16-SPM 
CAC (µM) 40.0 ± 1.0 51.0 ± 2.0 65.0 ± 20.0 
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increasing the temperature makes the ΔG value for assembly more favourable, as 
commonly seen for surfactant assembly.  
 
3.3.2 Dynamic Light Scattering (DLS)  
DLS analysis was performed on C16-ligands with the same methods described before. The 
micelle size for all three binders was around 6 nm and the nanoparticles were all positively 
charged (Table 3-2). Interestingly the zeta potential was lowest for C16-SPM in spite of 
the fact that the ligand itself can carry a higher charge. This is consistent with a view in 
which this compound struggles to assemble as a result of charge-charge repulsions at the 
micellar surface – hence leading to a looser, less well-packed assembly. 
Sample in 
Buffer 
Volume distribution 
(nm) 
PdI 
Zeta potential 
(mV) 
C16-DAPMA 6.2 ± 1.3 0.21 ± 0.01 +51.5 ± 3.1  
C16-SPD 6.6 ± 0.2 0.45 ± 0.09 +44.0 ± 1.7 
C16-SPM   6.2 ± 0.1  0.32 ± 0.09  +40.5 ± 0.9  
Table 3-2 DLS analysis of C16-ligands. 
 
In addition, DLS analysis was performed in the presence of heparin and also in the 
presence of DNA. The aim of these measurements was to monitor the binders’ behavior 
in terms of size and charge after binding to heparin or DNA. The results showed that the 
binders’ zeta potential decreased and the particle size has increased after binding to 
heparin and DNA (Tables 3-3 and 3-4).  
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Sample in Buffer + 
Heparin (27 µM) 
Volume distribution 
(nm) 
PdI 
Zeta potential 
(mV) 
C16-DAPMA 137 ± 4.0 0.87 ± 0.18  +38.1 ± 1.0 
C16-SPD 140 ± 50 0.24 ± 0.04 +9.8 ± 1.8 
C16-SPM  304 ± 55 0.52 ± 0.13 +21.3 ± 4.2 
Table 3-3 DLS analysis for the C16-ligands after binding to heparin showing an increase in the particles’ 
size and a decrease in zeta potential values. 
 
For C16-DAPMA zeta potential before binding to heparin (27 µM) was +51.5 mV (Table 
3-2), and after binding to heparin it was +38.1 mV (Table 3-3), showing that the binder 
is somewhat binding to heparin but not completely. In addition, the particle size increased 
after binding to heparin from 6.2 ± 1.3 nm to 137.0 ± 4.0 nm, indicating electrostatic 
binding and aggregation on the heparin surface which is supported by TEM images as 
will be discussed later. Notably, the decrease in zeta potential was much more significant 
for C16-SPD after binding heparin; from +44.0 mV (Table 3-2) to ca. +10 mV (Table 3-
3), suggesting that C16-SPD is binding better than C16-DAPMA. Once again, the size of 
C16-SPD particles increased after binding to heparin to 140.0 nm (Table 3-3). 
The third binder (C16-SPM) particle size increased very significantly. The excess charge 
was expected to be less than the other two binders, due to its three positive charges. 
However, the zeta potential value for this binder was relatively high; before binding to 
heparin it was around +40.5 mV and after binding it was +21.3 mV. Unexpectedly, for a 
binder that has three positive charges, which was expected to bind better to heparin – 
however, probably due to the repulsion between the positive charges within its micelles, 
the binder was poorly organized and did not bind completely (see further evidence 
below).  
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Moreover, DLS analysis for the three binders on binding to DNA once again showed that 
the size increased (Table 3-4) consistent with aggregation on binding between nanoscale 
cations and anions. Zeta potential values were negative and we think that these negative 
charges are associated with the present unbound DNA. After binding to DNA, C16-
DAPMA and C16-SPD zeta potential values were -24.6 mV and -21.1 mV respectively 
(Table 3-4). This shows that when these two compounds were presented to DNA, there 
was excess negative charge from DNA. However, the excess negative charge from DNA 
when it was mixed with C16-SPM was significantly less (-11.2 mV). This suggests that it 
is binding better than the other compounds. These values support the results of Mallard 
Blue (MalB) and Ethidium Bromide (EthBr) displacement assays (Table 3-5), which we 
will discuss in more detail later in this chapter.   
Sample in Buffer + 
DNA (4 µM) 
Volume distribution 
(nm) 
PdI 
Zeta potential 
(mV) 
C16-DAPMA 152.8 ± 42.5  0.2 ± 0.07  -24.6 ± 0.3 
C16-SPD   209.8 ± 11.4 0.16 ± 0.01   -21.1 ± 2.1 
C16-SPM   192.4 ± 44.8 0.11 ± 0.06    -11.2 ± 0.5 
Table 3-4 DLS analysis for the C16-ligands after binding to DNA showing an increase in the particles’ size 
and a major decrease in zeta potential values. 
 
3.3.3 TEM Images  
TEM images were recorded using standard methods for all C16-ligands. The images (Fig. 
3-2) were in agreement with similar reported studies on related systems171,221 the micelles 
remained remarkably intact, and were organised into hierarchical nanoscale arrays. We 
suggest these is a result of close packing interactions between the spherical micellar 
polycations and the linear polyanions. As such, we are confident that the micelles do 
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indeed remain intact on binding, and this supports our suggested methodological 
approach for computational modelling (described in more detail below) in which the pre-
formed micelle is brought into contact with a polyanion chain in order to determine the 
fundamental binding interactions. These images allow us to rule out a model in which 
micellar assembly is disrupted on addition of the polyanion, with individual surfactant 
coating the anionic surface and clearly shows the self-assemblies remain intact.  
 
Fig. 3-2 TEM image of self-assembled micellar nanostructures in the presence of heparin showing self-
assembled micellar nanostructures binding on its surface yielding a hierarchically organised self-assembled 
nanoscale aggregate, (a) C16-DAPMA, (b) C16-SPD and (c) C16-SPM. All scale bars are 100 nm. 
 
Although DLS analysis for C16-SPM proved that the particles’ size after binding to 
heparin has increased (Table 3-3), TEM images (Fig. 3-2) showed less aggregation of 
C16-SPM on the surface of heparin than the images of the other two binders (C16-DAPMA 
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and C16-SPD) which supports the idea of less binding due to the repulsive forces between 
the positive charges of the micelles. Certainly, the organization of interactions between 
self-assembled micelles and heparin appears to be much less effective.   
 
3.4 Binding Data 
3.4.1 Polyanions Binding  
C16-ligands were then tested for heparin and DNA binding to compare the binding affinity 
of such systems between different biological polyanions. The results are shown in Figures 
3-3, 3-4 and Table 3-5. It was found from Table 3-5 that the more highly charged C16-
SPM ligand appears to be the best DNA binder with a low CE50 value (4.3 ± 0.1). 
However, C16-SPD and C16-DAPMA were less effective with CE50 values of (6.0 ± 0.3) 
and (5.0 ± 0.1) respectively. Notably, although C16-DAPMA and C16-SPD have the same 
ligand charge (+2), C16-DAPMA is a slightly better DNA binder. 
 
Binder C16-DAPMA C16-SPD C16-SPM 
CE50 with DNA 5.0 ± 0.1 6.0 ± 0.3 4.3 ± 0.1 
CE50 with Heparin 0.70 ± 0.10 0.34 ± 0.05 0.49 ± 0.01 
Table 3-5 CE50 values of C16-ligands from Ethidium Bromide (EtBr) and MalB displacement assays. 
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Fig. 3-3 Charge ratio against normalized emission at 595 nm from EthBr assay for all the C16-ligands. 
 
Fig. 3-4 Charge ratio against normalized absorbance at 615 nm of C16-liganda in buffer, showing the effect 
of ligand variation on binding heparin. 
 
In contrast, although C16-DAPMA was the slightly better DNA binder and has the same 
surface charge as C16-SPD, the latter compound, for heparin binding, was by some margin 
the most charge-efficient binder as measured by its CE50 value. In addition to significantly 
outperforming C16-DAPMA, C16-SPD also performs better than more highly charged 
C16-SPM in terms of its CE50 value. Although these differences are relatively small, they 
were reproducible and outside of error range – as such, they provide a hint that DNA (Fig. 
3-5) and heparin (Fig. 3-6) behave differently in these assays when faced with these 
SAMul nanostructures as binders.   
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All of the reported EC50 values (Table 3-5) were below the CAC values of these 
compounds (Table 3-1). It is well-known that polyanions can assist self-assembly by 
limiting electrostatic repulsion on the cationic SAMul surface.229,230 As such, the 
competition assay suggests different polyanion preferences dependent on ligand choice. 
In order to ensure this was not an artefact of our choice of assays, we wanted to collect 
data using a different, non-competition assay method.   
 
Fig. 3-5 CE50 values showing binding selectivity of C16-ligands between different biological polyanions; 
when binding to DNA: C16-SPM > C16-DAPMA > C16-SPD. 
 
Fig. 3-6 CE50 values showing binding selectivity of C16-ligands between different biological polyanions; 
when binding to heparin: C16-SPD > C16-SPM > C16-DAPMA.  
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3.4.2 Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) experiments were conducted using a Nano ITC 
Technology (TA Instruments, New Castle, DE, USA). ITC is a technique used in 
quantitative studies of a wide variety of biomolecular interactions.231,232 It works by 
directly measuring the heat that is either released or absorbed during a biomolecular 
binding event. It is the only technique that uses a single experiment to simulate and 
determine all binding parameters.233,234 These experiments were performed by our 
collaborators, Sabrina Pricl and co-workers, in the Molecular Simulation Engineering 
(MOSE) Laboratory, Department of Engineering and Architectures (DEA), University of 
Trieste. We have summarized here the key findings. 
The thermodynamics of micellization of all SAMul molecules was investigated in Tris 
HCl/150 mM NaCl buffered solutions using a dilution methodology. The results showed 
that CACs (Table 3-6) were in very good agreement with those from the Nile Red assay 
(Table 3-1). In addition, treatment of the ITC data also provided thermodynamic 
parameters for self-assembly (ΔHmic, TΔSmic and ΔGmic) which supported the proposal 
that C16-SPM had the least favourable self-assembly, primarily as a result of the enthalpic 
term which reflects electronic repulsions between the more highly charged cationic 
surfaces.  
Compound   C16-DAPMA C16-SPD C16-SPM 
CAC (µM) 34 52 71 
ΔHmic/kJ mol-1 -10.81 -8.61 -8.41 
TΔSmic/kJ mol-1 14.72 15.86 15.29 
ΔGmic/kJ mol-1 -25.52 -24.47 -23.70 
Table 3-6 ITC-derived thermodynamic data of micellisation (CAC) at 298 K.  ΔGmic = ΔHmic - TΔSmic, 
where ΔGmic, ΔHmic, and TΔSmic are the free energy, enthalpy and entropy of micellisation, respectively.217  
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Furthermore, they went on to compare the thermodynamics of aggregation of those 
systems in the presence and absence of polyanion (Table 3-7).217 The aim of this step was 
to estimate the difference, which represents the effective binding between the SAMul 
nanostructures and the polyanion (i.e., ΔHbind = ΔHagg - ΔHmic). This simple approach 
allows extraction and quantification of the effective change in solution thermodynamics 
induced by the polyanion. Pleasingly, ITC data were in good agreement with the trends 
recorded from the dye displacement assays; those results were in terms of relative binding 
affinity.217 Specifically, for heparin ΔGbind was most favourable with C16-SPD while for 
DNA ΔGbind was most favourable with C16-SPM.  
 
Parameter Polyanion 
C16-DAPMA 
(+2) 
C16-SPD 
(+2) 
C16-SPM 
(+3) 
CAC 
(with polyanion)/µM 
DNA 
Heparin 
6.1 
13.6 
9.8 
7.2 
3.4 
9.8 
ΔHagg/kJ mol-1 
DNA 
Heparin 
-12.2 
-12.8 
-12.5 
-13.5 
-15.0 
-11.0 
TΔSagg/kJ mol-1 
DNA 
Heparin 
17.6 
15.0 
16.2 
15.9 
16.0 
17.6 
ΔGagg/kJ mol-1 
DNA 
Heparin 
-29.8 
-27.8 
-28.7 
-29.4 
-31.0 
-28.6 
ΔHbind/kJ mol-1 
DNA 
Heparin 
-1.4 
-1.9 
-3.9 
-4.9 
-6.6 
-2.6 
TΔSbind/kJ mol-1 
DNA 
Heparin 
2.9 
0.3 
0.4 
0.0 
0.7 
2.3 
ΔGbind/kJ mol-1 
DNA 
Heparin 
-4.3 
-2.2 
-4.2 
-4.9 
-7.3 
-4.9 
Table 3-7 Thermodynamic parameters of aggregation (ΔGagg, TΔSagg and ΔGagg) and critical aggregation 
concentrations (CACs) in the presence of polyanion as obtained from ITC measurements at 298 K in a 30 
µM solution of DNA or heparin at 150 mM NaCl. Binding parameters ΔHbind, TΔSbind, and ΔGbind are 
defined as the difference between parameters for aggregation in the presence and absence of polyanion, 
respectively (e.g., ΔHbind - ΔHagg  - ΔHmic).217  
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3.4.3 Multiscale Modelling of Self-Assembly Process 
To further understand self-assembly in 150 mM aqueous NaCl, Sabrina Pricl and co-
workers at the Molecular Simulation Engineering (MOSE) Laboratory, Department of 
Engineering and Architectures (DEA), University of Trieste performed multiscale 
modelling of the self-assembly and polyanion binding process. They employed a well-
validated multiscale molecular modelling procedure102,199,235-237 based on a mesoscopic 
model. Using the information obtained from atomistic molecular dynamics simulation 
(MD), they parameterized the dissipative particle dynamics (DPD)238,239 models that 
incorporate all essential physics/phenomena observed at the finer level. In outline: i) 
explicit solvent atomistic MD calculations240,241 were performed on C16-DAPMA, C16-
SPD, and C16-SPM and their assembly; ii) using the information from (i) coarse-grained 
DPD simulations were carried out at concentrations higher than the experimental CAC 
and the aggregates were characterized in terms of dimension and aggregation number; iii) 
the equilibrium configurations of the self-assembled systems obtained using (ii) were 
mapped back to the corresponding atomistic MD models, and then new atomistic MD 
simulations conducted to calculate binding energies between the micelle and polyanions. 
All atomistic simulations and data analysis were performed with the AMBER 14 suite of 
programs.242 
 In all cases, spherical micelles were obtained (Fig. 3-7 and 3-8). Interestingly, simulation 
indicated that the compounds formed micelles with different packing densities. The 
aggregation number (Nagg, Table 3-8) suggests that C16-DAPMA forms more tightly 
packed micelles than C16-SPD, which in turn is more densely packed than C16-SPM. As 
suggested from experimental results discussed above, the hydrophobic C16 chain does 
indeed have difficulties in bringing together the more highly charged SPM ligands. As a 
result of the decrease in Nagg for C16-SPM, the electrostatic potential (ψs) also decreases 
Chapter 3 – Effects of Modifying Ligands of Polycationic SAMul Nanostructures on Binding Affinities to 
Different Polyanions  
129 
(Table 3-8), leading to simulated zeta potentials (ζ) in good agreement with the DLS data 
(Table 3-2), with C16-DAPMA > C16-SPD > C16-SPM. 
Compound Nagg ψs (mV) ζ (mV) 
C16-DAPMA 16 ± 2 172.4 50.2 
C16-SPD 13 ± 1 153.3 45.1 
C16-SPM   10 ± 1  144.6 41.8 
Table 3-8 Main characteristics of the spherical SAMul micelles as obtained from multiscale molecular 
simulations. Nagg = aggregation number and ψs = surface electrostatic potential.217 
 
Fig. 3-7 Mesoscopic (left) and atomistic (right) simulations of C16-SPM self-assembling into micelles. The 
C16 hydrophobic portion is shown as steel blue spheres whereas the SPM residues are portrayed as navy 
blue spheres. In the left panel, water, ions and counter-ions are shown as light grey field; in the right panel, 
water molecules are depicted as transparent light blue spheres, some Na+ and Cl¯ ions are shown as purple 
and green spheres, respectively.217 
 
Fig. 3-8 Atomistic simulations of C16-SPM self-assembly process into spherical micelles. The panel 
represent the MD snapshots of the starting point (A, 0 ns), an intermediate state (B, 10 ns) and the final 
stage (C, 100 ns) of the assembly. The C16- hydrophobic portion is shown as steel blue spheres whereas the 
SPM residues are portrayed as navy blue spheres. Water molecules are depicted as transparent light blue 
spheres whereas some Na+ and Cl¯ ions are shown as purple and green spheres, respectively.217  
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As indicated by TEM imaging (Fig. 3-2), the micelles remained significantly intact on 
polyanion binding. Therefore, a modelling approach which contacts a single micelle with 
a single polyanion is a valid methodology for obtaining an insight into the fundamental 
forces responsible for the primary binding event. Clearly, further understanding of the 
hierarchical assembly and aggregation event is more complex, and was beyond the aim 
of this study, which was specifically focussed on the differences produced by different 
ligands at the initial polyanion binding interface.  
 
For DNA binding (Fig. 3-9, top), the C16-SPM micelles contain 10 SPM residues, 9 of 
which effectively contact DNA (a parameter they define as Neff), resulting in a charge-
normalized binding free energy (per-effective residue) ΔG* of -14.32 kJ mol-1. However, 
C16-SPD and C16-DAPMA nanostructures only used 7 and 8 (out of 13 and 16) SPM 
residues, respectively, to bind DNA. For C16-SPD and C16-DAPMA, the per-effective-
residue interactions were lower, with ΔG* values of -9.76 and -10.80 kJ mol-1, 
respectively. The simulated ΔG* values (Fig. 3-6) therefore follow the same trend as the 
experimental CE50 values and ITC data: C16-SPM > C16-DAPMA > C16-SPD.  
 
For heparin binding (Fig. 3-9, bottom), the micelles formed by C16-SPD engage 12 out 
of 13 available ligands in productive binding, resulting in charge normalized ΔG* of -
14.98 kJ mol-1. However, C16-DAPMA and C16-SPM assemblies only exploit 9/16 and 
6/10 ligands, giving ΔG* values of -8.65 and -11.97 kJ mol-1, respectively. The predicted 
ΔG* (Fig. 3-9) values are thus in agreement with the trend of experimental data: C16-SPD 
> C16-SPM > C16-DAPMA. To understand why polyanions appear to have different 
selectivities towards SAMul nanostructures, they then broke apart these overall ΔG* 
values into enthalpic (ΔH*) and entropic (-TΔS*) components (Fig. 3-10). C16-SPM 
emerges as the optimal DNA binder on enthalpic grounds (Fig. 3-10A), whereas C16-SPD 
emerges as the optimal system for heparin binding, in agreement with ITC (ΔGbind, Fig. 
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3-10C). This indicated that for DNA, each anionic charge behaves exactly the same as a 
result of the rigid repetitive nature of the polymer (Fig. 3-10B). However, for heparin this 
is not the case, and the more flexible, ‘adaptive’ structure adapts to optimize each 
individual interaction (Fig. 3-10D).  
 
 
 
Fig. 3-9 Equilibrated atomistic molecular dynamics (MD) simulation snapshots of SAMul micelles binding 
DNA (upper panel, orange) and heparin (lower panel, firebrick). In both panels, from left to right: C16-
DAPMA (light grey (C16) and plum (DAPMA)), C16-SPD (lime green (C16) and forest green (SPD)), and 
C16-SPM (steel blue (C16) and navy blue (SPM)). Hydrogen atoms, water molecules, ions and counter-ions 
are not shown for clarity.217  
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Fig. 3-10 Charge-normalized per-residue effective free energy of binding (ΔG*), and enthalpic (ΔH*) and 
entropic (TΔS*) components for: (A) each SAMul micelle ligand-type complexed with DNA; (B) DNA 
bases complexed with each of the SAMul micelles; (C) each SAMul micelle ligand-type complexed with 
heparin; (D) heparin sugars complexed with each of the SAMul micelles.217  
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3.5 Conclusions and Future Work  
 
This chapter reports the results of a highly collaborative project. We demonstrated that 
the ligand choice in SAMul nanostructures can have an effect in terms of binding 
selectivity. We found that electrostatic ion–ion binding depends on structural detail, not 
only charge density – as confirmed by the complementary experimental methods of 
competition binding assays and isothermal calorimetry. The results showed that, for the 
compounds studied here, C16-SPM is optimal for DNA binding, while C16-SPD is 
optimal for heparin binding. We observed that the polyanions (heparin/DNA) play a role 
in facilitating self-assembly and hence switching on the multivalent binding, and suggest 
that specifics of ligand-polyanion interactions help mediate subtle differences in this 
overall process. In addition, molecular simulation studies lead us to propose that the 
shape-persistence (DNA), or adaptability (heparin) of the polyanionic targets help 
mediate the selectivity of interaction with different ligands. These results provide an 
intriguing insight into molecular recognition processes at nanoscale surfaces and suggest 
that SAMul nanostructures may deliver some selectivity in addressing the challenging 
problem of the ‘polyanion world’. 
For future work, the hydrophobic part of the SAMul systems could be changed to 
investigate its effect on the performance of the ligands. In addition, different ligands could 
be used to explore more binding abilities which the different structures might induce.  
 
Chapter 4 – Alternative Approaches to Stabilizing Displays of Heparin-Binding Ligands 
134 
4 Alternative Approaches to Stabilizing Displays of Heparin-
Binding Ligands 
4.1 Introduction  
So far, all of the synthesized systems (binders) were linear and surfactant-like in nature, 
consisting of an amine (ligand) polar head group as the positively binding site and a fatty 
acid as the hydrophobic chain providing the driving force for assembly (in aqueous 
solution). We noted that in all cases, self-assembly was disrupted in highly competitive 
serum-containing conditions. In this stage of the work we therefore decided to investigate 
other options of scaffolds for displaying these ligands. Three different approaches were 
employed to broaden our understanding of the effects of such modifications on ligand 
display and heparin binding on the surface of different nanostructures.  
The first target compound (Binder-Dend) was a branched system containing multiple 
ligands, but which still had hydrophobic modification and hence the potential to self-
assemble. This was selected to compare the effect of head group size and charge density 
on self-assembly and heparin binding affinity. This system was designed with a branched 
dendron scaffold243 displaying three ligands, with a total of 6 positive charges on the 
periphery. In addition, because the head group was larger than in previous chapters, the 
hydrophobic tail in this compound was chosen to be longer and saturated (saturated-C22) 
to encourage self-assembly.  
For the second compound (Binder-NC) we decided to use gold nanoparticles to stabilize 
the nanostructured self-assembled system. Gold Nanoparticles (AuNPs) have attracted 
the attention of researchers due to their unique properties and multi-applications.69,70 
AuNPs are widely used as biomarkers and bio-delivery vehicles in medicine and 
pharmacy.71,72 The unique optical properties of AuNPs, their size dependent behaviour 
and their high chemical stability have made them ideal systems for exploring many 
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aspects including self-assembly, bio-labelling, catalysis, etc. These nanoparticles when 
stabilized or protected by a shell of thiolate ligands,70 display good stability toward 
aggregation and other modes of decay.73 Clearly they are well placed to display multiple 
ligands on their surfaces and can exhibit high stabilities in challenging conditions.  
Therefore, we decided to display our heparin-binding ligands on AuNP surfaces.  
The third compound (Binder-Poly) was designed using a polymer as a hydrophobic 
support able to display multiple heparin-binding ligands on its stable covalent backbone. 
Researchers in nanomedicine face limitations such as toxicity, instability and lack of 
disease site selectivity.244,245 However, in recent years they have often overcome these 
limitations by attaching drug molecules to biocompatible polymers. Such a combination 
of nanotechnology and polymer chemistry has been widely employed in the development 
of cancer therapeutics.246-248 Indeed, polymers therapeutics are increasingly entering into 
clinical use and can have wide-ranging potential use. Polymers are usually retained in the 
bloodstream because of the enhanced permeability and retention (EPR) effect.249 As such 
they have appropriate properties for potential application as heparin rescue agents. 
Therefore, Binder-Poly used a polymer scaffold primarily to study the differences 
between self-assembled systems and polymers in terms of heparin-binding ability.  
 
4.2 C22-Branched SAMul Nanostructure (Binder-Dend) 
We constructed this scaffold by initially synthesizing compound 2 (Scheme 4-1) using 
methods originally developed by Newkome and co-workers109,250 and refined by Cardona 
and Gawley.251 This scaffold was made by dissolving tris(hydroxymethyl)aminoethane 
in DMSO with KOH, then adding tert-butyl acrylate drop-wise. The reaction duration 
was 24 h and the compound needed purification by column chromatography (SiO2, 2:1 
v/v, EtOAc/Hexane, 0.05% v/v NH4OH) and was obtained in excellent 80% yield. The 
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reaction is a Michael addition of each of the three deprotonated alcohols into one 
equivalents of the conjugated alkene.   
 
Scheme  4-1 Synthesis of H2/Newkome-G1/O-tert-Butyl Branching (2). 
 
The next step consisted of protection of the amine group at the focal point using benzyl 
chloroformate to give compound 3 (Scheme 4-2). This step took 48 h and the crude 
product was purified by silica column chromatography to give pure product in a 83% 
yield. 1H NMR clearly demonstrated the presence of the benzene ring with integration in 
the correct ratio.   
 
Scheme  4-2 The protection of the amine group by benzyl chloroformate (3).  
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The following step was deprotection of the tert-butyl ester-groups243 from the surface of 
compound 3 to produce acid-functionalized compound 4 (Scheme 4-3). tert-Butyl ester-
deprotection was achieved by using formic acid as both reagent and solvent. No further 
purification was needed for this compound; completion of the reaction was evidenced by 
the loss of the NMR peak associated with the tert-butyl group at 1.4 ppm. 
 
Scheme  4-3 Deprotection of compound 3 Boc-groups to produce compound 4. 
  
Once compound 3 had been deprotected to produce compound 4, a coupling reaction 
between compound 1 (Chapter 2) and compound 4 was made using DCC as the coupling 
agent. This allowed us to attach the Boc-protected amine ligand to the surface of the 
dendron. The reaction lasted 3 days (Scheme 4-4). The product was separated using gel 
permeation chromatography (GPC) column (Bio-beads SX-1, 100% DCM). The yield 
was 50% and mass spectrometry confirmed the presence of the molecular ion and 
successful three-fold coupling.    
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Scheme  4-4 Coupling reaction between compound 1 and compound 4 to give compound 5. 
  
We next deprotected the Z group (Benzyloxy or benzyl ester) to give compound 6 with an 
amine group at the focal point in order to allow coupling with the hydrophobic fatty acid 
in a future step.  This was achieved using palladium on carbon (Pd/C, 10%) as the 
deprotecting agent. This reaction was performed under H2 for almost four days and was 
monitored by TLC (Scheme 4-5). The success of the deprotection was determined by the 
loss of the aromatic signal at 7.26 ppm. The relatively slow nature of this reaction is 
accounted for by the steric hindrance associated with the location of this benzyloxy 
carbonyl group at the focal point of a dendritic structure, limiting access to the 
heterogeneous catalyst surface.  
 
Scheme  4-5 Deprotection of compound 5 Z group to yield compound 6.  
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The free amine group at the focal point of the dendron was then coupled with a saturated 
fatty acid selected to have longer hydrocarbon chain than C18. The saturated fatty acid, 
docosanoic acid, also known as behenic acid, which consists of C22, was reacted with 
compound 6 to produce a product (compound 7) with a yield of 65% (Scheme 4-6). The 
reaction was performed using TBTU-mediated peptide coupling methods and the product 
was purified by gel permeation chromatography (GPC) column (Bio-beads SX-1, 100% 
DCM). The success of the reaction was demonstrated by mass spectrometric molecular 
ion at HRMS: Calc. [M+2H]2+ (C49H100N10O12) m/z = 510.3756 Found [M+2H]
2+ = 
510.3760.  
 
Scheme  4-6 TBTU coupling reaction between behenic acid and compound 6 to produce compound 7.  
 
The target compound was finally achieved by deprotection of the Boc groups from the 
three surface ligands. To achieve this, HCl gas was applied for 15-20 seconds to 
compound 7 and then left to stir for 3 hours (Scheme 4-7). The removal of the Boc group 
was demonstrated by the loss of CH3 protons at 1.4 ppm in the 
1H NMR. The final product 
was named Binder-Dend and has six positive charges on it three amine ligands. The 
identity of the product was demonstrated using all key analytical techniques including 
mass spectrometry (MS); HRMS: Calc. [M+H] 3+ (C56H119N10O7) m/z = 347.9749 x 3 
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Found [M+H]3+ = 347.9797 x 3 and Calc. [M+H] 2+ (C56H118N10O7) m/z = 521.4587 x 2 
Found [M+H] 2+ = 521.4598 x 2. 
 
Scheme  4-7 Deprotection of compound 7 Boc groups with HCl gas to produce Binder-Dend.  
 
 
4.2.1  Self-Assembly Studies 
4.2.1.1 Nile Red Assay  
A Nile Red assay was performed to obtain the CAC of Binder-Dend in the same way as 
described in previous chapters. The CAC for this compound was found to be 117 µM (± 
5) (Fig. 4-2). This value shows that self-assembly for such a compound was achieved 
only at higher concentration than the previously reported compounds. The three amine 
branches in this compound, holding a total of six positive surface charges, clearly lead to 
repulsive forces. These charge-chare repulsion forces make it hard for the hydrophobicity 
of the C22 to overcome them and hence for the compound to self-assemble at lower 
concentrations. However, the self-assembly does occur making this compound a potential 
nanoscale heparin binder.    
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Fig. 4-1 Critical aggregation concentration (CAC) for the branched system (Binder-Dend) showing the 
effect of the density of positive charges on self-assembly.  
 
 
4.2.1.2 Dynamic Light Scattering (DLS)  
DLS analysis of Binder-Dend was performed using the same conditions described in 
previous chapter for other binders. However, Binder-Dend assemblies were clearly much 
larger than the micelles formed by the previous binders. The diameter from the volume 
distribution was found to be around 138 ± 3 nm (Table 4-1 and Fig. 4-2). Using the 
intensity distribution gave a diameter of 162 ± 4 nm. This size enhancement is thought to 
be due to the three amine branches that hold the six positive charges, which give rise to 
the zeta potential value of 34.1 ± 3.6 mV (Table 4-1). We suggest that the larger repulsive 
forces between these positive charges led to separation distances in the outer shell of the 
assemblies. As such the single C22 chain in unable to coordinate assembly of the system 
into a well-defined micelle and instead much larger, less well-defined assemblies – very 
much larger than the molecular-scale dimensions – are being formed.   
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Compound 
Intensity 
distribution 
(nm) 
Volume 
distribution 
(nm) 
PdI 
Zeta 
potential 
(mV) 
Binder-Dend 162 ± 4  138 ± 3 0.20 ± 0.02 34.1 ± 3.6 
Table 4-1 DLS analysis of Binder-Dend in NaCl (150 mM) / Tris HCl (10 mM). 
 
 
Fig. 4-2 Size distribution by volume from DLS analysis, showing the average size of Binder-Dend around 
138 ± 3 nm. 
 
 
 
4.2.1.3 TEM Images  
TEM images of Binder-Dend were recorded as described in previous chapter. In the 
presence of heparin, Binder-Dend (Fig. 4-3) showed clear micellar aggregation on the 
surface of heparin. However, the morphology of these aggregates was less-defined than 
other compounds reported in previous chapters. These micelles are much smaller than 
would be suggested by the DLS data in Table 4-1 (≤ 10 nm).   
We suggest that the presence of polyanionic heparin helps these compounds to assemble 
into well-defined micelles because it helps neutralize the cationic surface charge of 
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Binder-Dend such that the C22 hydrophobic chain becomes capable of holding them in 
close proximity. Indeed, the ability of polyanions to assist the assembly of cationic 
micelles is a well-known phenomenon.229,230  
 
Fig. 4-3 TEM image of Binder-Dend dried from aqueous solution (200 µM); in the presence of heparin, 
showing large connected yet less-defined micellar assemblies on the surface of heparin, scale bar = 100 
nm.  
 
4.2.2 Heparin Binding  
4.2.2.1 Mallard Blue (MalB) Assay 
To gain more insight into the binding behavior of the branched system, we tested the 
ability of Binder-Dend to bind heparin using MalB assay as described in previous 
chapters. As expected from Nile Red assay and DLS data, this compound only self-
assembled at high concentrations. Therefore, the binding ability of this compound was 
rather weak in these competitive conditions. Binder-Dend’s CE50 values were calculated 
from the graph below (Fig. 4-4), and found to be 5.7 ± 0.2 (Table 4-2). This gave an EC50 
value of 103 µM which suggested that binding was only significantly occurring around 
the CAC (117 µM) for this compound, suggesting that self-assembly is pre-requisite for 
effective binding (a SAMul effect). The high value of the charge excess indicated weak 
binding. We suggest that the poor binding ability of this compound is due to the 
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difficulties of forming micelles with too many branches and positive charges that causes 
repulsion effects at micellar surface and gives rise to poorly defined assemblies with 
relatively low zeta potentials. Unfortunately, due to these unsatisfying results, compared 
to the previous compounds, we decided not to test this compound in more competitive 
conditions, such as human serum. 
Binder-Dend  
(in buffer)  
CE50 5.7 ± 0.2 
EC50 (μM) 103 ± 1.1 
Dose (mg) / 100 IU 3.7 ± 0.04 
Table 4-2 Calculated CE50, EC50 and required dose (in buffer) of Binder-Dend, showing the effect of the 
branched amine groups and positive charges density on the binding abilities. 
 
 
Fig. 4-4 Charge ratio against normalized absorbance at 615 nm in buffer for Binder-Dend. 
 
We therefore decided to investigate other methods of displaying multiple ligands on a 
nanoscale surface to determine how alternative strategies performed in this heparin 
binding application.   
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4.3 Thiol Stabilized Gold Nanocomposites; AuNCs-Thiol-DAPMA 
(Binder-NC) 
 
The search for therapeutic inorganic nanoparticles is growing and becoming an important 
area of research in the field of nanomedicine.252-255 For the past couple of decades, gold 
nanoparticles (AuNPs) have been one of the most studied nanoparticle types for 
biomedical applications.256-260 Due to their well-defined nanostructures and unique 
optical properties, AuNPs  have been used as sensors for signaling molecular recognition 
events such as heparin/protamine aggregation/de-aggregation.261-263 In addition, upon 
negative/positive binding of heparin and AuNPs that changes color, in solution, from red 
to blue has provided a simple and visual approach detecting heparin. Moreover, in cases 
where gold nanoparticles aggregate, they can be referred to as gold nanocomposites 
(AuNCs).261,263-265  
In this work, gold nanoparticles were the original target but their aggregation meant that 
we obtained gold nanocomposites. AuNCs were stabilized by the thiol group in the new 
target nanostructure (Binder-NC) driving the self-assembly event in solution. The 
hydrophilic part of the target nanoparticles was the same amine used in the previous 
compounds with its two positive charges, constituting the binding site to heparin (Fig. 4-
5). The stability of metal nanocomposites based on nanoparticles and their ability to 
display multiple ligands were the main reasons that drew our attention to use them. In 
addition, the simple agglomeration of these thiolate functionalized AuNCs should allow 
them to drive the self-assembly in solution, in a controlled way, to secure the heparin 
binding.   
 
 
Fig. 4-5 AuNCs-Thiol-DAPMA (Binder-NC).  
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4.3.1 Synthesis of AuNCs-Thiol-DAPMA  
 
The target nanoparticles were produced by coupling protected N,N-di-(3-aminopropyl)-
N-methylamine (Boc-DAPMA) or compound 1 (Scheme. 2-1), with thioglycolic acid. 
The coupling was performed using a standard TBTU coupling reaction as described 
previously. The product was purified by GPC column (Bio-beads, 100% DCM) and was 
obtained in 81% yield (Scheme 4-8).  
 
Scheme  4-8 TBTU coupling of compound 1 and thioglycolic acid to produce compound 8. 
 
The Boc-protected coupled compound (8) was then introduced to gold nanocomposites 
(AuNCs) (Scheme 4-9) in a one pot reaction.266,267 The AuNCs were synthesized by 
reducing tetrachloroauric acid (HAuCl4), which has a yellow colour (Fig. 4-6a) using 
sodium citrate, the colour changed to dark grey/black. The mixture was boiled to 95-100 
ºC for an hour and on prolonged heating the colour changed from black to dark red (ruby) 
(Fig. 4-6b) indicating the full reduction of the gold nanoparticles (as AuNPs, at around 
30 nm in diameter, tend to absorb light in blue-green region, hence reflect it at around 
700 nm; the region of red light).268,269 In this reaction, gold nanoparticles aggregate to 
form nanocomposites. Synthesis of Au-thiol-DAPMA (Binder-NC) was then done by 
adding compound 8 to the citrate-stabilized AuNCs in the reaction flask. The colour 
changed to black (Fig. 4-6c) indicating that the AuNCs had bonded to compound 8 to 
produce Au-Thiol-DAPMA-Boc (Au-8) in 91% yield. The mixture was purified using a 
dialysis membrane 30 (MWCO-12, 1400 Dalton) in ultra-pure water overnight to remove 
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any excess ligand and citrate (Fig. 4-7). The water was changed (2-3 times/day) and 
monitored by UV-Vis spectroscopy. The dialysis was stopped when the UV-Vis spectra 
showed no trace of ligand around 200-300 nm, which meant that the compound was 
totally purified. The Boc group was then removed by treatment with HCl gas (Scheme 4-
9) to produce Binder-NC in 92% yield.  
 
Fig. 4-6 Au-8 synthesis; (a) HAuCl4 in water has a yellow colour, (b) adding sodium citrate changed the 
colour to red due to reduction to citrate-stabilized AuNCs and (c) adding compound 8 to the reaction flask 
changed the colour to black as ligand bound to the NCs surface. 
 
 
Fig. 4-7 Dialysis of Au-8 in ultrapure water overnight. 
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Scheme  4-9 Synthesis of Binder-NC. 
 
The removal of the Boc group was successful, as 1H NMR spectra showed the loss of the 
resonance at 1.4 ppm.  Furthermore, UV-Vis measurements before and after removal of 
the Boc group indicated no major changes in lineshape (around 700 nm) indicating that 
AuNPs were not significantly affected by the deprotection reaction (Fig. 4-8). However, 
in these UV-Vis spectra a considerable amount of light scattering was observed – 
indicated by absorbance across the wavelength range. This led us to conclude that the 
AuNPs may be aggregating to give AuNCs, with the degree of aggregation increasing 
after Boc removal. 
 
Fig. 4-8 UV.Vis spectra before (red line) and after (blue line) removing the Boc group, showing a 
considerable amount of light scattering in the absorbance band for AuNPs (maxAbs ≈ 700 nm), in water, 
indicating that AuNPs aggregated to give AuNCs. The aggregation was higher after Boc removal.   
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4.3.2 Characterization and Analysis 
4.3.2.1 Energy Dispersive X-Ray (EDX) Analysis 
Energy dispersive X-Ray (EDX)270 composition analysis can be used to identify the 
composition of a compound. The method is based on focusing an X-ray beam on a dry 
sample of the compound (specimen). The scattered electron beam displays the 
compositional contrast resulting from different atomic number elements as seen in the 
scanning electron microscopy (SEM) image (Fig. 4-9).  
 
Fig. 4-9 SEM images of Binder-NC showing gold nanoparticles charging after exposing to the X-ray beam, 
scale bar = 20 µm.  
 
The software associates the energy level of the X-rays with the elements and shell levels 
that generated them, giving Table 4-3 and Fig. 4-10 which show the main elements in the 
material under analysis. EDX analysis of Binder-NC showed the presence of all the main 
components which would be expected; Au, S, O, N and C (Table 4-3 and Fig. 4-10). As 
expected the dominant contribution from the metallic gold core, but the ligand shell, 
containing C/N/O/S could also be detected.  
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Table 4-3 EDX analysis of Binder-NC showing all its main components; Au, S, O, N and C. (Al is one of 
the EDX pin stub components). 
 
 
Fig. 4-10 EDX analysis of Binder-NC showing all its main components; Au, S, O, N and C. The Y-axis 
shows the counts (number of X-rays received and processed by the detector) and the X-axis shows the 
energy level of those counts. 
 
Using the N:Au ratio this allowed us to estimate the ratio of ligand:gold. The ligand 
contains 3 N atoms, given the atom ratio found by EDX of N:Au is 16.17:11.07 = 1.46. 
If we assume that there was one ligand per gold atom this value should be 3. Therefore, 
we can estimate a molecular formula of Au(ligand)1.46/3 = Au(ligand)0.49 = Au2.05 Ligand. 
However, this should only be considered an estimate of the composition. This is a 
 
Element 
Line 
Net 
Counts 
Int. 
Cps/nA 
Int. 
Error 
Atom % Compnd 
% 
Norm. 
Compnd% 
C K* 60687 133.2730 +/-  1.2034 29.129 9.915 9.915 
N K* 18988 41.6990 +/-  1.5614 16.167 6.417 6.417 
O K* 102193 224.4232 +/-  1.6558 33.719 15.288 15.288 
Na K* 72354 158.8946 +/-  1.0695 9.220 6.006 6.006 
Al K* 1548 3.3995 +/-  0.4480 0.206 0.158 0.158 
S K* 2090 4.5898 +/-  0.7818 0.493 0.448 0.448 
S L* 7522 16.5189 +/-  0.5227 --- --- --- 
Au M* 160112 351.6175 +/-  2.2356 11.066 61.769 61.769 
Total    100.000 100.000 100.000 
* -- Standard 
Unavailable        
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relatively small amount of gold and suggest there may be some free ligand presence in 
the overall system.  
 
4.3.2.2 Dynamic Light Scattering (DLS)  
Binder-NC was then characterized in terms of size and charge by dynamic light scattering 
(DLS). In addition, the precursor, protected AuNCs-Thiol-DAPMA-Boc was also 
characterized to see the effect of removing the Boc group on the size and/or charge. The 
samples were prepared as described previously – however, the solvent was methanol. 
Before removing the Boc group (deprotection), the apparent compound size was bigger, 
around 300 nm, then it decreased after deprotection to 70 ± 5 nm (Table 4-4). These 
relatively large diameters are suggestive of aggregation between smaller nanoparticles 
(see TEM below). Indeed, we can better consider these systems to be nanocomposites. 
We suspect that most nanoparticle aggregation was probably introduced during the Boc 
deprotection step, although even with the protected ligand in place, some scattering was 
seen, so it is likely that replacement of citrate also led to some aggregation. Nonetheless, 
zeta potential values were negative before removing the protecting group (-7 ± 2.5 mV), 
but after removing Boc group the resulting nanocomposite gained the required positive 
charges (+22 ± 0.5 mV), which would allow it to bind electrostatically to heparin. 
Table 4-4 DLS Analysis of Binder-NC (AuNCs-S-DAPMA) before and after removing the Boc group, 
showing the decrees of size and change of charge. 
  
Compound 
(in methanol) 
Intensity 
distribution 
(nm) 
Volume 
distribution 
(nm) 
PdI 
Zeta 
potential 
(mV) 
AuNCs-S-DAPMA-
Boc 
275 ± 53 244 ± 36 0.38 ± 0.04 -7.0 ± 2.5 
AuNCs-S-DAPMA 
(Deprotectd) 
72 ± 5 70 ± 5  0.63 ± 0.07 +22.0 ± 0.5 
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4.3.2.3 TEM Images 
 
Transmission Electron Microscopy (TEM) images were recorded using standard 
methods. The images showed that Binder-NC, does indeed contain spherical gold 
nanoparticles (AuNPs) although these are aggregated into an overall nanocomposite 
(AuNCs). These TEM images (Fig. 4-11) make clear that gold nanoparticles are present 
in the sample and that they have roughly spherical shapes. We used ImageJ to work out 
the size distribution of these particles and this is plotted in Fig. 4-12 The average AuNP 
diameter was 22.5 ± 2.5 nm. The larger size observed by DLS that combines with TEM 
does suggest that some aggregation of Binder-NC takes place. As such, we have formed 
ligand-modified nanoparticles which aggregated into nanocomposite form. 
 
 
Fig. 4-11 TEM images of Binder-NC after dialysis showing spherical particles and a degree of aggregation, 
scale bar = 200 nm (left) and 100 nm (right).  
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Fig. 4-12 Particle size distribution of Binder-NC within the overall nanocomposite; the red bar shows the 
dominating size between 20-25 nm. 
 
4.3.3  Heparin Binding  
4.3.3.1 MalB Assay in Buffer 
The heparin binding ability of Binder-NC was then determined using the MalB assay. 
Usually this assay is performed in room temperature, however, due to solubility 
difficulties we faced with Binder-NC, presumably associated with the aggregation 
observed by DLS and TEM, and made worse in buffer we had to perform the assay at 
elevated temperatures. The binder precipitated at room temperature (Fig. 13.a), but on 
increasing temperature, it completely dissolved in the buffer (Fig. 13.b). The assay was 
performed under heating; being kept in a water bath at 50-55 ºC during the titration (Fig. 
14). In addition, the UV-Vis instrument had a thermoelectrically temperature-controlled 
cell positioner to maintain the same conditions during the assay.   
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Fig. 4-13 Binder-NC stock solution; precipitating at room temperature (a) and completely dissolving after 
heating to 50-55 ºC (b).  
  
 
Fig. 4-14 Binder-NC stock solution; kept in water bath at 50 - 55 ºC during MalB assay titration process. 
 
On binding heparin, the MalB peak dropped in intensity and after starting to add Binder-
NC solution, the peak increased showing a partial replacement of the dye (Fig. 4-15). 
This demonstrated that Binder-NC can bind heparin but not fully replacing the MalB 
dye, under the titration conditions.   
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Fig. 4-15 UV-Vis spectra showing Binder-NC incomplete replacement of MalB. 
 
Table 4-5 presents the calculated values, from Fig. 4-16, for Binder-NC; CE50 was 3.8 ± 
0.1 and the EC50 was 203 ± 7 µM, which are considered high values in terms of heparin 
binding, comparing to the current commercial heparin binder; protamine. As reported, 
protamine replacement assay results were; CE50 = 0.52 and EC50 = 2.34 µM.
173 we suggest 
that the low observed solubility of this nanocomposite may contribute to the relatively 
low binding. It is also possible that the optical properties of the AuNPs themselves may 
be disrupting this assay somewhat.     
 
Fig. 4-16 Charge ratio against normalized absorbance at 615 nm in buffer for Binder-NC from MalB assay 
at 50-55 °C.  
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Binder-NC  
in buffer (50-55 ºC) 
CE50 3.8 ± 0.1  
EC50 (μM) 203 ± 7 
Dose (mg) / 100 IU 4.1 ± 0.2 
Table 4-5 Calculated CE50, EC50 and required dose of Binder-NC at 50-55 ºC. 
 
In addition, we performed the MalB assay at higher temperature than 55 °C using a 
heating gun (> 80 °C). The assay under these conditions gave better binding results (Fig. 
4-17); CE50 was 2.07 ± 0.03 and the EC50 was 112 ± 4 μM (Table. 4-6). We suggest that 
the elevated temperatures improved the solubility hence the binding ability. Clearly, 
however, such systems would be limited with regards to their use in biologically relevant 
conditions. As such we turned to other strategies for multivalent ligand display.  
 
Fig. 4-17 Charge ratio against normalized absorbance at 615 nm in buffer for Binder-NC from MalB assay 
at > 80 °C. 
Binder-NC  
in buffer (> 80 ºC) 
CE50 2.07 ± 0.03  
EC50 (μM) 112 ± 4 
Dose (mg) / 100 IU 2.23 ± 0.02 
 Table 4-6 Calculated CE50, EC50 and required dose of Binder-NC at > 80 ºC; improvement of the binding 
ability due to enhancement in the solubility after heating.  
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4.4 Polymer Scaffold (Binder-Poly) 
The importance of drug polymer conjugates, which was outlined in this chapter’s 
introduction (4-1), lead us to aim to replace the focal group (hydrophobic tail) with a 
polymer. As a simple first approach, we decided to modify poly(acrylic acid) with the 
ligands in order to produce Binder-Poly (Fig. 4-18).  
 
Fig. 4-18 Acrylic acid and poly(acrylic acid). 
 
 
Fig. 4-19 DAPMA-Poly(acrylic acid) (Binder-Poly). 
 
4.4.1 Synthesis of Polymer Stabilized DAPMA   
Boc-DAPMA (compound 1) was reacted with poly(acrylic acid), average MW ≈ 1800 
g/mol, n = 25 units, in 1:1 ratio of reactive groups to produce Boc-DAPMA-Poly(acrylic 
acid). The reaction was done using TBTU as the coupling reagent (Scheme 4-10) to yield 
Boc-Binder-Poly (54%).     
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Scheme  4-10 TBTU coupling of compound 1 and poly(acrylic acid), n = 25 units.. 
 
This product was then deprotected to produce DAPMA-Poly(acrylic acid) or Binder-
Poly. The deprotection was performed using HCl gas (Scheme 4-11) to give the desired 
product in 86% yield. Binder-Poly was characterized by MS – however we could not 
detect the polymer. In addition, 1H NMR spectra showed only some of the ligands 
protons, and most importantly demonstrated the loss of Boc group after the deprotection 
reaction at 1.4 ppm (Fig. 4-20). As such we went on to characterize Binder-Poly using 
CHN elemental analysis as described in more detail below. In this way, the actual average 
molar mass was predicted as 2268.22, calculated from the proposed chemical formula of 
C103H170N12O46. 
 
Scheme  4-11 Removal of Boc group by HCl gas to produce Binder-Poly.  
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Fig. 4-20 NMR spectra of Binder-Poly before Boc deprotection (blue line) and after the deprotection (red 
line) showing no resonance at 1.4 ppm.  
 
4.4.2 Characterization and Analysis 
4.4.2.1 CHN Elemental Analysis 
 In order to analyse the synthesized compound (Binder-Poly) in terms of C, H, and N 
composition we performed CHN Elemental Analysis. This was performed to calculate 
each element percentage then the software formed the formula that matched the 
percentage of each element. The instrument was an Exeter Analytical CE-440 analyzer, 
used in conjunction with a Sartorius SE2 analytical balance. Samples (~2 mg) were 
weighed into tin capsules before being sealed and placed in the analyzer. The samples 
were then burnt in pure oxygen, in a 975 °C furnace, before passing through a cooler 
furnace containing Cu to remove any traces of O2 and nitrogen oxides. The combustion 
products then pass onto the detectors where levels of C, H ad N are calculated (Table 4-
7).  
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The formula of C103H170N12O46, gives the suggested structure shown below (Fig. 4-21). 
This suggested average structure contained four DAPMAs loaded onto the polymer 
backbone, and would carry 8 positive charges in total after the deprotection reaction. 
 
 
 
 
 
 
 
 
 
Table 4-7 Elemental Composition of C103H178N12O46; mass composition by element (g/mol), molecular 
weight: 2312.31g/mol. 
 
 
 
Fig. 4-21 Suggested structure of Binder-Poly, generated by ChemDraw software, of the calculated mass 
from CHN elemental analysis; contained four DAPMA groups carrying 8 positive charges.  
 
4.4.2.2 Dynamic Light Scattering (DLS) 
DLS was then performed to measure the size and charge of Binder-Poly as described 
before. Table 4-8 showed that the size, by volume distribution, was 97 ± 8 nm. This is 
significantly larger than would be expected for a single polymer chain, and is suggestive 
of aggregation in the solution phase – acrylic acid polymers are well-known to have 
Symbol Element Atomic weight Atoms Mass percent 
C Carbon 12.0107 103 53.4962 % 
H Hydrogen  1.00794 170 7.4097 % 
N Nitrogen  14.0067 12 7.2683 % 
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aggregation potential in the presence of polycations.271 The zeta potential was recorded 
as +25.0 ± 3.0 mV, confirming the required positive charges we aimed to gain after the 
deprotection reaction.  
 
Compound 
Intensity 
distribution 
(nm) 
Volume 
distribution 
(nm) 
PdI 
Zeta potential 
(mV) 
Binder-Poly 148 ± 3 97 ± 8 0.24 ± 0.01 +25 ± 3 
Table 4-8 DLS analysis of Binder-Poly. 
 
 
4.4.2.3 TEM Images 
TEM images were recorded for Binder-Poly as described above. The images (Fig. 4-22b-
d) showed very defined spherical aggregations after binding to heparin – however, clearly 
this is very different to the micellar arrangements seen in previous systems. Once again 
it is clear that the presence of heparin induces hierarchical assembly of the polycationic 
system. We suggest that individual polymers can be seen on the surface of these 
aggregates (Fig. 4-22d) – the estimated diameter of the polymer used should be ca. 5 nm.     
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Fig. 4-22 TEM images of Binder-Poly before binding to heparin (a) showing dispersed nanostructures and 
after binding to heparin (b), (c) and (d) the nanostructures were aggregating in an organized spherical 
shapes on the surface of heparin, scale bar = 100, 200 and 50 respectively. 
 
 
4.4.3 Heparin Binding 
4.4.3.1 MalB Assay in Buffer   
To test this compound’s (Binder-Poly) ability to bind heparin we performed the MalB 
assay in buffer as described previously. Surprisingly, for a large compound with relatively 
low loading of ligand, the binding was relatively good (Fig. 4-23). In addition, it was very 
easy to dissolve in solution. The binding data from Table 4-9 showed that CE50 was 2.00 
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± 0.03, indicating less charge excess, i.e. better binding than either of the two other 
binders reported in this chapter (Binder-Dend and Binder-NC). As such, we decided to 
test its binding to heparin in more biologically relevant competitive conditions, such as 
human serum.   
 
Fig. 4-23 Charge ratio against normalized absorbance at 615 nm in buffer for Binder-Poly. 
 
 
 
 
 
Table 4-9 Calculated CE50, EC50 and required dose of Binder-Poly in buffer.  
Binder-Poly 
 in Buffer  
CE50 2.0 ± 0.03  
EC50 (μM) 27 ± 0.4 
Dose (mg) / 100 IU 2.1 ± 0.04 
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4.4.3.2 MalB Assay in Human Serum  
The binding ability of Binder-Poly was then tested in human serum using the MalB assay 
as described previously. Although the compound showed relatively stable binding to 
heparin (Fig. 4-24), from Table 4-10, the CE50 value was higher than desirable (4.0 ± 0.5).  
 
Fig. 4-24 Charge ratio against normalized absorbance at 615 nm in human serum for Binder-Poly. 
 
Binder-Poly 
 in Human Serum  
CE50 4.0 ± 0.5  
EC50 (μM) 57 ± 6 
Dose (mg) / 100 IU 4.3 ± 0.4 
Table 4-10 Calculated CE50, EC50 and required dose of Binder-Poly in human serum. 
 
Clearly the presence of serum quite significantly disrupts the binding process – we 
suggest there may be non-specific binding processes between serum proteins and the 
poly(acrylic acid) backbone.272   
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4.5 Conclusions and Future Work  
 
Three major modifications to the hydrophobic/hydrophilic units were introduced to the 
synthesized systems in order to study the effect of such approaches on heparin binding. 
The first modification was branched system with more charge dense hydrophilic groups 
and a longer hydrophobic chain (saturated-C22) to produce Binder-Dend. The results 
showed that binding to heparin (in buffer) for Binder-Dend was affected due to the poor 
self-assembly of this system, as measured by the Nile Red assay. Although it had more 
positive charges (6 +ve) than the previously reported binders, this did not improve the 
binding as they were not being organized effectively on the nanoscale. For future work, 
this compound could be enhanced by using more than one hydrophobic group in order to 
improve the self-assembly or by increasing the dendritic generation so the number of 
ligands is even greater, to enhance multivalent binding even in the absence of self-
assembly. 
The second modification was to display the ligands on a gold nanoparticle (AuNPs) core. 
In all cases aggregation of nanoparticles to give nanocomposites was observed – as 
characterized by UV-Vis, TEM and DLS. The aim of this step was to stabilize the 
compound (Binder-NC) to obtain better heparin binding. Unfortunately, Binder-NC had 
solubility difficulties in buffer as the nanoparticles were aggregated into a nanocomposite, 
therefore, performing the binding assay was only possible at elevated temperatures (50-
55 °C and >80 °C). Nevertheless, the assay results showed that replacement of MalB was 
incomplete, we suggest that might be due to AuNCs interfering with the UV-Vis 
absorbance around Absmax ≈ 700 nm as well as the lower solubility. We decided then not 
to proceed with performing more tests on this system. For future work, improving binding 
to heparin could be achieved if this system was introduced to a different thiol group 
(longer); with a spacer group to help optimize ligand display, or more positive charges on 
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the hydrophilic group (binding site). Importantly, in future work, nanoparticles 
aggregation should be avoided, possibly by using a different, non-citrate, method of 
synthesis.    
The third modification was made by using a polymer to display the ligands. TEM images 
showed a highly defined spherical aggregation of Binder-Poly when binding to heparin. 
The binding assay data from the MalB assay showed a low CE50 (2.0 ± 0.03) which 
indicated good heparin binding. Therefore, we proceeded to perform the assay in more 
competitive conditions by using human serum as the medium of the binding process. The 
result was somewhat promising (CE50 = 4.2 ± 0.5) as Binder-Poly showed rather more 
stable binding than the other two systems reported in this chapter. For future work, this 
compound could be synthesized by using different ratios of the reactants other than the 
one that was used in this work; polymer:DAPMA (1:1). Changing the ratio by increasing 
the amount of DAPMA in the reaction would load more ligand onto the polymer, gaining 
more positive charges along the polymer chain to obtain better heparin binding. 
Furthermore, different polymer backbones or capping the unpacked sites could be tested 
to try and avoid any non-specific interactions with serum proteins which may be 
disrupting the binding process in these highly competitive conditions. For example, 
ethylene glycol (PEG) units are known to be relatively non-interactive in human serum.273 
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5 Multicomponent SAMul Systems for Multifunctional 
Binding 
5.1 Introduction 
The function of a simple micellar system could have limitations of performance. Mixing 
two or more surfactants has therefore been pursued for over 60 years.274-278 These studies 
showed that the surfactants either form mixed micelles or aggregate into separate 
structures; depending on their chemical nature.279,280 Structurally similar surfactants tend 
to aggregate into the same supramolecular structure, whereas chemically different 
surfactants, for example fluorinated and non- fluorinated surfactants, show de-mixing into 
separate micelles.281,282 Synthetic cancer vaccines, have been found to yield a much 
higher antibody response if they had multiple components, covalently attached in some 
cases283,284 but also co-assembled in other cases.285 The dynamic nature of supramolecular 
chemistry can therefore be employed to harness enhanced performance and could turn an 
existing set of amphiphiles into new systems with unique properties. Co-assembly, the 
assembly of more than one amphiphile into a single supramolecular structure (Fig. 5-1), 
is therefore a powerful tool that can potentially improve existing properties and even 
incorporate new functionalities. 
 
Fig. 5-1 Schematic representation of the aggregation of two amphiphilic components into a single mixed 
assembly.  
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A simple example of co-assembly benefits is observed when alkyl sulfate surfactants of 
different chain lengths are mixed, both amphiphiles assemble into the same micelle but 
the critical micelle concentration is lower than expected from a linear extrapolation of 
critical micelle concentration (CMC = CAC) values versus mole fraction (Fig. 5-2).286 
This shows that mixed systems have a stronger driving force to aggregate – an important 
observation for the development of stable self-assembling systems. In more detail, the 
curves for the CMC versus mole fraction were quite similar when the difference in the 
chain lengths was small but dropped significantly when a small amount of longer chain 
surfactant was added to a solution of shorter chain surfactant.286 This behaviour was 
credited to the ineffective penetration of longer surfactant molecules into short-surfactant 
micelles and lack of mixing. 
 
Fig. 5-2 Typical CMC (CAC) versus mol fraction plot of a binary surfactant system. Solid line indicates 
experimental data, whereas dotted line shows linear extrapolation.286 
 
In addition to the fundamental discoveries, which tend to influence aggregation strength, 
there have been examples of how the co-assembling nature of similar amphiphiles can be 
used to incorporate additional functionality. Stupp and co-workers have demonstrated 
beautiful co-assembly of peptide-amphiphilic molecules into nanofibers,287 as well as co-
assembly of opposite peptide polarities into nanofibers where the complementary termini 
result in the same β-sheet arrangement as the single-component system whilst exhibiting 
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higher thermal stability compared to the co-assembly of peptide amphiphiles with 
identical polarity (Fig. 5-3).288 This strategy is considered to be very powerful as some 
peptide amphiphiles are epitopes, which have the ability to mimic extracellular matrix 
proteins hence enhancingcell adhesion or differentiation.289 By mixing different systems 
into a co-assembly it is possible to harness their individual advantages.  
 
 
Fig. 5-3 Co-assembly of peptide-amphiphilic molecules with identical polarity (top) and co-assembly of 
opposite peptide polarities (bottom) into nanofibers. Investigated by circular dichroism (CD); the co-
assembly of opposite peptide polarities exhibited higher thermal stability compared to the co-assembly of 
peptide amphiphiles with identical polarity, Stupp and co-workers, 2005.288 
 
PEG lipids are an excellent choice as a second non-ionic amphiphile due to their flexible, 
non-immunogenic yet hydrophilic nature that sterically stabilises all kinds of colloids and 
reduces the adsorption to blood components290,291 (see section 5.2). Therefore, we have 
chosen them to be inserted to our SAMul nanostructures (Fig. 5-6), employing the co-
assembly approach to study its effect on self-assembly and hence binding abilities and 
selectivities towards polyanionic targets.   
 
5.2 PEGylation and the ‘Stealth Effect’ 
The search for more stable biological systems has led to several approaches on how to 
protect such systems from being excreted from the blood stream and minimise 
interactions with non-target sites to maximise efficacy and create a means of regulating 
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circulation time.292 One of the strategies to create biocompatibility is to encapsulate active 
targets into poly(ethylene glycol)-based (PEG-based) micelles, which bury the actives in 
their interiors,293 for example, quantum dots were encapsulated in PEG-stabilised 
phospholipid micelles and used for in vivo imaging.294 The non-immunogenic and 
antigenic PEG components essentially mask the highly bio-incompatible nanocrystals 
and protect them from rapid opsonisation whilst giving them sufficient stability for the 
imaging to be achieved.295  
One of the major reasons that drug delivery systems have now entered the mainstream is 
that the initial problem of rapid removal from the blood stream has been solved, inter 
alia, by ‘stealth’ systems.296 In addition to simple stabilisation, superior properties for a 
variety of applications have been demonstrated. Hanes and co-workers reported297,298 
several examples of block-co-polymeric nanoparticles with low-molecular-weight PEG 
as the hydrophilic part that facilitates mucus transport for application in gene delivery. 
They also showed that the PEG chain length can have an effect on adhesive interactions 
with mucus components limiting them, and enabling delivery.299 
PEG ‘stealth systems’ offer a distinctive advantage of increasing stability in biological 
systems as well as minimizing off-target interactions that maximise efficacy. As such, the 
‘stealth system’ concept can be transferred to self-assembled multivalent systems with 
potential nanomedical applications. This has been demonstrated by Toft et al., who 
reported300 a multicomponent system consisting of membrane-active peptide amphiphiles 
(PAs) and pegylated peptide amphiphiles designed as a breast cancer antitumor agent. 
The addition of the pegylated amphiphile delayed the degradation time 8-fold without 
increasing the cytotoxicity (Fig. 5-4),300 preventing the unwanted breakdown of the 
medicinally-active assembly. 
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Fig. 5-4 Addition of the pegylated amphiphile delayed the degradation time 8-fold of Pas without increasing 
the cytotoxicity, Toft et al., 2012.300 
 
Barnard et al. demonstrated the effects of co-assembling low-molecular-weight 
cholesterol-functionalized PEG units of either triethylene glycol (Chol-PEG-3) or 
octaethylene glycol (Chol-PEG-8) (Fig. 5-5).113 In their systems, the addition of Chol 
PEG-3 decreased the DNA binding affinity as a consequence of steric crowding and loss 
of overall solubility. The Chol-PEG-8 additives, however, not only lowered the surface 
charge and thereby increased the ability to cross a model mucus layer, but also exhibited 
a much higher binding affinity towards DNA. It was postulated that longer PEG 
derivatives enhanced DNA binding due to the higher solubility of the nanostructures and 
their complexes with DNA.  
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Fig. 5-5 Molecular structures of the SAMul dendron Chol-G2 with cholesterol-functionalised ethylene 
glycol derivatives (Chol-PEG-3 and Chol-PEG-8) by Barnard et al.113 
 
So far, however, the effect of PEGylation towards binding actions of self-assembled 
multivalent systems remains largely unexplored. In this work we attempt to explore this 
aspect in terms of self-assembly and binding affinities towards different biological 
polyanions; heparin and DNA. We recognised that the surface of our micelles reported in 
previous chapters is highly charge-dense and that repulsions between cationic charges are 
likely to be significant. Certainly this played a role in limiting the solubility of the 
amphiphilic synthesised systems reported in Chapter 3. This can also potentially lead to 
all-target binding and toxicity effects. Co-assembling a second, non-ionic amphiphile was 
therefore expected to reduce the electrostatic repulsions on the nanostructure surface, as 
fundamentally demonstrated with simple ionic and non-ionic surfactants that have a lower 
CMC (CAC) than expected from the linear extrapolation of the CMC (CAC) values 
versus mole fraction.301  
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5.3 Synthesis of Multicomponent SAMul Systems 
 
This study was performed by MChem student Constantin Voll under my supervision. I 
helped with advice and training on both the synthesis and the binding assays.  
In a previous chapter (Chapter 3), we investigated surface ligand effects on the binding 
of heparin and DNA using the C16 hydrophobic chain. In this chapter we used a longer 
saturated fatty acid (C18) in an attempt to overcome some of the solubility problems. We 
selected C18-SPD and C18-SPM, both consisting of a saturated chain (C18) as the 
hydrophobic part as well as the previously utilized polyamine; spermidine (SPD) and 
spermine (SPM) (Fig. 5-6), which exhibited the best binding results for heparin and DNA, 
respectively. Beyond these simple structural modifications, two PEG lipids, C18-PEG-3 
and C18-PEG-8 (Fig. 5-5), were then synthesised and co-assembled in 1 and 10 mol% 
compositions, with the intention of gaining an understanding of the influence of this 
second component on binding strength, selectivity towards DNA or heparin, and stability 
and activity in highly competitive biologically relevant conditions such as human serum. 
 
Fig. 5-6 Structures of the investigated binders C18-SPD and C18-SPM as well as the PEG lipids C18-PEG-
3 and C18-PEG-8. 
 
For C18-SPD and C18-SPM, we used Boc-SPD and Boc-SPM respectively (previously 
synthesized in Chapter 3), which were coupled with stearic acid (C18 saturated 
hydrophobic chain).   
C
18
-SPD 
C
18
-SPM C
18
-PEG-8 
C
18
-PEG-3 
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The coupled compounds were then purified and deprotected by HCl (individually) C18-
SPD was achieved in overall 36% yield and C18-SPM gave 32% yield (Scheme 5-1).  
 
 
Scheme  5-1 Synthesis of C18-SPD and C18-SPM SAMul binders. 
 
For the PEG lipids, non-literature based, simple acid-catalysed condensation was chosen 
for the synthesis of C18-PEG-3 due to the low cost of the reactants; stearic acid and 
triethylene glycol (Scheme 5-3). The compound needed purification by column 
chromatography (SiO2, 2:1 v/v, hexane/ethyl acetate), and was obtained as yellow powder 
in 32% yield (Scheme 5-2).  The product fully characterized and its high purity confirmed 
by all available techniques (see experimental section for details).    
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Scheme  5-2 Synthesis of C18-PEG-3. 
 
The coupling agent TBTU was used for the synthesis of C18-PEG-8 from octaethylene 
glycol and stearic acid in order to minimise the quantities of the more expensive 
octaethylene glycol. The scale of this non-literature based method could thereby be 
decreased significantly whilst still producing a sufficient quantity for the desired studies. 
The mixture was stirred overnight and then dried before it was purified by column 
chromatography (SiO2, 1:1 v/v, hexane/ethyl acetate, then 100% ethyl acetate) and was 
obtained as sticky off-white product in 27% yield (Scheme 5-3). The product was 
characterised by all available techniques (see experimental section for details) and 
obtained in high purity. 
 
 
Scheme  5-3 Synthesis of C18-PEG-8.  
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5.4 Self-Assembly Studies 
5.4.1 Nile Red Assay  
Self-assembly of C18-SPD and C18-SPM was characterized by the Nile Red assay, as 
described before, to determine their CAC values. The measurements were done before 
and after inserting the PEG lipids (Table 5-1).  
 
Compound   PEG lipid PEG lipid mol% CAC (µM) 
C18-SPD None __ 48.2 ± 2.1 
C18-SPD C18-PEG–3 10% 52.5 ± 1.7 
C18-SPM None __ 57.6 ± 0.9 
C18-SPM C18-PEG–3 10% 31.6 ± 2.1 
C18-SPM C18-PEG–8 10% 35.9 ± 1.2 
Table 5-1 CAC values µMfor the SAMul binders and mixed aggregates with C18-PEG–3 or C18-PEG–
8. C18-SPD values measured in PBS buffer, C18-SPM values measured in Tris + NaCl buffer. 
 
C18-SPD self-assembled at a concentration of 48.2 ± 2.1 μM in PBS buffer, which is 
different to the previously reported C16-SPD (Chapter 3), which did not dissolve in PBS 
buffer and had to be examined in Tris-HCl (10 mM) in the presence of NaCl (150 mM). 
This observation suggests that the longer stearic acid chain provides sufficient 
hydrophobic force to overcome the electrostatic repulsions on the surface of the 
nanostructure between the cationic protonated SPD groups and hence enable self-
assembly and solubility. It was however necessary to initially encourage the self-
assembly by gentle heating, consistent with the self-assembly being entropically driven. 
C18-SPM however, did not dissolve in PBS buffer unless heated vigorously. We therefore 
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decided to dissolve it in Tris buffer + NaCl. C18-SPM (+3 charges) self-assembled at 57.6 
± 0.9 (Table 5-1), although comparison with C18-SPD cannot really be made because of 
the different buffer.  
It is worth noting that the different solubility in PBS compared to Tris is probably a result 
of interactions between the phosphate anions of the buffer and the cationic self-assembled 
structures lowering the overall solubility. In Tris, the counterions are chloride and will 
not interact in the same way with the SAMul nanostructures.    
The introduction of the second component, C18-PEG-3 (10 mol%) to C18-SPD did not 
have a major effect on the CAC, which increased slightly from 48.0 ± 2.1 to 53.0 ± 1.7 
μM. However, these values are within the error range of one another. The spermidine 
head group possesses two nominal cationic charges and the incorporation of the PEG lipid 
was anticipated to reduce those to some extent. However, the PEG lipids somewhat 
decreased solubility and we suggest this offsets any benefit from the loss of charge-charge 
interactions in this case. Furthermore, this study was performed in PBS and the phosphate 
ions will be interacting with C16-SPD – potentially lowering the effective CAC. Limited 
quantities of C18-SPD meant that the experiment with 10 mol% C18-PEG-8 could not be 
carried out, nor could the buffer be changed to Tri-HCl.  
The addition of the second component C18-PEG-3 or C18-PEG-8 to C18-SPM had a much 
more significant effect decreasing the CAC from 58 to ca. 35 μM. Both PEG lipids seem 
to decrease the aggregation concentration to a similar extent. This distinct difference to 
C18-SPD is suggested to result from the more severe charge-charge repulsions on the 
micellar surface that can be lowered by either PEG lipid. Furthermore, the studies are in 
Tris buffer and the counterions will not be binding to the SAMul surface – hence the PEG 
lipid will also have a more significant effect.   
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5.4.2 Dynamic Light Scattering (DLS)   
The effects on surface charge and nanoscale dimensions of co-assembling C18-PEG-3 or 
C18-PEG-8 with C18-SPD and C18-SPM were then determined by DLS. The size and zeta 
potential of the nanostructures are important tools in assessing possible effects on 
polyanion binding capabilities. These studies were all carried out in Tris buffer (10 mM) 
in the presence of NaCl (150 mM) (Table 5-2) – preventing any possible problems with 
PBS buffer binding to the micelles. 
Compound   PEG lipid 
PEG lipid 
mol% 
Volume 
distribution 
(nm) 
Zeta potential 
(mV) 
C18-SPD None __ 10.2 ± 0.3 +49.8 ± 1.6 
C18-SPD C18-PEG-3 1% 9.7 ± 0.1 +36.2 ± 4.3 
C18-SPD C18-PEG-3 10% 10.7 ± 0.3 +35.1 ± 3.1 
C18-SPD C18-PEG-8 1% 9.5 ± 0.2 +39.3 ± 6.2 
C18-SPD C18-PEG-8 10% 11.6 ± 0.7 +53.6 ± 2.6 
C18-SPM None __ 9.8 ± 0.4 +33.8 ± 10.5 
C18-SPM C18-PEG-3 1% 10.9 ± 2.0 +45.2 ± 10.1 
C18-SPM C18-PEG-3 10% unobtainable +45.2 ± 6.3 
C18-SPM C18-PEG-8 1% unobtainable +45.6 ± 10.1 
C18-SPM C18-PEG-8 10% 19.1 ± 4.5 +37.4 ± 11.6 
Table 5-2 Zeta potential (mV) and average diameter (nm) assessed by zeta sizing and intensity distribution 
in DLS measurements (Tris + NaCl buffer, pH 7.4) at 25 °C.  
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C18-SPD had a high overall surface charge of +50 mV and a diameter of ca. 10 nm. 
Conversely, C18-SPM had a surface charge of only +34 mV and a diameter of around 10 
nm. C18-SPM has three positive charges on its surface group and it would be expected to 
have a higher zeta potential than for C18-SPD with two cationic surface charges. We 
postulated that this reflects the charge-charge repulsions that do not allow the formation 
of such densely packed nanostructures resulting in a decreased overall surface charge. 
Similar effects were seen in Chapter 3.   
 
The insertion of uncharged ethylene glycol-type surfactants into cationic assemblies was 
expected to decrease the overall surface charge density and indeed, this is the case for 
C18- SPD when co-assembled with 1 or 10 mol% C18-PEG–3 or 1 mol% C18-PEG-8. 
The exception is C18-SPD with 10 mol% C18-PEG-8, where the overall surface charge 
slightly increased or, including the error margins, may be unaffected. The average 
diameter of the assembly with the addition of 1 mol% of either PEG lipid is somewhat 
decreased, but slightly increased when the lipid is present in 10 mol%, possibly as a result 
of more molecules being incorporated into each nanostructure. 
 
Surprisingly, the addition of C18-PEG-3 in 1 or 10 mol% and C18-PEG-8 in 1 mol% to 
C18-SPM increased the zeta potential. Since the C18-SPM solutions remained cloudy 
without heating, this trend suggest that the insertion of an uncharged amphiphile 
facilitates self-assembly and thereby increases the surprisingly low starting zeta potential 
of C18-SPM, i.e., the PEG lipid encourages the overall self-assembly process and hence 
more charged better packed structures can be formed than in its absence. Once 10 mol% 
of C18-PEG-8 has been added, the large uncharged moiety may be screening the charge 
and thereby reduces the zeta potential of the overall micellar nanostructure. The values in 
Table 5-2 were obtained at 25 °C but the sizes of the C18-SPM mol% C18-PEG–3 as well 
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as the C18-SPM 1 mol% C18-PEG-8 system were unobtainable under those conditions. 
Once 10% of PEG lipid was present, the system assembled at room temperature – 
supporting the view it assists nanostructure formation. 
 
5.5 Binding Data 
5.5.1 Heparin Binding  
 
5.5.1.1 MalB Assay in Buffer 
 
 The MalB assay was then performed as described previously, on C18-SPD and C18-SPM 
before and after of the insertion of the PEG lipids (Table 5-3). It should be noted that 
under these assay conditions, both C18-SPD and C18-SPM showed excellent solubility. 
Table 5-3 CE50 and EC50 values (in 150 mM NaCl and 10 mM Tris HCl), for C18-SPD, C18-SPM and 
multicomponent systems with 1 or 10 mol% C18-PEG-3 or C18-PEG-8.  
Compound   PEG lipid PEG lipid mol% CE50 EC50 (µM) 
C18-SPD None __ 0.90 ± 0.02 48.7 ± 1.3  
C18-SPD C18-PEG-3 1% 0.76 ± 0.01 41.7 ± 0.6  
C18-SPD C18-PEG-3 10% 0.76 ± 0.03  45.9 ± 1.9  
C18-SPD C18-PEG-8 1% 0.99 ± 0.09  54.3 ± 4.7  
C18-SPD C18-PEG-8 10% 0.98 ± 0.01    49.4 ± 0.9 
C18-SPM None __ 1.93 ± 0.10  69.7 ± 3.6  
C18-SPM C18-PEG-3 1% 2.13 ± 0.20  77.8 ± 7.4  
C18-SPM C18-PEG-8 1% 1.43 ± 0.15    51.9 ± 5.4 
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From Table 3-5 we can observe that C18-SPD showed effective binding for heparin with 
a CE50 value of 0.90 ± 0.02. However, C18-SPM with its three cationic charges performed 
much worse exhibiting a CE50 value of 1.93 ± 0.10. This suggests that self-assembly of 
C18-SPM under the assay conditions is incomplete or that the precise structural details 
are simply not well optimised for heparin binding. This is in agreement with the 
discussions above about the relatively ineffective packing of C18-SPM (as noted by DLS).   
 
Interestingly, the insertion of C18-PEG-3 (1 or 10 mol%) lowered the CE50 value of C18-
SPD from 0.90 to 0.76 (Table 5-3). It appears that this effect is already induced at 1 mol% 
and does not scale with a higher concentration (10 mol%), in agreement with prior 
observations in the binding of DNA by mixed aggregates.113 We suggest that the 
increased solubility of the co-assembly enhanced its heparin binding ability. However, 
mixed aggregates consisting of C18-SPD and the larger C18-PEG-8 (1 or 10 mol%) 
showed slightly increased CE50 values of 0.99 and 0.98, respectively. It is possible that 
the insertion of C18-PEG-8 results in partial blockage of the micellar surface owing to the 
greater length of the uncharged PEG chain. This would suggest that the larger PEG moiety 
shields charge and the increased solubility does not compensate for the reduction in the 
surface charge. 
 
The performance of C18-SPM was essentially unaffected by C18-PEG-3 but was 
improved slightly by C18-PEG-8. This is different to the effect of C18-PEG-8 on C18-
SPD and may suggest that its role with C18-SPM is to facilitate self-assembly and binding 
– in agreement with the observations above about the ineffective assembly of this 
compound.   
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5.5.1.2 MalB Assay in Human Serum  
We then wanted to determine whether the improvements in heparin binding are 
transferable into the biologically more relevant medium of human serum. We reasoned 
that the PEG additive, by screening the micellar surface charge, may improve stability 
and hence activity in serum. Therefore, the MalB assay in human serum was performed 
on C18-SPD as it showed more binding ability (in buffer) than C18-SPM (Table 5-3). 
 
Table 5-4 CE50 and EC50 values (in human serum) for C18-SPD and the multicomponent systems consisting 
of C18-SPD with 1 mol% C18-PEG-8. 
 
The results from Table 5-4 clearly suggest that the second component C18-PEG-8 may 
stabilise the micelles and cause slightly increased binding affinity in human serum. The 
binding ability of C18-SPD, however, appears to be slightly weakened compared to the 
heparin binding in buffered solution (Table 5-3). This may be due to partial disassembly 
of the nanostructures. Importantly, the obtained CE50 value in the presence of the 
stabilising PEG lipid of 1.07 ± 0.02 is still good – in particular when the benefits of the 
SAMul approach are considered. This preliminary result therefore suggests that PEG 
lipids may have some role to play in stabilizing our SAMul nanostructures in serum, and 
enhancing performance.    
Compound   PEG lipid PEG lipid mol% CE50 EC50 (µM) 
C18-SPD None __ 1.19 ± 0.01 64.1 ± 0.3 
C18-SPD C18-PEG-8 1%   1.07 ± 0.02 58.3 ± 1.3   
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5.5.2 DNA Binding  
DNA binding affinities were measured using ethidium bromide displacement assay as 
described previously. The data from Table 5-5 shows that the CE50 values of 0.85 and 
6.63 for C18-SPD and C18-SPM, respectively, demonstrated a very different ability 
towards DNA for these two systems. C18-SPD has a high affinity for DNA, whereas, the 
very high CE50 value for C18-SPM suggested that the self-assembly is impeded and the 
multivalent organisation cannot be fully formed as discussed above.  
Compound   PEG lipid PEG lipid mol%  CE50 EC50 (µM) 
C18-SPD None __ 0.85 ± 0.13  1.70 ± 0.25  
C18-SPD C18-PEG-3 1%  0.25 ± 0.01 0.57 ± 0.10  
C18-SPD C18-PEG-3 10% 0.13 ± 0.06  0.30 ± 0.01  
C18-SPD C18-PEG-8 1% 0.39 ± 0.08  0.79 ± 0.02  
C18-SPD C18-PEG-8 10% 0.10 ± 0.07   0.22 ± 0.15 
C18-SPM None __  4.63 ± 0.98  6.18 ± 1.32 
C18-SPM C18-PEG-3 1% 1.36 ± 0.07   1.83 ± 0.09 
C18-SPM C18-PEG-3 10%  0.91 ± 0.12 1.34 ± 0.19  
C18-SPM C18-PEG-8 1% 0.27 ± 0.03   0.55 ± 0.06 
C18-SPM C18-PEG-8 10% 0.30 ± 0.04  0.67 ± 0.09  
Table 5-5 DNA binding efficiency (in buffer); CE50 and EC50 values for C18-SPD, C18-SPM and 
multicomponent systems with 1 or 10 mol% C18-PEG-3 or C18-PEG-8. 
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Several reports indicate that the structure of spermine is optimised for the binding of 
DNA302 and hence stronger binding affinities might be expected. We suggest that the high 
surface charge of the SPM ligands make it hard for the C18 chain to nucleate self-assembly 
especially at the very low concentrations of this particular assay. 
 
Remarkably, the introduction of the second component C18-PEG-3 to C18-SPD in 1 or 
10 mol% has an enormous influence on the binding affinity in this assay, yielding CE50 
values of 0.25 and 0.13, respectively (Table 5-5). A similar trend is observed for the 
mixed aggregates with C18-PEG-8, where the binding affinity is also greatly increased. 
In this system, the 10 mol% PEG lipid yields a higher binding affinity than the 1 mol% 
PEG lipid. In the 10 mol% C18-PEG-8 to C18-SPD system, only 0.10 positive charges are 
required for each anionic charge on DNA to displace half of the EthBr. As such the 
presence of PEG lipids very significantly improves DNA binding. 
 
The insertion of just 1 mol% C18-PEG-3 to C18-SPM already has a major influence on 
the binding affinity; presumably due to increased solubility and reductions in electrostatic 
repulsions. Increasing to 10 mol% C18-PEG-3 yields an even lower CE50 value. Mixed 
aggregates with C18-PEG-8 lower this binding affinity even further to around 0.3 with 
virtually no difference observable between 1 and 10 mol%. This trend clearly suggests 
the severe electrostatic repulsions on the head groups and that the insertion of an 
uncharged second component greatly reduces them (Table 5-5). This enables self-
assembly and switches of full SAMul binding towards DNA.  
 
Notably, the EC50 values obtained from the DNA assays were much lower than the CAC 
values obtained in the Nile Red assay (up to 175-fold decrease), suggesting that the 
presence of DNA assists the aggregation of those poorly assembling binders. Indeed 
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charge-charge repulsions between the cationic surface charges are very likely to be 
reduced by the anionic charges present.229,303 This suggests that multivalent binding can 
positively influence self-assembly, as well as vice versa. This effect seems to be more 
noticeable for DNA binding than heparin binding, which may be associated with the 
lower concentration of the DNA assay making self-assembly the key limitation in terms 
of activity. It is also worth noting that the impact of PEG lipids on binding DNA here is 
much more significant than in the example previously reported by Barnard et. al.113 This 
may reflect the less effective initial assembly of the ligands in this study.  
 
Overall, the results from this work, performed by Constantin Voll under my supervision, 
demonstrated that PEG-lipids could be useful additives and significantly improve 
polyanion binding (DNA) as well as potentially improving serum stability (heparin). 
 
 
5.6 MalB Assay  
We were then interested in other mixtures of self-assembling components and the impact 
of mixing on polyanion binding. This study was performed in collaboration with 
postdoctoral researcher Ana Rodrigo who has been developing methodology for 
screening heparin binding – all the compounds used in these studies were synthesized by 
me. 
 
We performed a multicomponent MalB assay on some of our synthesized SAMul systems 
in buffer for heparin binding. In the pharmaceutical industry, screening assays such as 
high-throughput screening (HTS) assays are common. In general, they involve the 
process of rapidly differentiating the tested compounds; those that target active vs.  those 
that are inactive.304  In this step we screened mixtures that consisted of Binder 2 (Fig 2-
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1) which contained unsaturated hydrophobic chain (2 alkene groups), C16-DAPMA (Fig. 
3-1) which contained shorter saturated hydrophobic chains.  
 
For those mixtures, we performed two assays. Firstly, we varied the charge ratio; the 
variation of the charge ratio was C16-DAPMA:Binder 2 (50:50), (+: -) = 0.1/, 0.2, 0.25, 
0.4, 0.5, 0.75, 1, 1.5, 1.75 and 2. The assay data (Fig. 5-7) showed the effect that alkene 
groups have on disrupting the binding to heparin by increasing the CE50 values. C16-
DAPMA binds heparin most effectively, whereas Binder 2 is much less effective because 
the bent alkene disrupts hydrophobic packing. The 50:50 mixture behaved similarly to 
Binder 2, suggesting that the bent alkene dominates the behaviour of the mixture.   
 
Fig. 5-7 MalB assay (in buffer); charge ratio against normalized absorbance at 615 nm of Binder 2, C16-
DAPMA and mixtures of both binders using variations of charge ratio showing the effect of mixing 
different SAMul systems on binding heparin. 
 
In the second assay the charge ratio was kept at (+ : -) = 1.0 and the amount of each binder 
varied as follows; C16-DAPMA:Binder 2 = 0:100, 15:85; 25:75, 40:40, 50:50, 60:40, 
75:25, 85:15 and 100:0 (Fig. 5-8). This provides a rapid insight into ability of different 
binder mixtures to displace MalB from its complex with heparin. The higher the 
absorbance value, the more MalB displaced and the better the binder is.   
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Fig. 5-8 MalB assay (in buffer) for C16-DAPMA:Binder 2 mixture at 0:100, 15:85; 25:75, 40:40, 50:50, 
60:40, 75:25, 85:15 and 100:0.  
 
It is clear that with more than 50% of Binder 2 present, very little MalB is displaced from 
the complex. However, once less than 50% Binder 2 is present the binding ability of C16-
DAPMA begins to exert an influence.  
 
It is apparent that the mixing relationship is non-linear. This indicates that even relatively 
small amounts of Binder 2 disrupt the binding quite significantly. This is in agreement 
with a view that the bent alkene limits self-assembly and hence inhibits effective 
multivalent binding – even if only small amounts of it are present as an additive.  
 
As such, this assay allows rapid assessment of mixtures of self-assembling components 
to determine whether they have a neutral influence on one another (linear relationship), a 
negative influence on one another (concave plot, as here) or a positive synergistic 
influence when mixed (convex plot).   
 
We anticipate this approach may help identify mixtures of self-assembling components 
which have positive synergistic effects. Ana Rodrigo is investigating other mixtures of 
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self-assembling lipids to determine whether this is the case, and results will be reported 
by her elsewhere.  
 
 
5.7 Conclusions and Future Work  
 
MChem student Constantin Voll synthesized two novel SAMul binders, C18-SPD and 
C18-SPM, and they were analysed in terms of self-assembly, size, surface charge as well 
as binding affinities towards heparin and DNA. Their mixed aggregates with C18-PEG-3 
and C18-PEG-8 were investigated to see if the uncharged nature of these lipids can 
influence self-assembly without effecting binding efficiency to the polyanions heparin 
and DNA. Both PEG lipids induced observed changes in size and surface charge. C18-
SPD performed better in binding to heparin and insertion of C18-PEG-3 in both 1 and 10 
mol% increased the binding strength. However, mixed aggregates with C18-PEG-8 
performed worse under those assay conditions. The binding results for C18-SPD 
suggested that this approach of co-assembly may also enhance and inforce heparin 
binding in human serum. The C18-SPD 1 mol% C18-PEG-8 system outperformed C18-
SPD binder on its own in human serum indicating that the PEG lipid may stabilize these 
assemblies somewhat in this competitive environment. These results are promising for 
the development of clinical heparin reversal agents since the introduction of just 1 mol% 
of a simple uncharged species may have an influence on binding strength in the clinically 
relevant medium. Future research may synthesize the corresponding PEG lipid for the 
C22-G1 binder, which is an inherently much better heparin binder than C18–SPD and may 
decrease the dose that would be needed to be given to a patient and significantly enhance 
its serum stability. It may also limit off target interactions in vivo – future work will need 
to probe this.  
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In addition, mixed SAMul multicomponent systems based on systems synthesized by me 
were tested in collaboration with Ana Rodrigo using MalB assay. The systems consisted 
of mixtures of C16-DAPMA and Binder 2; the components were varied in terms of charge 
ratio as well as concentration. The results indicated that the alkene disrupts self-assembly 
and even relatively small amounts limited the performance of a better binder. In the 
future, this approach may help us rapidly uncover positive synergistic binding effects in 
mixed lipid systems.  
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6 Conclusions and Future Work 
6.1 Conclusions 
 
In this work we synthesized a number of multivalent systems, most of which were based 
on a self-assembly approach. These systems were self-assembled multivalent (SAMul) 
nanostructures with two significant parts; hydrophilic (binding site) and hydrophilic (as 
driving force for the assembly). All the synthesized systems were designed to have 
positive surface charges in order to be able to bind, electrostatically, different polyanions 
such as heparin and DNA. All the compounds/systems in this work were tested in terms 
of their binding ability towards heparin using the MalB assay, and most of them were 
tested towards binding DNA using the EthBr assay. Prior to those tests most of these 
compounds were tested for their self-assembly ability using Nile Red assay (2. 4. 1), to 
determine their CACs. In addition, DLS characterizations for particle size and zeta 
potential were performed on all the compounds.  
 
In the first Results and Discussions chapter (Chapter 2) we synthesized three compounds 
using different unsaturated acids as the hydrophobic part (Fig 2-1). The variation of the 
alkene group in those compounds, from one to three, induced significant selectivity 
towards different biological polyanions (heparin and DNA), in addition to different 
binding ability in competitive conditions such as human serum.  We found that human 
serum disrupted self-assembly and heparin binding. We suggested that the more 
organized and tightly packed nanostructures are better able to bind heparin while the 
looser ones are preferentially bound by DNA. The presence of more alkenes disrupts 
surfactant packing.  
Those three systems were also cross-liked in an attempt to stabilize them when binding 
to heparin or DNA. The cross-linking process was performed using a radical initiator 
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agent AIBN (Fig 2-29) for the polymerization reaction. However, the cross-linking 
reaction for the binder with one alkene group (Binder 1) was not achieved, while Binder-
3 with the most alkene groups it was the highest conversion. However, cross-linking did 
not significantly improve polyanion binding or serum stability.  
 
In Chapter 3, we made modifications to the ligands using DAPMA, SPD and SPM, but 
kept the hydrophobic part unchanged as a saturated C16 chain (Fig 3-1). We found that 
for C16 ligands, C16-SPM is optimal for DNA binding, while C16-SPD is optimal for 
heparin binding. Also, electrostatic ion–ion binding depends on structural detail, not only 
charge density – as confirmed by the complementary experimental methods of 
competition binding assays and isothermal calorimetry. Molecular simulation studies led 
us to propose that the shape-persistence (DNA), or adaptability (heparin) of the 
polyanionic targets help mediate the selectivity of interaction with different ligands. 
 
Other alternative approaches to stabilizing multivalent displays of heparin-binding 
ligands were employed in Chapter 4. Three systems were synthesized based on a branched 
scaffold (Binder-Dend), gold nanoparticles (Binder-NC) and a polymer (Binder-Poly).  
For the first system (Binder-Dend), although it had more positive charges (6 +ve) than 
the previously reported binders, did not show improved binding as they were not being 
organized effectively on the nanoscale. For the second (Binder-NC), solubility 
difficulties in buffer owing to aggregation of nanoparticles into a nanocomposite, meant 
less binding to heparin, from MalB assay results. We had to perform the assay at elevated 
temperatures (50-55 °C and >80 °C) – however the assay results showed that replacement 
of MalB was incomplete. This could be due to AuNPs interfering with the UV-Vis 
absorbance around Absmax ≈ 700 nm as well as the solubility difficulties. The third system 
(Binder-Poly), was synthesized using poly(acrylic acid):DAPMA (1:1). TEM images for 
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this system showed a highly defined spherical aggregation when binding to heparin (Fig. 
4-21). The MalB assay results were somewhat promising; CE50 = 2.0 ± 0.03 in buffer and 
CE50 = 4.2 ± 0.5 in human serum a rather more stable binding than the other systems 
reported in the same chapter. There is clearly scope to look at more tailored modified 
polymers in the future.  
 
In the final results chapter (Chapter 5), a multicomponent approach was tested for binding 
heparin and DNA. Two compounds; C18-SPD and C18-SPM were synthesized then 
introduced to PEG lipids (uncharged species); PEG-3 and PEG-8 (Fig. 5-6) to test the 
effect of mixture on binding heparin and DNA. C18-SPD performed better in binding to 
heparin and insertion of C18-PEG-3 in both 1 and 10 mol% increased the binding strength. 
However, mixed aggregates with C18-PEG-8 performed worse under those assay 
conditions. The C18-SPD 1 mol% C18-PEG-8 system outperformed C18-SPD binder on 
its own in human serum indicating that the PEG lipid may stabilize these assemblies 
somewhat in this competitive environment. In addition, mixed SAMul multicomponent 
systems based on C16-DAPMA and Binder 2 were tested using MalB assay. The results 
indicated that the alkenes disrupt self-assembly and even relatively small amounts limited 
the performance of a better binder on mixing. In the future, this assay may also help 
identify synergistic binding effects on mixing.  
 
Ion-ion binding is often considered as non-directional and as such only depends on the 
charge density of the species involved – however, these studies clearly demonstrate that 
under competitive biological conditions, the choice of hydrophobic group and its capacity 
to display and orientate the ligands has a major role in tuning the binding affinity. 
Furthermore, the precise choice of ligand and the presence of additives can have 
significant effects. 
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Overall, we observed that polyanions (heparin/DNA) play a role in facilitating self-
assembly event and hence switching on the multivalent binding effect, and suggest that 
specifics of ligand-polyanion interactions help mediate subtle differences in this overall 
process. These results provide an intriguing insight into molecular recognition processes 
at nanoscale surfaces and suggest that SAMul nanostructures may deliver some 
selectivity in addressing the challenging problem of the ‘polyanion world’.  
 
 
6.2 Future Work 
 
For future work, the unsaturated hydrophobic tails could be longer, with more alkene 
groups, to achieve more cross-linking between them. This would allow us to test the effect 
of more alkene density in such systems. In addition, two tails could be used to enhance 
the self-assembly hence, ability to bind to heparin. This should encourage the formation 
of vesicle structures and significantly enhance serum stability. By tuning these head 
groups and tails, we can modify the binding abilities of the SAMul nanostructures to 
heparin and DNA; nanoscale biological polyanions.  
 
For the branched system, Binder-Dend, binding performance could be enhanced by using 
more than one hydrophobic group in order to improve the self-assembly or by increasing 
the dendritic generation so the number of ligands is greater. Also, for the system based 
on thiol stabilized gold nanoparticles, improved binding to heparin could be achieved if 
this system was introduced to a different thiol group (longer); with a spacer group to help 
optimize ligand display, or incorporate more positive charges on the hydrophilic group 
(binding site). In addition, Binder-Poly system, based on a polymer backbone, could be 
synthesized with different ratios of polymer:DAPMA, other than 1:1 that we used in this 
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work. These variations could facilitate loading of more ligands onto the polymer, hence 
more positive charges that would bind heparin/DNA. Moreover, different polymer 
backbones could also be tested to try and avoid any non-specific interactions with serum 
proteins which may be disrupting the binding process in these highly competitive 
conditions.  
 
Future research may synthesize the corresponding PEG lipid for the C22-G1 binder, which 
is an inherently much better heparin binder than C18–SPD and may decrease the dose that 
would be needed to be given to a patient and significantly enhance its serum stability. The 
multicomponent approach may help us uncover positive synergistic binding effects, this 
will be achieved by investigating other mixtures to determine whether this is the case.   
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7 Experimental 
7.1 Synthetic Materials and Methods 
 
All reagents were purchased from commercial sources and were used directly without 
any further purification unless stated. Thin layer chromatography (TLC) was performed 
on Merck aluminium-backed plates coated with 0.25 nm silica gel 60; flash column 
chromatography was performed on silica gel 60 (35-70 µm) supplied by Fluka Ltd and 
preparative gel permeation chromatography (GPC) was performed on Biobeads SX-1 
supplied by Bio-Rad.  
NMR spectra were recorded on a JEOL ECX400 (1H 400 MHz, 13C 100 MHz) 
spectrometer. HRMS and ESI mass spectra were recorded on a Bruker Daltonics Micro-
Tof mass spectrometer. Infrared spectra were recorded on Shimadzu IRPrestige-21 FT-
IR spectrometer. Melting points were measured on a Stuart SMP3 melting point apparatus 
and are uncorrected. 
 
7.1.1 Chapter 2  
Synthesis of Mono-Boc DAPMA (Compound 1)171 
  
N,N-Di-(3-aminopropyl)-N-methylamine (DAPMA) (50 mL, 310 mmol) was dissolved 
in THF (200 mL) and cooled to 0
 
°C. Di-(tert-butyl) dicarbonate (Boc2O) (12.5 g, 57.2 
mmol) was dissolved in THF (50 mL) and added dropwise to the amine solution over 2 
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h. Then the reaction was quenched with water (25 mL). The solvent was dried and the 
residue was taken up in aqueous NaOH (pH >10, 1 M) and extracted with DCM (80 mL). 
The organic layer was washed with citrate (citric acid solution) (pH > 4-5, 1 M). The 
water layers (which contain the product) were combined and basified to pH > 10 with 4 
M NaOH. The mono-protected product was then extracted with DCM (80 mL). The 
organic phases were combined, dried over MgSO4, filtered and the solvent evaporated 
then the product was dried in vacuo. The product was a colorless oil (5.5 g, 39%). 
 
Rf  = 0.3 (4:1 MeOH:aqueous ammonia). 
1H NMR (DMSO d6 400 MHz) δ: 6.76 (br t, NH, 
J = 5.5 Hz, 1H); 2.88 (app q, CH2NHCO, J = 6.1 Hz, 2H); 2.50 (t, CH2NH2, J = 6.7 Hz, 
2H); 2.31 (t, CH2NCH3, J = 7.0 Hz, 2H); 2.27 (t, CH2NCH3, J = 7.3 Hz, 2H); 2.02 (s, 
NCH3, 3H); 1.47 (app. quin., CH2CH2NHCO and CH2CH2 NH2, J = 6.9 Hz, 4H); 1.38 (s, 
CCH3, 9H). 
13C NMR (DMSO d6 100 MHz) δ: 156.45 (C=O); 77.21 (CCH3); 55.03, 54.90 
(CH2NCH3); 41.76 (NCH3); 39.73 (CH2NHCO); 38.34 (CH2NH2); 30.20 
(CH2CH2NHCO); 28.14 (CCH3); 27.21 (CH2CH2NH2). HRMS: Calc. [M+H]
+ 
(C12H28N3O2) m/z = 246.2176, found [M+H]
+ = 246.2173 (100%). IR: νmax (cm-1): 
3350.3m (N-H); 2975w, 2931s, 2797s (all CH); 1795s 1621s (C=O); 1454w, 1391w, 
1367s, 1277w, 1250m, 1173w. 
 
Coupling of Boc-DAPMA and Oleic Acid (Mono-Unsaturated-C18-Boc-DAPMA) 
   
Oleic acid (1.00 g, 3.54 mmol) was dissolved in DCM (65 mL) then TBTU (1.25 g, 3.89 
mmol) and Et3N (5.4 mL) were added respectively. The mixture was stirred for 5 minutes 
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at room temperature. Compound 1 (0.87 g, 3.54 mmol) was dissolved in DCM (65 mL) 
then was added to the reaction flask. The reaction was stirred overnight, then the mixture 
was concentrated in vacuo and the residue was dissolved in EtOAc (50 mL) and washed 
with NaHSO4 (2 x 15 mL, 1.33 M), NaHCO3 (2 x 15 mL, saturated), deionized water (3 
x 15 mL) and brine (15 mL, saturated). The organic layer was collected, dried over 
MgSO4 and filtered (filter paper, 90 mm) then dried in vacuo. The product was 
concentrated and purified by gel permeation chromatography (GPC) column (Bio-beads, 
100% DCM). The solvent was dried in vacuo and the product was a gluey oil (700 mg, 
40%).    
 
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 6.85 (br s, NH, 
1H); 5.34 (br s, NHBoc, 1H); 5.33-5.30 (m, CHCH, 2H); 3.33 (app q, CH2NHCO, J = 6.0 
Hz, 2H); 3.22 (app q, CH2NCH3, J = 6.0 Hz, 2H); 3.14 .58 (t, CH2NCH3, J = 6.4 Hz, 4H); 
3.09 (q, CH2CH2CH, J = 7.2 Hz, 4H); 2.78 (s, NCH3, 3H); 2.26 (t, CH2CH2CO, J = 7.6 
Hz, 2H); 1.99-1.92 (m, CH2CH2NH, 4H); 11.41 (s, C(CH3)3, 9H); 1.27-1.29 (m, 
CH2CH2CH2, 20H); 0.87 (t, CH3CH2, J = 6.4 Hz, 3H). 
13C NMR (CDCl3, 100 MHz) δ: 
176.15(CONH); 156.16 (OCONH); 129.82 (2 x CH=CH); 79.84 (CCH3); 53.79 
(CH2NCH3); 46.41 (NCH3); 39.20 (CH2NH); 37.25 (CH2NHCO); 35.72 (CH2CO); 34,68 
(CH2CH2CO); 31.94 (CH2CH); 29.80 (CH2CH2CH2); 28.36 (C(CH3)3); 27.26 
(CH2CH2NCH3); 24.85 (CH2CH2NH); 22.72 (CH2CH3); 14.18 (CH3CH2). HRMS: Calc. 
[M+H]+ (C30H60N3O3) m/z = 510.4629, found [M+H]
+ = 510.4647 (100%).  IR: νmax (cm-
1): 3287m (N-H); 3009w, 2926s, 2855s (all CH); 1638s (C=O); 1542s (C=O); 1464m, 
1299m, 1272m, 1250s, 1171s, 1056m 1049s, 867w, 723w.   
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Deprotection of Mono-Unsaturated-C18-Boc-DAPMA (Binder 1) 
 
Mono-unsaturated-C18-Boc-DAPMA (700 mg, 1.37 mmol) was dissolved in methanol 
(25 mL) then HCl gas was applied for 15-20 seconds then the mixture was stirred for 3 
hours and monitored by TLC. The solvent was dried in vacuo and the product was a 
gummy orange solid (600 mg, 91%).   
 
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CD3OD, 400 MHz) δ: 7.25 (br s, NH, 
2H); 6.78 (br s, NH, 2H); 5.38-5.22 (m, CHCH, 2H); 5.16 (br s, NH, 1H); 3.27 (app q, 
CH2NHCO, J = 12 Hz, 2H); 3.14 (app q, CH2CH2NH, J = 4.1 Hz, 2H); 2.72 (t, CH2CH, 
J = 12.0 Hz, 2H); 2.37 (t, CH2NCH3, J = 12.0 Hz, 4H); 2.17 (s, NCH3, 3H); 2.12 (t, 
CH2CH2CO, J = 8.0 Hz, 2H); 2.01 (q, CH2CH, J = 8.0 Hz, 4H); 1.60 (m, CH2CH2NH, 
4H); 1.32-1.22 (m, CH2(CH2)10CH2, 20H); 0.84 (t, CH3CH2, J = 8.0 Hz, 3H). 
13C NMR 
(CD3OD, 100 MHz) δ: 172.55 (CONH); 130.61 (2 x CH=CH); 56.51 (CH2NCH3); 47.23 
(NCH3); 40.70 (CH2NH); 39.70 (CH2NH2); 36.82 (CH2CO); 32.52 (CH2CH2CO); 31.91 
(CH2CH2CH3); 29.11 (CH2CH2CH2); 27.15 (CH2CH); 26.23 (CH2CH2NCH3); 24.34 
(CH2CH2NH); 22.62 (CH2CH3); 14.16 (CH3CH2). HRMS: Calc. [M+H]
+ (C25H52N3O) 
m/z = 410.4105, found [M+H]+ = 410.4097 (100%).  IR: νmax (cm-1): 3285w (N-H); 
3011w, 2924s, 2854s (all CH); 1634s (C=O); 1542s (C=O); 1465m, 1377m, 1248m, 
1056m, 835s, 739m, 557s, 478w.  
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Coupling of Linoleic Acid and Boc-DAPMA (Di-Unsaturated-C18-Boc-DAPMA)  
 
 
Linoleic acid (1.00 g, 3.56 mmol) was dissolved in DCM (65 mL) then TBTU (1.25 g, 
3.89 mmol) and Et3N (5.4 mL) were added. The mixture was stirred for 5 minutes at room 
temperature. Compound 1 (0.875 g, 3.56 mmol) was dissolved in DCM (65 mL) then was 
added to the reaction flask. The reaction was stirred overnight, then the mixture was 
concentrated in vacuo and the residue was dissolved in EtOAc (50 mL) and washed with 
NaHSO4 (2 x 15 mL, 1.33 M), NaHCO3 (2 x 15 mL, saturated), deionised water (3 x 15 
mL) and brine (15 mL, saturated). The organic layer was collected, dried over MgSO4 
and filtered (filter paper, 90 mm) then dried in vacuo. The product was concentrated and 
purified by gel permeation chromatography (GPC) column (Bio-beads, 100% DCM). The 
product was a gluey orange solid (600 mg, 33%).   
 
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 6.78 (br s, NH, 
1H); 5.38-5.22 (m, CHCH, 4H); 5.16 (br s, NHBoc, 1H); 3.27 (app q, CH2NHCO, J = 
12.0 Hz, 2H); 3.14 (app q, CH2CH2NH, J = 4.0 Hz, 2H); 2.72 (t, CHCH2CH, J = 10.2 Hz, 
2H); 2.37 (t, CH2NCH3, J = 7.8 Hz, 4 H); 2.17 (s, NCH3, 3H); 2.12 (t, CH2CH2CO, J = 
8.0 Hz, 2H); 2.01 (q, CH2CH2CH, J = 8.0 Hz, 4H); 1.60-1.58 (m, CH2CH2NH, 4H); 1.39 
(s, C(CH3)3, 9H); 1.32-1.22 (m, CH2CH2CH2, 16H); 1.25 (sxt, CH2CH3, J = 8.4 Hz, 2H), 
0.84 (t, CH3CH2, J = 6.4 Hz, 3H).  
13C NMR (CDCl3, 100 MHz) δ: 173.41 (CONH); 
156.16 (OCONH); 130.23 (2 x CH=CH); 128.02 (2 x CH=CH); 79.06 (CCH3); 55.69 (2 
x CH2NCH3); 41.63 (NCH3); 39.11 (CH2NH); 38.12 (CH2NHCO); 36.82 (CH2CO); 
31.55 (CH2CH); 29.68 (7 x CH2CH2CH2); 28.47 (C(CH3)3); 27.23 (CH2CH2NCH3); 
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26.18 (CH2CH2NH); 25.91 (CH2); 22.61 (CH2CH3); 20 14.13 (CH3CH2). HRMS: Calc. 
[M+H]+ (C30H58N3O3) m/z = 508.4473, found [M+H]
+ = 508.4456 (100%). IR: νmax (cm-
1): 3300w (N-H); 3009w, 2926s, 2855s (all CH); 1692s, 1647s (C=O); 1538m, 1456m, 
1390m, 1272m, 1250s, 1171s, 1046s, 867w, 723w.  
 
Deprotection of Di-Unsaturated-C18-Boc-DAPMA (Binder 2) 
  
Di-unsaturated-C18-Boc-DAPMA (600 mg, 1.182 mmol) was dissolved in MeOH (25 
mL) then HCl gas was applied for 15-20 seconds then the mixture was stirred for 3 hours 
and monitored by TLC. The product was a gummy orange solid (0.455 g, 80%).   
 
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 6.78 (br s, NH, 
2H); 5.38-5.22 (m, CHCH, 4H); 5.16 (br s, NH, 1H); 3.27 (app q, CH2NHCO, J = 12Hz, 
2H); 3.14 (app q, CH2CH2NH, J = 4Hz, 2H); 2.72 (t, CHCH2CH, J = 4.0 Hz, 2H); 2.37 
(t, CH2NCH3, J = 6.2 Hz, 4H); 2.17 (s, NCH3, 3H); 2.12 (t, CH2CH2CO, J = 8.0 Hz, 2H); 
2.01 (q, CH2CH, J = 8.0 Hz, 4H); 1.62-1.57 (m, CH2CH2NH, 4H); 1.32-1.22 (m, 
CH2CH2CH2, 16H); 0.84 (t, CH3CH2, J = 7.0 Hz, 3H).  
13C NMR (CDCl3, 100 MHz) δ: 
173.41 (CONH); 135.17, 133.34, 131.56, 130.23 (4 x CHCH); 128.02 (CH2CH); 55.69 
(2 x CH2NCH3); 41.63 (NCH3); 39.11 (CH2NH); 38.12 (CH2NHCO); 36.82 (CH2CO); 
33.52 (CH2CH); 31.43, 31.02, 30.98, 30.52, 30.19, 29.68, 29.45 (7 x CH2CH2CH2); 27.23 
(CH2CH2NCH3); 26.18 (CH2CH2NH); 25.91 (CH2CH2CH); 22.61 (CH2CH3); 14.13 
(CH3CH2). HRMS: Calc. [M+H]
+ (C25H50N3O) m/z = 408.3948, found [M+H]
+ = 
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408.3931 (100%). IR: νmax (cm-1): 3315w (N-H); 3007w, 2923s, 2785s (all CH); 1682s 
(C=O); 1646s (C=O); 1552m, 1452m, 1380m, 1262m, 1245s, 1143s, 1016s, 867w, 723w.  
 
Coupling of Boc-DAPMA and Linolenic Acid (Tri-Unsaturated-C18-Boc-DAPMA) 
 
Linolenic acid (1.00 g, 3.56 mmol) was dissolved in DCM (65 mL) then TBTU (1.25 g, 
3.95 mmol) and Et3N (5.4 mL) were added. The mixture was stirred for 5 minutes at room 
temperature. Compound 1 (0.87 g, 3.56 mmol) was dissolved in DCM (65 mL) then was 
added to the reaction flask. The reaction was stirred overnight, then the mixture was 
concentrated in vacuo and the residue was dissolved in EtOAc (50 mL) and washed with 
NaHSO4 (2 x 15 mL, 1.33 M), NaHCO3 (2 x 15 mL, saturated), deionised water (3 x 15 
mL) and brine (15 mL, saturated). The organic layer was collected, dried over MgSO4 
and filtered (filter paper 90 mm) then dried in vacuo. The product was concentrated and 
purified by gel permeation chromatography (GPC) column (Bio-beads, 100% DCM). The 
product was a gluey brown oil (620 mg, 34%).   
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 7.24 (br s, NH, 
1H); 5.41 (br s, NHBoc, 1H); 5.31-5.25 (m, CHCH, 6H); 3.24 (app q, CH2NHCO, J = 6.2 
Hz, 2H); 3.22 (app q, CH2NHBoc, J = 6.1 Hz, 2H); 3.09 (t, CHCH2CH, J = 7.2 Hz, 4H); 
2.48 (t, CH2NCH3, J = 6.4 Hz, 4H);2.19 (s, NCH3, 3H); 2.06 (t, CH2CH2CO, J = 7.6 Hz, 
2H); 2.02 (q, CH2CH2CH J = 6.0 Hz, 2H); 1.99-1.92 (m, CH2CH2NH, 4H); 1.41 (s, 
C(CH3)3, 9H); 1.27-1.29 (m, CH2(CH2)5CH2, 10H); 0.87 (t, CH3CH2, J = 6.4 Hz, 3H). 
13C NMR (CDCl3, 100 MHz) δ: 175.40 (CONH); 154.13 (OCONH); 133.19, 132.87, 
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132.43, 131.65, 131.26, 130.72 (6 x CH=CH); 81.34 (CCH3); 56.24 (2 x CH2NCH3); 
47.31 (NCH3); 39.80 (CH2NH); 37.42 (CH2NHCO); 34.89 (CH2CO); 32.43 (2 x CH2CH); 
29.92 (5 x CH2CH2CH2); 28.46 (C(CH3)3); 26.98 (CH2CH2NCH3); 24.76 (CH2CH2NH); 
23.76 (CH2CH2CO); 21.82 (CH2CH3); 14.34 (CH3CH2). HRMS: Calc. [M+H]
+ 
(C30H56N3O3) m/z = 506.4316, found [M+H]
+ = 506.4322 (100%).  IR: νmax (cm-1): 3300w 
(N-H); 3009w, 2926s, 2855s, (all CH); 1692s (C=O); 1647s (C=O); 1538m (C=O); 
1456m, 1389m, 1275m, 1254s, 1165s, 1048s, 850w, 733w. 
 
Deprotection of Tri-Unsaturated-C18-Boc-DAPMA (Binder 3) 
  
Tri-unsaturated-C18-Boc-DAPMA (400 mg, 0.791 mmol) was dissolved in MeOH (25 
mL) then HCl gas was applied for 15-20 seconds then the mixture was stirred for 3 hours 
and monitored by TLC. The solvent was dried in vacuo product was a gummy brown 
solid (295 mg, 92%). 
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 6.97 (br s, NH, 
1H); 5.34 (br s, NH2, 2H); 5.33-5.30 (m, CHCH, 6H); 3.33 (app q, CH2NHCO, J = 6.1 
Hz, 2H); 3.14 (app q, CH2CH2NH, J = 6.1 Hz, 2H); 3.09 (q, CH2CH, J = 7.2 Hz, 4H); 
2.78 (s, NCH3, 3H); 2.58 (t, CH2NCH3, J = 6.3 Hz, 4H); 2.26 (t, CH2CH2CO, J = 7.6 Hz, 
2H); 1.99-1.92 (m, CH2CH2NH, 4H); 1.27-1.29 (m, CH2(CH2)5CH2, 10H); 0.87 (t, 
CH3CH2, J = 6.3 Hz, 3H. 
13C NMR (CD3OD, 100 MHz) δ: 172.55 (CONH); 134.35, 
134.13, 133.45, 132.85, 130.61, 130.23 (6 x CH=CH); 56.51 (2 x CH2NCH3); 47.23 
(NCH3); 40.70 (CH2NH); 39.70 (CH2NH2); 36.82 (CH2CO); 31.91 (5 x CH2CH2CH2); 
29.11 (CH2CH2CH); 27.15 (2 x CH2CH); 26.23 (CH2CH2NCH3); 24.34 (CH2CH2NH); 
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22.62 (CH2CH3); 14.16 (CH3CH2). HRMS: Calc. [M+H]
+ (C25H52N3O) m/z = 406.3792, 
found [M+H]+ = 406.3783 (100%). IR: νmax (cm-1): 3284w (N-H); 3008w, 2927s, 2855s, 
(all CH); 1716s (C=O); 1642s (C=O); 1547m, 1460s, 1367m, 1196m, 1065s, 844w, 747s, 
596s. 
 
Cross-linking Alkene Groups (Polymerization) of Binder 1175 
Binder 1 (40 mg, 0.083 mmol) was dissolved in methanol (4 mL). The mixture was 
sonicated for 5 minutes to ensure homogeneity. The solvent was evaporated under a flow 
of nitrogen. The resultant film was hydrated (water, 10 mL) then sonicated for 10 minutes. 
The resultant was centrifuged at 4000 rpm for 15 minutes, then filtered (0.22 µm nylon 
filter). The solution was deoxygenated by bubbling with nitrogen for 1 hour. A solution 
of 2,2-azo-bis(isobutyronitrile) (AIBN) (10 wt % of Binder 1 = 4 mg, 0.024 mmol) in 
THF (1 mL) was added then the mixture was stirred for 2 hours before the temperature 
was raised to 70 °C for 24 h under nitrogen. The solution was washed with DCM (10 mL) 
to remove excess AIBN and the product was collected from the water layer by vacuum 
distillation (50 °C). The product was a yellowish sticky solid (31 mg 77%).  
Rf = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR data showed similar spectra comparing to 
Binder 1. 13C NMR could not be obtained due the weak sample.  HRMS: Calc. [M+H]+ 
(C25H52N3O) m/z = 410.4105, found [M+H]
+ = 410.4097 (100%). IR: νmax (cm-1): 3286w 
(N-H); 2927w, 2853s (all CH); 1545s (C=O); 1257m, 1052w, 865s, 734w, 554s. 
 
Cross-linking Alkene Groups (Polymerization) of Binder 2175 
Binder 2 (40 mg, 0.083 mmol) was dissolved in methanol (4 mL). The mixture was 
sonicated for 5 minutes to ensure homogeneity. The solvent was evaporated under a flow 
of nitrogen. The resultant film was hydrated (water, 10 mL) then sonicated for 10 minutes. 
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The resultant was centrifuged at 4000 rpm for 15 minutes, then filtered (0.22 µm nylon 
filter). The solution was deoxygenated by bubbling with nitrogen for 1 hour. A solution 
of 2,2-azo-bis(isobutyronitrile) (AIBN) (10 wt % of Binder 2 = 4 mg, 0.024 mmol) in 
THF (1 mL) was added then the mixture was stirred for 2 hours before the temperature 
was raised to 70 °C for 24 h under nitrogen. The solution was washed with DCM (10 mL) 
to remove excess AIBN and the product was collected from the water layer by vacuum 
distillation (50 °C). The product was an orange sticky solid (26 mg 65%).  
 
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CD3OD, 400 MHz) δ: 5.62 (br s, NH, 
1H); 4.84 (br s, NH2, 2H); 3.25 (q, CH2NHCO, J = 1.6 Hz, 2H); 3.22 (t, CH2NH2, J = 6.0 
Hz, 2H) 3.14 (q, CH2CH2NH2, J = 6.0 Hz, 2H); 2.78 (s, NCH3, 3H); 2.52 (t, CH2NCH3, 
J = 6.4 Hz, 4H); 2.26 (t, CH2CH2CO, J = 7.6 Hz, 2H); 1.99-1.92 (m, CH2CH2NH, 4H); 
1.27-1.29 (m, CH2CH2CH2, 12H); 0.87 (t, CH3CH2, J = 6.4 Hz, 3H). The rest of 
1H NMR 
spectra was not clear although some unreacted alkenes were observed at 5.32 ppm ca. 
24%. 13C NMR could not be obtained due the weak sample. MS spectra were not obtained 
as the product is a cross-linked nanostructure. IR: νmax (cm-1): 3286w (N-H); 3154s, 
2924m, 2854s (all CH); 1638s, 1543s (C=O); 1258m, 1056w, 863s, 739w, 557s.  
 
Cross-linking Alkene Groups (Polymerization) of Binder 3175  
Binder 3 (60 mg, 0.125 mmol) was dissolved in methanol (6 mL). The mixture was 
sonicated for 5 minutes to ensure homogeneity. The solvent was evaporated under a flow 
of nitrogen. The resultant film was hydrated (water, 10 mL) then sonicated for 10 minutes. 
The resultant was centrifuged at 4000 rpm for 15 minutes, then filtered (0.22 µm nylon 
filter). The solution was deoxygenated by bubbling with nitrogen for 1 hour. A solution 
of 2,2-azo-bis(isobutyronitrile) (AIBN) (10 wt % of Binder 3 = 6 mg, 0.024 mmol) in 
THF (1 mL) was added then the mixture was stirred for 2 hours before the temperature 
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was raised to 70 °C for 24 h under nitrogen. The solution was washed with DCM (10 mL) 
to remove excess AIBN and the product was collected from the water layer by vacuum 
distillation (50 °C). The product was a yellowish sticky solid (38 mg 63%). 
 
Rf  = 0.3 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CD3OD, 400 MHz) δ: 5.75 (br s, NH, 
1H); 4.84 (br s, NH2, 2H); 3.26 (q, CH2NHCO, J = 1.6 Hz, 2H); 3.21 (t, CH2NH2, J = 6.0 
Hz, 2H) 3.17 (q, CH2CH2NH2, J = 6.0 Hz, 2H); 2.73 (s, NCH3, 3H); 2.31 (t, CH2CH2CO, 
J = 7.6 Hz, 2H); 2.01-1.93 (m, CH2CH2NH, 4H); 1.54 (t, CH2NCH3, J = 6.4 Hz, 4H); 
0.87 (t, CH3CH2, J = 6.4 Hz, 3H). The rest of 
1H NMR spectra was not clear (some 
unreacted alkenes were observed at 5.34 ppm ca. 19%.). 13C NMR could not be obtained 
due the weak sample. MS spectra were not obtained as the product is a cross-linked 
nanostructure. IR: νmax (cm-1): 3286w (N-H); 2924w, 2854s (all CH); 1543s (C=O); 
1258m, 1056w, 863s, 739w, 557s. 
 
7.1.2 Chapter 3  
Synthesis of Mono-Boc-DAP  
 
 
 
Di-aminopropane (22.2 ml, 335 mmol) was dissolved in absolute EtOH (80 ml) then 
Boc2O (14.6 g, 67 mmol) was dissolved in EtOH (8 ml) and added to the mixture 
dropwise over a period of one hour. Afterwards the mixture was quenched with water (10 
ml) and the solvent was evaporated in vacuo. The product was dissolved in NaOHaq (50 
ml, 1M), so that the pH >10, and the mixture was extracted three times with DCM (50 
ml). The combined organic layers were washed with citrate (1M) until the pH was 3-4. 
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The aqueous layer was then basified with NaOHaq (5M) (pH >10) and the product was 
extracted three times with DCM (50 ml). The solution was dried over MgSO4, filtered 
and dried in vacuo resulting in a white oily liquid (4.0 g, 34%). 
Rf  = 0.13 (DCM/MeOH =1:1). 
1H NMR (400 MHz, CDCl3) δ: 4.93 (s, NH, 1H); 3.20 
(app q, CH2NHCO, J = 5.2 Hz, 2H); 2.75 (t, H2NCH2, J = 6.0 Hz 2H); 1.60 (app quint, 
CH2CH2CH2, J = 6.4 Hz, 4H); 1.42 (s, C(CH3)3, 9 H). 
13C NMR (100 MHz, CDCl3) δ: 
153.27 (NHCOOtBu); 79.17(C(CH3)3); 39.77(CH2NH); 38.54 (NH2CH2); 33.41 
(CH2CH2CH2); 28.54 (C(CH3)3). HRMS: Calc. [M+H]
+ (C8H18N2O2) m/z = 175.1368, 
found [M+H]+ = 175.1447 (100%). IR: νmax (cm-1): 3340w (N-H); 2975w, 2928s, 2868s, 
(all CH); 1689s (C=O); 1538s (C=O); 1454m, 1391m, 1364m, 1327m, 1273m, 1250s, 
1170m, 1049m, 868w, 818w, 781w, 620w. 
 
Synthesis of Boc-C16-DAP 
 
Palmitic acid (1.00 g, 3.9 mmol) was dissolved in DCM (65 ml) then TBTU (1.25 g, 3.9 
mmol) and Et3N (approx. 5 ml) were added. The mixture was stirred for 5 minutes and 
mono-Boc-DAP (683 mg, 3.9 mmol) was dissolved in DCM (65 ml) and added. The 
solution was left stirring overnight. The solvent was evaporated in vacuo. After that the 
product was purified by column chromatography (DCM to DCM/MeOH (9:1)). The 
product was isolated as a white powder (1.50 g, 93%).  
Rf  =   0.43 (DCM/MeOH, 9:1). 
1H NMR (400 MHz, CDCl3) δ: 6.22 (br s, NH, 1H); 4.93 
(br s, NHBoc, 1H); 3.29 (q, CH2NHCO, J = 6.2, 6.4 Hz, 2H); 3.16 (app q, CH2NBoc, J = 
6.0, 5.6 Hz, 2H); 2.18 (t, CH2CONH, J = 7.6 Hz, 2H); 1.60 (m, CH2CH2CONH + 
CH2CH2CH2, 4H); 1.43 (s, C(CH3)3, 9H); 1.32-1.24 (m, CH3(CH2)12CH2, 24H); 0.87 (t, 
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CH3CH2, J = 7.0 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ: 173.85 (C=O); 153.15 
(OCONH); 79.52 (C(CH3)3); 37.02 (CH2NHCO); 32.07 (NHCH2CH2CH2NH); 30.44, 
29.83, 29.8, 29.65, 29.51, 29.45, 28.53, 25.95 (NHCH2CH2CH2NH + (CH2)12CO); 22.84 
(CH2CH3); 14.28 (CH3CH2). HRMS: Calc. [M+H]
+ (C24H50N2O3) m/z = 413.3738, found 
[M+H]+ = 413.3719 (33%,); Calc. [M+Na]+ (C24H48N2NaO3) m/z = 435.3571, found 
[M+Na]+ = 435.3565 (100%). IR: νmax (cm-1): 3360m (N-H); 3310m, 2918s, 2851s (all 
CH); 1685s (C=O); 1639s (C=O); 1538m, 1468w, 1444w, 1391w, 1364w, 1280m, 1253w, 
1173m, 1133w, 721w. 
 
Deprotection of Boc-C16-DAP (C16-DAP) 
 
 
Boc-Protected C16-DAP (1.3 g, 3.15 mmol) was dissolved in MeOH (25 mL) and HCl 
gas was applied for approx.15-20 seconds. The mixture was stirred for 3 hours and the 
solvent was removed in vacuo., and after drying in vacuum, the product was obtained as 
a white solid (1.1 g, 85%).  
Rf  = 0.1 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (400 MHz, CD3OD) δ: 3.24 (t, 
CH2NHCO, J = 6.8 Hz, 2H); 2.89 (t, CH2NH2, J = 7.2 Hz, 2H); 2.11 (t, CH2CO J = 6.8 
Hz, 2H); 1.80 (app quint, CH2CH2NH2, J = 7.0 Hz, 2H); 1.57 (app quint, CH2CH2CONH, 
J = 6.6 Hz, 2H); 1.25 (br s, (CH2)12, 24 H); 0.87 (t, CH3CH2, J = 7.0 Hz, 3H). 
13C NMR 
(100 MHz, CD3OD) δ: 38.19 (CH2NH2); 36.96 (CH2NHCO); 36.80 (CH2CONH); 33.08 
(CH2CH2NH2); 30.79 (CH3CH2CH2); 30.63, 30.48, 30.36 (C3H7(CH2)10); 28.84 
((CH2)2CH2CH2CONH); 27.00 (CH2CH2CONH); 23.74 (CH2CH3); 14.44 (CH3) (C=O 
peak was not observed owing to low intensity spectrum). HRMS: Calc. [M+H]+ 
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(C19H41N2O) m/z = 313.3213; found [M+H]
+ = 313.3215 (100%). IR: νmax (cm-1): 3287m 
(N-H); 2955m, 2918s, 2848s (all CH); 1642s (C=O); 1616w, 1555m, 1525w, 1468w, 
1438w, 1267w, 1163w, 1009w, 721w. 
 
Synthesis of Boc-Protected C16-DAPMA 
 
 
 
Palmitic acid (1.00 g, 3.9 mmol) was dissolved in DCM (65 ml) then TBTU (1.25 g, 3.9 
mmol) and Et3N (approx. 5 ml) were added. The mixture was stirred for 5 minutes and 
mono-Boc-DAPMA (compound 1) (950 mg, 3.9 mmol) was added. The solution was left 
stirring overnight. The solvent was evaporated in vacuo. After evaporation of solvent, the 
product was dissolved again in EtOAc (50 ml) and washed two times with sat. NaHSO4 
(15 ml), two times with sat. NaHCO3 (15 ml), three times with H2O (15 ml) and once 
with sat. NaCl (15 ml). After GPC on Bio-beads SX-1 (100%, DCM), the product was 
obtained as a white solid (1.70 g, 90 %).  
Rf = 0.08 (DCM:MeOH:Et3N, 90:10:0.1). 
1H NMR (400 MHz, CDCl3) δ: 6.82 (br s, NH, 
1H), 5.1 (br s, NHBoc, 1H); 3.34 (td, CH2NHCO, J = 5.9, 6.0 Hz, 2H); 3.20 (td, 
CH2NHBoc, J = 5.6, 5.5 Hz, 2H); 2.73 (br, CH2N(CH3), 4H); 2.47 (s, N(CH3), 3H); 2.18 
(t, CH2CONH, J = 7.2 Hz, 2H); 1.83-1.75 (m, CH2CH2N(CH3), 4H); 1.60 (t, 
CH2CH2CONH, J = 7.2 Hz, 2H); 1.43 (s, C(CH3)3, 9H); 1.32-1.24 (m, CH3(CH2)12CH2, 
24H); 0.87 (t, CH3CH2, J = 6.8 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ: 173.99 (C=O); 
156.31 (C=OBoc); 79.12 (CCH3); 36.83 (CH2NHCO); 31.87 (CH2); 29.60 (2 x CH2); 
29.39 (2 x CH2); 28.24 (C(CH3)3); 26.23 (2 x CH2); 25.84 (2 x CH2); 24.51 (CH2); 22.57 
(CH2CH3); 13.98 (CH3CH2). HRMS: Calc. [M+H]
+ (C28H58N3O3) m/z = 484.4473, found  
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[M+H]+ = 484.4474 (100%). IR: νmax (cm-1): 3300w (N-H); 3017w, 2936s, 2845s (all CH); 
1671s (C=O); 1647s (C=O); 1538m (C=O); 1456m, 1390m, 1272m, 1250s, 1171s, 1046s, 
867w, 723w.  
Deprotection of Boc-C16-DAPMA (C16-DAPMA) 
 
 
 
Boc-Protected C16-DAPMA (1.79 g 3.70 mmol) was dissolved in MeOH (25 mL) and 
HCl gas was applied for approx.15-20 seconds. The mixture was stirred for 3 hours and 
the solvent was removed in vacuo, and after drying in vacuum, the product was obtained 
as slightly orange solid (1.70 g, 95%.).  
Rf = 0.1 (90:10:1 DCM/MeOH/Et3N). 
1H-NMR (400 MHz, CD3OD) δ: 3.05-3.29 (m, 
CH2NH2 + CH2NHCO, 4H); 3.04 (t, CH2N(CH3), J = 7.4 Hz, 4H); 2.43 (s, N(CH3), 3H); 
2.22 (t, CH2CONH, J = 8.0 Hz, 2H); 2.12 (app. quint., CH2CH2N(CH3), J = 7.8 Hz, 2H); 
1.95 (quint., CH2CH2NH2, J = 6.8 Hz, 2H); 1.56 (app. quint., CH2CH2CONH, J = 6.0 Hz, 
2H); 1.24-1.19 (m, CH3(CH2)12, 24H); 0.86 (t, CH3CH2, J = 5.4 Hz, 3H). 
13C NMR (100 
MHz, CD3OD) δ: 177.42 (CONH); 55.24, 54.22 (CH2N(CH3)); 40.30 (N(CH3)); 37.77 
(CH2CO); 37.16 (CH2NHCO); 36.80 (CH2NH2); 32.99 (CH2); 30.71 (CH2); 30.39 (CH2); 
26.91 (2 x CH2); 26.71 (2 x CH2); 25.48 (2 x CH2); 23.65 (2 x CH2); 23.43(CH2CH3); 
14.37 (CH3CH2). HRMS: Calc. [M+H]
+ (C23H50N3O) m/z = 384.3948, found [M+H]
+ = 
384.3961 (100%). IR: νmax (cm-1): 3370m (N-H); 2955m, 2922s, 2851s, 2254m (all CH); 
1642m (C=O); 1612m, 1542m, 1468s, 1378m, 1260w, 1234w, 1160w, 1070w, 738s.  
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Synthesis of Mono-Boc-DAB226  
 
 
 
1,4-Diaminobutane (25 g, 284 mmol) was dissolved in THF (200 ml) and Boc2O (12.37 
g, 56.7 mmol) dissolved in THF was added dropwise over two hours. The mixture was 
then left stirring overnight, then the solvent was evaporated and the residue was dissolved 
again in water. The bis-protected water-insoluble side product was separated by filtration 
and the product was extracted from the filtrate three times with DCM (100 ml). The 
product was dried over MgSO4, filtered and dried in vacuum resulting in an oil (6.2 g, 58 
%).  
Rf  = 0.1 (DCM/MeOH/Et3N, 90:10:1). 
1H NMR (400 MHz, CDCl3): δ = 4.77 (br s, NH, 
1H); 3.07 (t, CH2NH, J = 6.2 Hz, 2H); 2.67 (t, CH2NH2, J = 6.6 Hz, 2H); 1.52-1.39 (m, 
CH2(CH2)2CH2 + C(CH3)3, 13H). 
13C NMR (100 MHz, CDCl3) δ: 156.10 (C=O); 79.05 
(C(CH3)3); 41.85 (H2NCH2); 40.48 (CH2NH); 28.49 (C(CH3)3 + CH2CH2NH2); 27.54 
(CH2CH2NH). HRMS: Calc. [M+H]
+ (C9H21N2O2) m/z = 189.1598, found [M+H]
+ = 
189.1595 (46%); Calc. [M+Na]+ (C9H20N2NaO2)  m/z = 211.1417, found [M+Na]
+ = 
211.1414 (100%). IR: νmax (cm-1): 3343m (N-H); 2975s, 2931s, 2864m (all C-H); 1686s 
(C=O); 1521s, 1481m, 1451w, 1310w, 1277m, 1170.0w, 1046w, 1006m, 818m, 778w, 
747, 614w.  
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Cyanoethyl-mono-Boc-DAB225 
 
 
Mono-Boc-DAB (5.0 g, 26.5 mmol) was dissolved in THF (15 ml) and cooled to 0 °C. 
Freshly distilled acrylonitrile (1.84 ml, 27.8 mmol) was added dropwise via syringe to the 
solution. The mixture was stirred at 0 °C for 20 min and then at 45 °C for 1.5 hour, 
afterwards the solvent was evaporated. Because mass spectrum and 1H-NMR indicated 
that the reaction was not complete, another portion of acrylonitrile (0.87 ml, 13.25 mmol) 
was added to the mixture at 0 °C. The solution was stirred for 30 min at 0 °C, for 1 h at 
45 °C and then for 2 h at 100 °C. After drying in vacuum the product was obtained as a 
yellow oil (5.35 g, 84 %). 
 
Rf  = 0.01 (DCM/MeOH/Et3N, 90:10:1). 
1H NMR (400 MHz, CDCl3) δ: 4.77 (br s, NH); 
3.10 (br t, CH2NHCO, J = 6.2 Hz, 2H); 2.90 (t, CH2CN, J = 6.8 Hz, 2H); 2.63 (t, 
CH2CH2CN, J = 8.2 Hz, 2H); 2.51 (t, CH2NH(CH2)2CN, J = 5.5 Hz, 2H); 2.48 (q, CH2NH 
J = 6.8 Hz, 2H); 1.56-1.50 (m, CH2CH2CH2CH2, 4H); 1.41 (br s, C(CH3)3, 9 H). 
13C NMR 
(100 MHz, CDCl3) δ: 153.11 (C=O); 118.81 (CN); 79.16 (C(CH3)3); 48.81 
(CH2NH(CH2)2CN); 45.09 (CH2CH2CN); 40.42 (CH2NHCO); 28.51 (C(CH3)3); 27.85 
(CH2); 25.70 (CH2); 18.79 (CH2). HRMS: Calc. [M+H]
+ (C13H26N3O2) m/z = 256.1790, 
found [M+H]+ = 256.1861 (85%); Calc. [M+Na]+ (C13H25N3NaO2) m/z = 287.1863, 
found [M+Na]+ 287.1673 (100%). IR: νmax (cm-1): 3343s (N-H); 2978s, 2935m, 2864s (all 
CH); 2245 (CN); 1689s (C=O); 1518s, 1478w, 1454m, 1391m, 1364m, 1273w, 1250w, 
1170s, 1046s, 1009w, 865w, 778w, 758m.   
  
Chapter 7 – Experimental  
212 
Cyanoethyl-Di-Boc-DAB225 
 
 
Cyanethyl-mono-Boc-DAB (5.44 g, 22.5 mmol) was dissolved in THF (25 ml) then a 
solution of Boc2O (5.41 g, 24.8 mmol) in THF (40 ml) was added at 0 °C. The reaction 
was allowed to reach r.t. while stirring for 4 h. Afterwards, water (5 ml) was added and 
the solvent evaporated. After drying in vacuum, the product was obtained in quant. yield 
(7.8 g, 97%). 
Rf  = 0.02 (DCM/MeOH/Et3N, 90:10:1). 
1HNMR (400 MHz, CDCl3) δ: 4.69 (br s, NH); 
3.42 (t, J = 6.6 Hz, CH2CH2CN, 2H); 3.24 (t, CH2NHBoc, J = 7.2 Hz, 2H); 3.10 (br t, 
CH2CN, J = 5.4 Hz, 2H); 2.60 (br t, CH2NBoc(CH2)2CN, J = 5.6 Hz, 2H); 2.01 (br s, 
NH); 1.50- 1.39 (m, CH2CH2CH2CH2 + C(CH3)3, 22H). 
13C NMR (100 MHz, CDCl3) δ: 
146.78 (CONBoc); 136.12 (CONHBoc); 118.38 (CN); 80.48 (C(CH3)3); 79.16 
(C(CH3)3); 48.25 (CH2NBoc); 43.90 (CH2NBoc); 40.05 (CH2NHBoc); 28.39 (C(CH3)3); 
27.44 (C(CH3)3); 26.02 (CH2CH2CH2NBoc); 25.51 (CH2CH2NBoc); 17.02 (CH2). 
HRMS: Calc. [M+H]+ (C18H34N3O4) m/z = 356.2315, found [M+H]
+ = 356.2208 (100%). 
IR: νmax (cm-1): 3363m (N-H); 2975s, 2935s, 2868s (all C-H); 2251 (CΞN); 1689 (C=O); 
1518m, 1478w, 1451w, 1414m, 1391w, 1267m, 1250w, 1093w, 1006w, 932m, 865m, 
774w.  
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Synthesis of N1,N2-Bis-Boc-spermidine (Boc-SPD)226 
 
 
Lithium aluminium hydride (0.389 g, 10.25 mmol) was suspended in dry ether (20 ml) 
then cyanoethyl-di-Boc-DAB (1.03 g) (2.98 mmol) dissolved in dry ether (30 ml) was 
added dropwise over 35 min at 0 °C. The mixture was stirred at 0 °C for 1 h and then 
carefully quenched with MeOH (30 ml) and water (10 ml). The resulting reaction mixture 
was strongly basic (pH > 10). The product was extracted three times with diethyl ether 
(30-40 ml). Afterwards the combined organic layers were acidified with citrate (1 M) 
until the pH was around 3-4. The product was extracted twice with water and the 
combined aqueous layers (just from second extraction) were washed with Et2O (30 ml) 
twice. The aqueous layer was basified with NaOH (1 M, ca. 200 ml) and the product was 
extracted with DCM (3 x 50 ml). The combined DCM layers were dried over MgSO4, 
filtered and the solvent was evaporated in vacuo. After drying, the product was obtained 
as a slightly yellow oil (0.63 g, 62 %). 
1H NMR (400 MHz, CDCl3) δ: 4.64 (br s, NH); 3.25-3.11 (m, CH2NBoc + CH2NHBoc, 
6H); 2.67 (t, CH2NH2, J = 6.6 Hz, 2H); 1.62 (quint., CH2CH2NH2, J = 6.9 Hz, 2H); 1.55-
1.36 (m, CH2CH2CH2CH2 + C(CH3)3, 22H). 
13C NMR (100 MHz, CDCl3) δ: 145.83 
(C=O); 136.11 (C=ONH); 81.32 (C(CH3)3); 79.48 (C(CH3)3); 46.62 (CH2NBoc); 40.33 
(CH2NHBoc + CH2NH2); 29.53 (C(CH3)3); 28.60 (C(CH3)3); 27.73 (CH2); 27.56 
((CH2)2CH2NBoc). HRMS: Calc. [M+H]
+ (C17H36N3O4) m/z = 346.2628, found [M+H]
+ 
= 346.2691 (100%). IR: νmax (cm-1): 3708m (N-H); 3665m (N-H); 3350w (N-H); 2971m, 
2935s, 2868s (all CH); 1679s (C=O); 1525s, 1478w, 1454w, 1421m, 1391w, 1364w, 
1300s, 1273m, 1250s, 1166m, 1170w, 868m, 818w, 771w.  
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Boc-Protected C16-Spermidine (Boc-C16-SPD) 
 
 
 
Palmitic acid (0.472 g, 1.84 mmol, 1.04 eq.), N1,N5-bis-Boc-spermidine (0.61 g, 1.76 
mmol), TBTU (0.585 g, 1.82 mmol) and Et3N (3.5 ml) were dissolved in DCM (65 ml). 
After the solvent was evaporated, some of the crude product (700 mg from 2.10 g) was 
purified, first by GPC in DCM and second by column chromatography (SiO2 in 
Hex/EtOAc 1:1). The product was obtained as a white powder (258 mg, purified material, 
equivalent to 76% if all was purified). 
 
Rf  = 0.23 (Hex:EtOAc, 1:1). 
1H NMR (400 MHz, CDCl3) δ: 6.72 (br s, NH, 1H); 4.55 (br 
s, NHBoc, 1H); 3.27-3.13 (m, CH2NHCO, 8H); 2.17 (t, CH2CONH, J = 7.6 Hz, 2H); 
1.68-1.52 (m, CH2CH2NBoc + (CH2)2CH2NHBoc + CH2CH2CONH, 8H); 1.45 + 1.43 (2 
s, C(CH3)3, 18H); 1.32-1.24 (m, CH3(CH2)12CH2, 24H); 0.87 (t, CH3CH2, J = 6.8 Hz, 
3H). 13C NMR (100 MHz, CDCl3) δ: 172.11 (C=O); 156.14, 152.54 (2 x C=OBoc); 
81.43, 79.88 (2 x C(CH3)3); 46.65 ((CH2)2NCO); 37.15 (CH2NHCO); 32.07 
(CH2NHCOBoc); 29.83, 29.80, 29.66, 29.53 (C(CH3)3); 29.50, 29.47, 28.55 (C(CH3)3); 
29.50 (CH2); 29.47 (CH2); 28.55 (CH2); 27.61 (CH2); 25.96 (CH2CH2CO); 24.76 (CH2); 
23.03 (CH2); 22.83 (CH2CH3); 14.27 (CH3CH2). HRMS: Calc. [M+Na]
+ (C33H65N3NaO5) 
m/z = 606.4831, found [M+Na]+ = 606.4829 (100%);  Calc. [M+H]+ (C33H66N3O5) m/z 
= 584.4997, found =  584.4986 (24%). IR: νmax (cm-1): 3819m (N-H); 3765m (N-H); 
2965m, 2943s, 2875s (all CH); 1682s, 1544s (C=O); 1525s, 1478w, 1454w, 1421m, 
1393w, 1361w, 1317s, 1265m, 1254s, 1132m, 1112w, 862m, 834w, 761w.  
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Deprotection of Boc-C16-SPD (C16-SPD) 
 
Boc-Protected Spermidine (258 mg, 0.44 mmol) was dissolved in MeOH (25 mL) and 
HCl gas was applied for ca. 15-20 seconds. The mixture was stirred for 3 hours and the 
solvent was removed in vacuo, and after drying in vacuum, product was obtained as a 
white solid (209 mg, 81%).  
Rf  = 0.2 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (400 MHz, CD3OD) δ: 3.25 (t, 
CH2NHCO J = 6.6 Hz, 2H); 3.12-3.03 (m, CH2NH + CH2NH2, 6H); 2.22 (t, CH2CONH, 
J = 7.6 Hz, 2H); 1.92 (app quint, CH2CH2NHCO J = 7.6 Hz, 2H); 1.78 (app. quint, 
CH2CH2NH2 + CH2CH2CONH, J = 4.0 Hz, 4H); 1.55 (br quint, CH2CH2CH2NH2, 2H); 
1.24 (br app s, CH3(CH2)12CH2, 24H); 0.84 (t, CH3CH2, J = 6.8 Hz, 3H). Solubility 
problems prevented the measurement of 13C NMR. HRMS: Calc. [M+H]+ (C23H50N3O) 
m/z = 384.3948, found [M+H]+ = 384.3948 (100%). IR: νmax (cm-1): 3308m (N-H); 
2954m, 2916s, 2849s, 2788m (all CH); 2746m, 1644s, 1613m (C=O); 1543s (N-H); 
1526s, 1464s, 1439w, 1360m, 1344m, 1269m, 1204, 1172m, 1090m, 1059m, 1015m, 
757m, 728m, 680m, 600w, 550m, 458w. 
 
Boc-Spermine (Boc-SPM)227 
 
 
Under a N2-atmosphere, spermine (4.92 g, 23.58 mmol) was dissolved in MeOH (100 ml) 
and cooled to -78 °C. Ethyl tri-fluoroacetate (2.45 ml, 23.58 mmol) was added gradually 
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and the mixture was stirred for 1 h at -78 °C and for 75 minutes at 0 °C. Afterwards, 
Boc2O (20.58 g, 95.32 mmol) was added, the solution was stirred for 1 h at 0 °C, then for 
105 min at r.t. and subsequently quenched with water (10 ml). NH3aq (concentrated) was 
added until the pH was higher than 10 and the mixture was stirred overnight. The solvent 
was evaporated and the crude product was dried in vacuum as a very sticky colourless 
yellow oil. Mass spectrometry suggested the ratio of desired product and tetra-Boc-
spermine as ca. 3:1. The crude product was used in the following coupling reaction 
without further purification.  
 
Rf = 0.18 (Hex:EtOAc, 1:1). 
1H NMR (400 MHz, CDCl3) δ: 8.29 (br s, NH, 1H); 4.45 (br 
s, NH2, 2H); 3.30-3.08 (m, CH2NHBoc + CH2NBoc, 10H); 2.90 (m, CH2CH2NH2, 2H); 
1.87 (m, CH2CH2NH2, 2H); 1.65 (m, CH2CH2NHBoc, 2H); 1.45-1.42 (m, CH2NHBoc + 
C(CH3)3, 31H). Solubility problems prevented the measurement of 
13C NMR. HRMS: 
Calc. [M+H]+ (C25H52N4O6) m/z = 502.688, found [M+H]
+ = 503.3794 (100%); Calc. 
[M+Na]+ (C25H50N4NaO6) m/z = 525.3803
, found [M+Na]+ = 625.4136 (54%). IR: νmax 
(cm-1): 3340w (N-H); 2971m, 2935s (all CH); 2871m, 1679s (C=O); 1531m, 1478w, 
1391m,1304w, 1200w, 1160m, 871w, 835w, 801m, 771w, 721w. 
 
Boc-Protected C16-Spermine (Boc-C16-SPM) 
 
 
 
 
Palmitic acid (0.76 g, 2.98 mmol) was dissolved in DCM (65 ml) then TBTU (1.25 g, 3.9 
mmol) and Et3N (approx. 5 ml) were added. The mixture was stirred for 5 minutes and 
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tri-Boc-spermidine (1.50 g, 2.98 mmol) was dissolved in DCM (65 ml) and added. The 
solution was left stirring overnight. After the solvent was evaporated, product was 
purified first by silica column in DCM/MeOH (1:0 to 9:1). Two fractions were combined 
(2.5 g) and purified again by a second column in Hex/EtOAc 2:1. The product was 
obtained as a colourless oil (448 mg, 28 %). After 72 h some white crystals formed in the 
oil.  
Rf = 0.22 (Hex:EtOAc, 1:1). 
1H NMR (400 MHz, CDCl3) δ: 8.29 (br s, NH, 1H); 5.27 (br 
s, NHBoc, 1H); 3.13-3.25 (m, CH2NHCO + CH2NBoc + CH2NHBoc, 12H); 2.17 (t, 
CH2CONH, J = 7.6 Hz, 2H); 1.69-1.60 (m, CH2CH2NBoc + (CH2)2CH2NHBoc, 8H); 
1.45 (s, C(CH3)3, 27H); 1.32-1.24 (m, CH3(CH2)12CH2 + CH2CH2CONH, 26H); 0.87 (t, 
CH3CH2, J = 7.0 Hz, 3H). Solubility problems prevented the measurement of 
13C NMR. 
HRMS: Calc. [M+H]+ (C41H81N4O7) m/z = 742.6100, found [M+H]
+ = 742.6095 (25%); 
Calc. [M+Na]+ (C41H80N4NaO7) m/z =  763.5921, found [M+Na]
+ = 763.5914 (100%). 
IR: νmax (cm-1): 3352w (N-H); 2998m, 2945s (all CH); 2887m, 1673s, 1561m (C=O); 
1478w, 1398m,1317w, 1246w, 1187m, 894w, 865w, 823m, 745w, 721w. 
 
Deprotection of Boc-C16-SPM (C16-SPM) 
 
 
 
Boc-Protected Spermine (448 mg), was dissolved in MeOH (25 mL) and HCl gas was 
applied for approx.15-20 seconds. The mixture was stirred for 3 hours and the solvent 
was removed in vacuo., and after drying in vacuum, the product was obtained as a white 
solid (323 mg, 97 %). 1H NMR (400 MHz, CDCl3) δ: 5.65 (br s, NH); 3.25 (t, CH2NHCO 
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J = 6.8 Hz, 2H); 3.17-3.03 (m, CH2NH + CH2NH2, 10H); 2.22 (t, CH2CONH, J = 7.4 Hz, 
2H); 2.08 (app. quint., CH2CH2NH2, J = 7.9 Hz, 2H); 1.89 (approx. quint., 
CH2CH2NHCO, J = 7.0 Hz, 2H); 1.78 (m, CH2(CH2)2CH2, 4H); 1.55 (approx. quint, 
CH2CH2CONH, J = 6.0 Hz, 2H); 1.24 (s, CH3(CH2)12CH2, 24H); 0.84 (t, CH3CH2, J = 
6.6 Hz, 3H). Solubility problems prevented the measurement of 13C NMR. HRMS: Calc. 
[M+H]+ (C26H58N4O) m/z=  441.4527, found [M+H]
+ = 441.4541 (100%). IR: νmax (cm-
1): 3317m, 2954s (N-H); 2918s, 2849s, 2782s, 2750s, 1703s (all CH); 1645s (C=O); 
1531s, 1488m, 1464s, 1444m, 1411w, 1388m, 1349m, 1269m, 1250m, 1209m, 1182s, 
1164s, 1087w, 1058m, 979w, 872w, 761m, 724m, 678m, 550w.   
 
7.1.3 Chapter 4 
Synthesis of H2/Newkome-G1/O-tert-Butyl Branching (Compound 2)109,250 
 
Tris (hydroxymethyl) aminoethane (6.01 g, 49.52 mmol) and DMSO (10 mL) were mixed 
and cooled to 15 °C under N2.  NaOH (1 mL, 5 M) was added to the reaction flask. Then 
tert-butyl acrylate (25 mL, 34 mmol) was added dropwise (40 mL/h, 37.5 min). The 
reaction was cooled to room temperature and stirred for 24 h. The solvent was removed 
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in vacuo (30-40 °C). The product was purified by column chromatography (SiO2, 2:1 v/v, 
EtOAc/Hexane, 0.05% v/v NH4OH). A colorless oil was recovered (4.80 g, 80%). 
Rf = 0.25 (2:1, EtOAc/Hexane, drops of NH4OH). 
1H NMR (CDCl3, 400 MHz) δ: 3.64 (t, 
OCH2CH2, J = 6.0 Hz, 6H); 3.41 (s, CCH2O, 6H); 2.43 (t, CH2CH2O, J = 6.0 Hz, 6H); 
1.81 (s, NH2, 2H); 1.38 (s, (CH3)3C, 27H). 
13C NMR (CDCl3, 100 MHz) δ: 170.15 (COOt-
Bu); 79.59 (C(CH3)3); 72.37 (CCH2O); 66.64 (OCH2CH2); 55.54 (CCH2O); 35.78 
(CH2CH2O); 27.62 ((CH3)3C). HRMS: Calc. [M+H]
+ (C25H48NO9) m/z = 506.3324, 
found [M+H]+ = 506.3320 (100%). IR: νmax (cm-1): 3412w (N-H); 2998m, 2945s (all CH); 
2857m, 1673s, 1561m, 1498w, 1496m,1317w, 1246w, 1152s, 1132s, 1112s, 1048s, 865w, 
823m, 670w, 543w. 
 
Synthesis of Z/Newkome-G1/O-tert-Butyl (Compound 3)251 
 
 
 
Compound 2 (1.33 g, 2.62 mmol) was dissolved in DCM (21 mL), Na2CO3 (25 mL, 25% 
by mass in water) was added while stirring, then benzyl chloroformate (1.17 mL, 6.8 
mmol) was added (rapidly), and the mixture was left to stir for 48 h. The product was 
extracted with DCM (40 mL) then dried over MgSO4 and the solvent was removed in 
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vacuo. The crude product was purified by column chromatography (SiO2, 2:1 v/v, 
Cyclohexane/EtOAc). The product was a colorless oil (1.40 g, 83%). 
Rf = 0.65 (2:1 Cyclohexane/EtOAc). 
1H NMR (CDCl3, 400 MHz) δ: 7.23-7.19 (m, CH 
aromatic, 5H); 5.16 (s, NH, 1H); 4.91 (s, CH2 benzylic, 2H); 3.55 (s, CCH2O, 6H); 3.54 
(t, OCH2CH2, J = 6.0 Hz, 6H); 2.33 (t, CH2CH2O, J = 6.0 Hz, 6H); 1.31 (s, (CH3)3C, 
27H). 13C NMR (CDCl3, 100 MHz) δ: 171.14 (COOt-Bu); 155.53 (CONH); 137.03, 
128.69.128.26, 128.18 (CH aromatic); 80.76 (C(CH3)3); 73.65 (CCH2O); 69.66 (CH2O); 
67.37 (CH2CH2O); 66.39 (CH2 benzylic); 59.00 (CH2O); 36.51 (CH2CH2O); 28.37 
((CH3)3C). HRMS: Calc. [M+H]
+ (C33H54NO11) m/z = 640.3691, found [M+H]
+ = 
640.3724 (100%). IR: νmax (cm-1): 3097m (CH, aromatic); 2987w (N-H); 2963m, 2927s, 
2851s, 2254m (all CH); 1751m, 1665s (C=O); 1652s (C=O); 1612m (C=C); 1542m, 
1468s, 1378m, 1260w, 1234w, 1160w, 1070w, 748s, 561w. 
 
Synthesis of Z/Newkome-G1/OH (Compound 4)251 
 
Compound 3 (1.30 g, 2.03 mmol) was mixed with formic acid (7.5 mL) and stirred for 24 
h at room temperature. Formic acid was removed in vacuo at 50 °C; the product was a 
colorless oil (950 mg, 99%). 
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Rf  = 0.25 (90:10 DCM/MeOH). 
1H NMR (Acetone-d6, 400 MHz) δ: 8.2 (s, COOH, 3H); 
7.37-7.29 (m, CH aromatic, 5H); 5.78 (s, NH, 1H); 5.02 (s, CH2 benzylic, 2H); 3.70 (s, 
CCH2O, 6H); 3.67 (t, OCH2CH2, J = 6.0 Hz, 6H); 2.54 (t, CH2CH2O, J = 6.0 Hz, 6H). 
13C NMR (Acetone-d6, 100 MHz) δ: 173.01 (COOH); 158.17 (CONH); 128.50, 128.54, 
129.16, 138.39 (CH aromatic); 69.91 (CCH2O); 67.67 (CH2CH2O); 66.12 (CH2 benzylic); 
59.81 (CCH2O); 35.11 (CH2CH2O). HRMS: Calc. [M+H]
+ (C21H30NO11) m/z = 
472.1813, found [M+H]+ = 472.1807 (100%). IR: νmax (cm-1): 3065m (CH, aromatic); 
3002w (N-H); 2956m, 2945s, 2875s, 2456m (all CH); 1745s (C=O); 1664s (C=O); 1635s 
(C=O); 1623m (C=C); 1534m, 1476s, 1340m, 1284w, 1245w, 1178w, 1082w, 734s, 585w.  
 
Synthesis of  Z/G1/mono-Boc DAPMA (Compound 5)251 
 
 
 
Compound 4 (800 g, 1.7 mmol) was dissolved in THF (40 mL), DCC (2.30 g, 11.5 mmol) 
and Et3N (1.20 g, (1.10 mL), 11.5 mmol) were added. The mixture was cooled to 0 °C. 
Compound 1 (1.30 g, 3.7 mmol) was dissolved in THF (40 mL) then the solution was 
added dropwise to the reaction flask. The reaction was left to stir for 3 days then it was 
filtered to remove the precipitate. The filtrate was collected and the solvent dried in vacuo. 
In order to remove the formed DCU (N,N’-Dicyclohexylurea), the residue was dissolved 
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in DCM (80 mL), filtered over Celite then dried in vacuo. The crude product was 
dissolved in chloroform (80 mL), filtered over Celite and dried in vacuo. The product at 
this stage was an oil-like that needed purification by GPC column (Bio-beads, 100% 
DCM). The compound was the first fraction to be collected; it was a yellowish orange 
(amber) oil. The yield was (980 mg, 50%). 
 
Rf = 0.1 (100% MeOH).  
1H NMR (CDCl3, 400 MHz) δ: 7.26-7.24 (m, CH aromatic, 5H); 
7.22-7.15 (br m, NH amides, 3H); 5.26 (s, NH, 1H); 5.25 (br m, NHBoc, 3H); 5.23 (s, 
CH2 benzylic, 2H); 3.61 (s, CCH2O, 6H); 3.60 (t, OCH2CH2, J = 6.0 Hz, 6H); 3.38 (d, 
NHCH2CH2CH2, J = 5.8 Hz 6H); 3.19 (d, CH2NHCOOt-Bu, J = 5.8 Hz, 6H); 2.32-2.13 
(CH2CH2O, CH2N(CH3)CH2 and CH2N(CH3)CH2, 18H); 2.18 (s, NCH3, 9H); 1.60 (m, 
CH2CH2CH2, 12H); 1.35 (s, C(CH3)3, 27H). 13C NMR (CDCl3, 100 MHz) δ: 176.21 
(CONH); 156.02, 154.22 (C=O); 154.22 137.22, 128.19, 127.30, 127.11 (CH aromatic); 
72.01 (NH2CCH2O); 67.91 (OCH2CH2O); 55.90 (CH2CH2NCH3); 41.80 (NCH3); 39.30 
(NHCH2CH2); 38.10 (OCNHCH2); 36.88 (OCH2CH2CO); 28.10 (OC(CH3)3); 26.90 
(CH2CH2NCH3); 26.30 (CH2CH2NH). HRMS: Calc. [M+2H]
2+ (C57H106N10O14) m/z = 
577.3940, found [M+2H]2+ = 577.3887 (100%). IR: νmax (cm-1): 3037w (CH, aromatic); 
3190m (N-H); 2963m, 2927s, 2851s, 2254m (all CH); 1772s (C=O); 1665s (C=O); 1652s 
(C=O); 1615m (C=C); 1554m, 1448s, 1338m, 1256w, 1214w, 1120w, 875w, 564s, 451w.  
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Removing Compound 5’s Z Group (Deprotection) (Compound 6)251 
 
Compound 5 (950 mg, 0.823 mmol) was dissolved in EtOH (7.5 mL) then Pd/C (10%, 65 
mg) was added as the catalyst. The reaction was left stirring under H2 for 72 h and 
monitored by TLC. The mixture was filtered over Celite to remove the catalyst. The 
solvent was dried in vacuo and the product was concentrated and purified by gel 
permeation chromatography (GPC) column (Bio-beads, 100% DCM).   The product was 
a gluey orange solid (700 mg, 83%).   
Rf = 0.01 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 7.31-7.26 (br m, 
NH amides, 3H); 5.32 (s, NH, 2H); 5.32 (br m, NHBoc, 3H); 3.68 (s, CCH2O, 6H); 3.66 
(t, OCH2CH2, J = 6.0 Hz, 6H); 3.43 (d, NHCH2CH2CH2, J = 5.8 Hz 6H); 3.14 (d, 
CH2NHCOO
t-Bu, J = 5.8 Hz, 6H); 2.39-2.35 (m, CH2CH2O, CH2N(CH3)CH2 and 
CH2N(CH3)CH2, 18H); 2.17 (s, NCH3, 9H); 1.67 (m, CH2CH2CH2, 12H); 1.43 (s, 
C(CH3)3, 27H). 
13C NMR (CDCl3, 100 MHz) δ: 171.03 (C=O); 154.98 (C=O); 72.60 
(NH2CCH2O); 67.91 (OCH2CH2O); 55.92 (CH2CH2NCH3); 41.80 (NCH3); 39.30 
(NHCH2CH2); 38.10 (OCNHCH2); 36.88 (OCH2CH2CO); 28.15 (OC(CH3)3); 26.97 
(CH2CH2NCH3); 26.30 (CH2CH2NH). HRMS: Calc. [M+2H]
2+ (C49H100N10O12) m/z = 
510.3756, found [M+2H]2+ = 510.3760 (100%). IR: νmax (cm-1): 3112m (N-H); 2976m, 
2935s, 2764s, 2388m (all CH); 1745s (C=O); 1675s (C=O); 1657s (C=O); 1519m, 1439s, 
1348m, 1276w, 1226w, 1174w, 765w, 536s.  
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Coupling of Compound 6 and Behenic Acid (Compound 7) 
 
 
Behenic acid (1.00 g, 3 mmol) was dissolved in DCM (65 mL). TBTU (1.25 g, 3.95 
mmol) and Et3N (5.4 mL) were added. The mixture was stirred for 5 minutes at room 
temperature. Compound 6 (680 mg, 0.66 mmol) was dissolved in DCM (65 mL) then was 
added to the reaction flask. The reaction was stirred overnight, then the mixture was 
concentrated in vacuo. The product was concentrated and purified by gel permeation 
chromatography (GPC) column (Bio-beads, 100% DCM).   The product was a gluey 
orange solid (840 mg, 95%).   
 
Rf = 0.01 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 7.28-7.23 (br m, 
NH amides, 3H); 5.30 (s, NH, 1H); 5.24 (br m, NHBoc, 3H); 3.68 (s, CCH2O, 6H); 3.66 
(t, OCH2CH2, J = 6.0 Hz, 6H); 3.43 (d, NHCH2CH2CH2, J = 5.8 Hz 6H); 3.14 (d, 
CH2NHCOO
t-Bu, J = 5.8 Hz, 6H); 2.72 (t, CHCH2CH, 2H); 2.39-2.35 (m, CH2CH2O, 
CH2N(CH3)CH2 and CH2N(CH3)CH2, 18H); 2.17 (s, NCH3, 9H); 2.12 (t, CH2CH2CO, J 
= 8 Hz, 2H); 1.67-1.62 (m, CH2CH2CH2, 34H); 1.43 (s, C(CH3)3, 27H); 0.84 (t, CH3CH2, 
J = 8 Hz, 3H).  13C NMR (CDCl3, 100 MHz) δ: 174.43 (CHNHCO); 144.80 (CONH); 
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77.24 (CCH3); 67.68 (OCH2CH2O); 54.15 (CH2CH2NCH3); 51.54 (CH2NCH3); 42.04 
(NCH3); 40.10 (NHCH2CH2); 34.19 (OCNHCH2); 33.26 (OCH2CH2CO); 31.60 
(CH2CO); 29.43 (OC(CH3)3); 29.23 (CH2CH2NCH3); 29.19 (CH2CH2NH) 29.17 
(CH2CH2CO); 28.49 (CH2CH3); 28.11 (CH2); 27.62 (CH2); 26.23 (CH2); 25.54 (CH2); 
14.16 (CH3CH2). HRMS: Calc. [M+2H]
2+ (C71H142N10O13) m/z = 671.4904, found 
[M+2H]2+ = 671.4917 (100%). IR: νmax (cm-1): 3290w (N-H); 2928s, 2857s (all CH); 
1694s (C=O); 1652s (C=O); 1532m, 1250s, 1168s, 1094s, 864m, 745m. 
 
De-protection of Compound 7 (Binder-Dend) 
 
 
 
Compound 7 (800 mg, 0.6 mmol) was dissolved in methanol (25 mL) then HCl gas was 
applied for 15-20 seconds then the mixture was stirred for 3 hours and monitored by TLC. 
The solvent was dried in vacuo and the product was a gummy orange solid (680 mg, 
90%). 
Rf = 0.03 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (CDCl3, 400 MHz) δ: 7.31-7.26 (br m, 
NH amides, 3H); 6.34-6.12 (br m, NH2, 6H); 5.20 (s, NH, 1H); 3.63 (s, CCH2O, 6H); 
3.60 (t, OCH2CH2, J = 6.0 Hz, 6H); 3.55 (d, NHCH2CH2CH2, J = 5.8 Hz 6H); 3.27 (d, 
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CH2NHCOO
t-Bu, J = 5.8 Hz, 6H);3.66 (t, OCH2CH2, J = 6.0 Hz, 6H); 3.43 (d, 
NHCH2CH2CH2, J = 5.8 Hz, 6H); 3.14 (d, CH2NHCOOt-Bu, J = 5.8 Hz, 6H); 2.72 (t, 
CHCH2CH, J = 5.4 Hz, 2H); 2.39-2.35 (m, CH2CH2O, CH2N(CH3)CH2 and 
CH2N(CH3)CH2, 18H); 2.17 (s, NCH3, 9H); 2.12 (t, CH2CH2CO, J = 8.0 Hz, 2H); 1.67-
1.59 (m, CH2CH2CH2, 34H); 0.84 (t, CH3CH2, J = 8.0 Hz, 3H).  
13C NMR (CDCl3, 100 
MHz) δ: 174.43 (CHNHCO); 164.82 (CONH); 67.68 (OCH2CH2O); 54.15 
(CH2CH2NCH3); 51.54 (CH2NCH3); 42.04 (NCH3); 40.10 (NHCH2CH2); 34.19 
(OCNHCH2); 33.26 (OCH2CH2CO); 31.60 (CH2CO); 29.43 (OC(CH3)3); 29.23 
(CH2CH2NCH3); 29.19 (CH2CH2NH) 29.17 (CH2CH2CO); 28.49 (CH2CH3); 26.75 
(CH2); 25.73 (CH2); 24.31 (CH2); 22.17 (CH2); 20.98 (CH2); 14.16 (CH3CH2). HRMS: 
Calc. [M+3H]3+ (C56H119N10O7) m/z = 347.9749, found [M+3H]
3+ = 347.9797 (100%); 
Calc. [M+2H]2+ (C56H118N10O7) m/z = 521.4587, found [M+2H]
2+ = 521.4598 (45%). IR: 
νmax (cm-1): 3290w (N-H); 2928s, 2857s (C-H); 1694s (C=O); 1574s, 1250s, 1170s, 
1092s, 862m, 668m, 580w. 
 
Coupling of Thioglycolic acid and Compound 1 (Compound 8) 
 
 
 
Thioglycolic acid (1.0 g, 0.76 mL, 10.86) was dissolved in DCM (65 mL), then TBTU 
(3.7 g, 11.50 mmol) and Et3N (5.4 mL, 38.72 mmol) were added respectively. The 
mixture was stirred for 5 minutes at room temperature. The mixture was stirred for 5 
minutes then compound 1 (2.66 g, 10.86 mmol) was dissolved in DCM (65 mL) and 
added to the reaction flask. The reaction was stirred overnight then the mixture was 
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concentrated in vacuo and the residue purified by GPC column chromatography (Bio-
beads, 100% DCM). The product was a sticky orange solid with a distinct sulfur smell 
(2.80 g, 81%).  
Rf = 0.15 (90:10:1 DCM/MeOH/Et3N).
 1H NMR (CDCl3, 400 MHz) δ: 7.45 (br t, NH 
amides, J = 6.2 Hz, 2H); 3.45 (d, CH2SH, J = 5.8 Hz, 2H); 3.42 (q CH2NHCO, J = 5.6 
Hz, 2H); 3.18 (q, CH2CH2NH, J = 6.8 Hz, 2H); 2.45 (t, CH2N(CH3), J = 6.4 Hz, 4H); 2.26 
(s, CH2N(CH3), 3H); 1.70 (m, CH2CH2NH, 4H); 1.51 (t, CH2SH, J = 5.8 Hz, 1H). 
13C 
NMR (CDCl3, 100 MHz) δ: 165.76 (CONH); 162.37 (OCONH); 81.15 (CCH3); 59.34 
(CH2NCH3); 48.43 (NCH3); 37.86 (CH2NH); 36.98 (CH2NHCO); 35.74 (CH2CO); 32.05 
(CH2SH); 27.65 (C(CH3)3); 26.07 (CH2CH2NCH3); 25.11 (CH2CH2NH). HRMS: Calcd. 
[M+H]+ (C14H29N3O3S) m/z = 319.1924, found [M+H]
+ = 319.1921 (100%).  νmax (solid): 
3287w (N-H); 3009w, 2926s, 2855s, (all CH); 2603m, 2586m (S-H); 1638s (C=O); 1542s 
(C=O); 1464m, 1299m, 1272m, 1250s, 1171s, 1056m 1049s, 867w, 723w.  
 
Synthesis of Au-Thiol-DAPMA-Boc (Au-8) 
 
 
 
Tetrachloroauric acid (210 mg. 0.6 mmol) was diluted by ultra-pure water (50 ml) to give 
a yellow soulution. Sodium citrate (3 mL, 50 mg/mL) was added to the solution, boiled 
at > 97 °C and the colour changed to dark grey/black indicating the success of the 
reduction. The mixture was boiled for a further hour, and on prolonged heating the colour 
changed from black to dark red (ruby). Compound 8 (192 mg, 0.6 mmol) was dissolved 
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in ultra-pure water (50 mL) then added to the reaction flask and left to boil for another 
hour; the colour changed to black indicating the coupling of compound 8 and the citrate-
stabilized AuNPs. Once the reaction flask reached room temperature, the mixture was 
purified using a dialysis membrane 30 (MWCO-12, 1400 Dalton), the dialysis process 
took place overnight (water was replaced twice). The pure product was collected from the 
dialysis membrane and solvent was dried in vacuo and the product was obtained in 91% 
yield (280 mg).  
Rf = 0.01 (MeOH). 
1H NMR (CD3OD, 400 MHz) δ: 6.85 (br s, NH, 1H); 5.34 (br s, 
NHBoc, 1H); 3.48 (br s, CH2S, 2H); 3.32 (q, CH2NHCO, J = 6.0 Hz, 2H); 3.21 (q, 
CH2NHBoc, J = 6.0 Hz, 2H); 2.54 (m, CH2CH2NH, 4H); 2.23 (s, NCH3, 3H); 1.62 (t, 
CH2CH2NCH3, J = 6.4 Hz, 4H); 1.41 (s, C(CH3)3, 9H). 
13C NMR (CDCl3, 100 MHz) δ: 
169.27 (CONH); 158.32 (OCONH); 80.04 (CCH3); 58.42 (CH2NCH3); 46.65 (NCH3); 
38.91 (CH2NH); 37.76 (CH2NHCO); 34.92 (CH2CO); 31.65 (CH2S); 27.93 (C(CH3)3); 
25.98 (CH2CH2NCH3); 24.21 (CH2CH2NH). IR: νmax (cm-1): 3107w (N-H); 2981w, 2942s 
(all CH); 1683s (C=O); 1532s (C=O); 1443w, 1397w, 1361s, 1278w, 1245m, 1109w. 
UV-Vis, TEM and DLS indicated aggregation of the nanoparticles into nanocomposite.  
 
Deprotection of Au-8 (Binder-NC) 
 
 
Au-8 (260 mg, 0.51 mmol) was dissolved in methanol (20 mL) then HCl gas was applied 
for 15-20 seconds and the mixture was stirred for 3 hours and monitored by TLC. The 
solvent was dried in vacuo and the product was a gummy orange solid (680 mg, 90%).   
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Characterizing this product was achieved by energy dispersive X-Ray (EDX) analysis as 
described in Chapter 4. 1H NMR (CDCl3, 400 MHz) showed the loss of the Boc group at 
1.4 ppm. MS spectra could not be obtained. 1H NMR (CD3OD, 400 MHz) δ: 7.02 (br s, 
NH, 1H); 6.76 (br s, NH2, 2H); 4.12 (br s, CH2S, 2H); 3.35 (q, CH2NHCO, J = 6.0 Hz, 
2H); 3.26 (q, CH2NH2, J = 6.0 Hz, 2H); 2.67 (m, CH2CH2NH, 4H); 2.29 (s, NCH3, 3H); 
1.71 (t, CH2CH2NCH3, J = 6.4 Hz, 4H). 
13C NMR (CDCl3, 100 MHz) δ: 170.06 (CONH); 
78.61 (CCH3); 61.34 (CH2NCH3); 47.71 (NCH3); 39.64 (CH2NH); 37.22 (CH2NH2); 
35.37 (CH2CO); 32.09 (CH2S); 24.67 (CH2CH2NCH3); 23.82 (CH2CH2NH). IR: νmax (cm-
1): 3350w (N-H); 2975w, 2931s, 2797s (all CH); 1695s (C=O); 1521s (C=O); 1454.7w, 
1391w, 1367s, 1277w, 1250m, 1173w. 
UV-Vis, TEM and DLS indicated aggregation of the nanoparticles into nanocomposite.  
 
Coupling Poly(acrylic acid) and Compound 1 (Boc-Binder-Poly) 
 
 
 
Poly(acrylic acid) (2.50 g, 1.4 mmol) was dissolved in DCM (65 mL) then TBTU (1.25 
g, 3.95 mmol) and Et3N (4.5 mL, 38.72 mmol) were added. The mixture was stirred for 
5 minutes, then compound 1 (0.34 g, 1.4 mmol) was dissolved in DCM (65 mL) and 
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added to the reaction flask. The reaction was stirred overnight then the mixture was 
concentrated in vacuo and the residue was purified by GPC column (Bio-beads, 100% 
DCM). The product was a white powder (1.80 g, 54%). This system could not be analyzed 
by MS or NMR, therefore it was characterized after deprotection by CHN elemental 
analysis (section 4. 4. 2), C = 53%, H = 7% and N = 7%.  
 
Deprotection of Boc-Binder-Poly (Binder-Poly) 
 
 
Boc-Binder-Poly (1.50 g, 0.63 mmol) was dissolved in MeOH (45 mL) then HCl gas was 
applied for 15-20 seconds then the mixture was stirred for 3 hours and monitored by TLC. 
The solvent was dried in vacuo product was a gummy brown solid (1.23 g, 86%).   
The product was characterized by MS – however we could not detect the polymer due to 
its polydispersity. In addition, 1H NMR spectra showed only some of the ligand protons 
although importantly demonstrated the loss of Boc group, after the deprotection reaction, 
at 1.4 ppm. CHN elemental analysis; C (53.49%), H (7.40%) and N (7.26%), allowed 
molar mass to be predicted as 2604.20 (+ 8HCl), calculated from the proposed chemical 
formula of C103H170N12O46; molar mass = 2312.31. IR: νmax (cm-1): 3012w (N-H); 2951w 
(CH); 1642s (C=O); 1626s (C=O); 1531w (CONH); 1454w, 1391w, 1367s 1277w, 
1250m, 1173w. 687m, 544w.  
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7.1.4 Chapter 5  
Synthesis of C18-di-Boc-SPD 
 
Stearic acid (334 mg, 1.17 mmol) was dissolved in CH2Cl2 (23 mL), and TBTU (373 mg, 
1.16 mmol) and triethylamine (ca. 2.3 mL) were added. The reaction mixture was stirred 
for 5 min before di-boc-spermidine (390 mg, 1.13 mmol) in CH2Cl2 (19 mL) was added. 
The solution was stirred overnight and the solvent removed in vacuo to give an orange 
oil as the crude, which was purified by gel permeation chromatography (GPC) column 
(Bio-beads, 100% DCM) and secondly on silica gel using hexane/ethyl acetate (1:1) to 
give a white solid product (0.345 g, 49%). 
Rf = 0.69 (1:1 hexane/ethyl acetate). 
1H NMR (400 MHz, CD3OD) δ: 6.72 (br s, NH, 1H); 
4.55 (br s, NHBoc, 1H); 3.27-3.13 (m, CH2NHCO, 8H); 2.17 (t, CH2CONH, J = 7.6 Hz, 
2H); 1.68-1.52 (m, CH2CH2NBoc + (CH2)2CH2NHBoc + CH2CH2CONH, 8H); 1.45 + 
1.43 (2 s, C(CH3)3, 18H); 1.32-1.24 (m, CH3(CH2)12CH2, 24H); 0.87 (t, CH3CH2, J = 6.8 
Hz, 3H). 13C NMR (100 MHz, CDCl3) δ: 172.11 (C=O); 156.14, 152.54 (2 x C=OBoc); 
81.43, 79.88 (2 x C(CH3)3); 46.65 ((CH2)2NCO); 37.15 (CH2NHCO); 32.07 
(CH2NHCOBoc); 29.53, 29.50(C(CH3)3); 29.47, 28.55 (C(CH3)3); 27.61 (CH2CH2CO); 
25.96 (CH2); 24.23 (CH2); 23.16 (CH2); 22.97 (CH2); 22.63 (CH2CH3); 14.27 (CH3CH2). 
HRMS: Calc. [M+H]+ (C35H70N3O5) m/z = 612.5315, found [M+H]
+ = 612.5304 (65%); 
Calc. [M+Na]+ (C35H69N3 NaO5) m/z = 634.5135, found [M+Na]
+ = 634.5126 (100%). 
IR: νmax (cm-1): 3819m (N-H); 3765m (N-H); 2965m, 2943s, 2875s (all CH); 1682s, 1544s 
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(C=O); 1525s, 1478w, 1454w, 1421m, 1393w, 1361w, 1317s, 1265m, 1254s, 1132m, 
1112w, 862m, 834w, 761w. 
 
Synthesis of C18-SPD 
 
C18-di-boc-SPD (345 mg, 0.563 mmol) was dissolved in methanol (25 mL) and HCl gas 
was applied for approx. 15-20 seconds. The reaction mixture was stirred for 3 h and the 
solvent removed in vacuo to yield a white solid. MS indicated incomplete deprotection, 
so the same HCl gas cycle was repeated to yield a white product (67 mg, 92%).  
 
Rf  = 0.2 (90:10:1 DCM/MeOH/Et3N). 
1H NMR (400 MHz, CD3OD) δ: 3.24 (t, 
CH2NHCO J = 6.4 Hz, 2H); 3.15-3.07 (m, CH2NH + CH2NH2, 6H); 2.25 (t, CH2CONH, 
J = 7.2 Hz, 2H); 1.92 (app quint, CH2CH2NHCO J = 7.6 Hz, 2H); 1.78 (app. quint, 
CH2CH2NH2 + CH2CH2CONH, J = 4.0 Hz, 4H); 1.55 (br quint, CH2CH2CH2NH2, 2H); 
1.25 (br app s, CH3(CH2)12CH2, 24H); 0.82 (t, CH3CH2, J = 6.5 Hz, 3H). HRMS: Calcd. 
[M+H]+ (C25H54N3O) m/z = 412.4267, found [M+H]
+ = 412.4250 (100%). IR: νmax (cm-
1): 3309w (N-H); 2956m, 2917s, 2848s, 2787w, 2746w (all CH); 1642.6m (C=O); 
1526.0m (C=O); 1464m, 1435w, 1365w, 1259.2w, 1170.1m, 1014.8w, 720.0m. 
Decomposition point: 211 °C. It was not possible to obtain a 13C NMR spectrum due to 
the low solubility of the compound – even when run overnight on a 500 MHz instrument.  
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Synthesis of C18-tri-Boc-SPM  
 
Stearic acid (0.85 g, 3.0 mmol) was dissolved in DCM (65 mL), and TBTU (1.05 g, 3.3 
mmol) and triethylamine (ca. 5 mL) were added. The reaction mixture was stirred for 5 
min before tri-Boc-spermine (Boc-SPM) (1.50 g, 3.0 mmol) in DCM (80 mL) was added. 
The solution was stirred overnight and the solvent removed in vacuo to give a cream solid 
as the crude, which was chromatographed on silica gel using pure DCM and hexane/ethyl 
acetate (2:1) as the second silica column to give the product as a white powder (0.844 g, 
37%). 
Rf = 0.68 (DCM), 0.22 (1:1 hexane/ethyl acetate). 
1H NMR (400 MHz, CD3OD) δ: 6.29 
(br s, NH, 1H); 5.54 (br s, NHBoc, 1H); 3.87-3.58 (m, CH2NHCO + CH2NBoc + 
CH2NHBoc, 12H); 2.21 (t, CH2CONH, J = 7.6 Hz, 2H); 1.68-1.64 (m, CH2CH2NBoc + 
(CH2)2CH2NHBoc, 8H); 1.42 (s, C(CH3)3, 27H); 1.30-1.23 (m, CH3(CH2)14CH2 + 
CH2CH2CONH, 30H); 0.85 (t, CH3CH2, J = 7.0 Hz, 3H). Solubility problems prevented 
the measurement of 13C NMR. HRMS: Calc. [M+H]+ (C43H85N4O7) m/z = 770.6340, 
found [M+H]+ = 770.6213 (56%); Calc. [M+Na]+ (C43H84N4NaO7) m/z = 791.6238, found 
[M+Na]+ = 791.6213 (100%). IR: νmax (cm-1): 3316w (N-H); 2986m, 2976s (all CH); 
2869m, 1665s, 1523m (C=O); 1490w, 1378m,1317w, 1248w, 1174m, 837w, 820w, 723m, 
616w, 523w.  
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Synthesis of C18-SPM 
 
 
 
C18-tri-boc-SPM (844 mg, 1.1 mmol) was dissolved in methanol (25 mL) and HCl gas 
was applied for approx. 15-20 seconds. The reaction mixture was stirred for 3 h and the 
solvent removed in vacuo to yield a white solid (138.8 mg, 90%). 
 
Rf = 0.65 (DCM). 
1HNMR (400 MHz, CD3OD) δ: 5.65 (br s, NH); 3.25 (t, CH2NHCO J 
= 6.8 Hz, 2H); 3.17-3.03 (m, CH2NH + CH2NH2, 10H); 2.22 (t, CH2CONH, J = 7.4 Hz, 
2H); 2.08 (app. quint., CH2CH2NH2, J = 7.9 Hz, 2H); 1.89 (approx. quint., 
CH2CH2NHCO, J = 7.0 Hz, 2H); 1.78 (m, CH2(CH2)2CH2, 4H); 1.55 (approx. quint, 
CH2CH2CONH, J = 6.0 Hz, 2H); 1.24 (s, CH3(CH2)12CH2, 24H); 0.84 (t, CH3CH2, J = 
6.6 Hz, 3H). HRMS: Calc. [M+H]+ (C28H60N4O) m/z = 468.4767, found [M+H]
+ = 
469.4824 (100%). IR: νmax (cm-1): 3339.7w (N-H); 2954m, 2918s, 2848s, 2782s, 2747m, 
2689w (all CH); 1702m (C=O); 1643m (C=O); 1529m (CONH); 1463m, 1439w, 1348w, 
1265w, 1249w, 1208m, 1182m, 1165m, 1058m, 721m, 677w. It was not possible to obtain 
a 13C NMR spectrum due to the low solubility of the compound – even when run 
overnight on a 500 MHz instrument.  
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Synthesis C18-PEG-3 
 
 
Stearic acid (1.50 g, 5.3 mmol) and concentrated HCl (aq) (ca. 2 mL) were added to a 
solution of triethylene glycol (3.52 mL, 26.4 mmol) in dry DCM (50 mL). The reaction 
was stirred overnight, dried over MgSO4, filtered and dried in vacuo to yield a white 
sticky solid that was chromatographed using hexane/ethyl acetate (2:1) to yield a yellow 
powder (704 mg, 32%). 
 
Rf  = 0.05 (2:1 hexane/ethyl acetate). 
1H NMR (400 MHz, CD3OD) δ: 4.18 (t, CH2OCO, 
J = 4.8 Hz, 2H); 3.67 (t, CH2CH2O, J = 4.8 Hz, 4H); 3.64 (t, CH2OH, J = 4.7 Hz, 2H); 
3.63-3.58 (t, CH2CH2O, J = 5.2 Hz, 4H); 3.53 (t, CH2CO, J = 5.7 Hz, 2H); 2.26 (t, 
CH2CH2CO, J = 7.6 Hz, 2H); 1.65-1.55, 1.38-1.25, 1.22-1.17 (m, CH2CH2CH2, 28H); 
0.86 (t, CH3CH2, J = 6.9 Hz, 3H). HRMS: Calc. [M+H]
+ (C24H49O5) m/z = 417.3580, 
found [M+H]+ = 417.3572 (44%); Calc. [M+Na]+ (C24H48NaO5) m/z = 439.3399, found 
[M+Na]+ = 439.3388 (100%). IR: νmax (cm-1): 3319w (N-H); 2954m, 2916s, 2870m, 
2848s (all CH); 1740s (C=O); 1462m, 1325w, 1174m, 1138s, 1104m, 1058s, 1038s, 
895m, 861w, 730w, 719m, 558w. mp: 39.3-39.9 °C.   
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Synthesis of C18-PEG-8 
 
 
 
Stearic acid (155 mg, 0.5 mmol) was dissolved in DCM and Et3N (ca. 1.5 mL) 
and TBTU (184 mg, 0.6 mmol) were added. After 5 min of stirring, 
octaethylene glycol (500 mg, 1.4 mmol) was added and the reaction mixture 
stirred overnight and chromatographed using hexane/ethyl acetate (1:1, then 
pure ethyl acetate) to give a sticky off-white product (80 mg, 27%). 
 
Rf  = 0.02 (2:1 hexane/ethyl acetate). 
1H NMR (400 MHz, CD3OD) δ: 4.21 (t, CH2OCO, 
J = 4.8 Hz, 2H); 3.76-3.68 (t, CH2CH2O, J = 4.8 Hz, 14H); 3.64 (t, CH2OH, J = 4.6 Hz, 
2H); 3.62-3.58 (CH2CH2O, J = 5.6 Hz, 14H); 3.56 (t, CH2CO, J = 5.2 Hz, 2H); 2.34 (t, J 
= 7.4 Hz, 2H); 2.26 (t, CH2CH2CO, J = 7.6 Hz, 2H); 1.36-1.21 (m, CH2CH2CH2, 28H); 
0.90 (t, CH3CH2, J = 6.9 Hz, 3H). IR: νmax (cm-1): 3025w (CH); 2916m (CH); 2848m 
(CH); 1723m (C=O); 1492m, 1452m, 1363w, 1260m, 1185m, 1080m, 1028m, 954m, 
802w, 758m, 696s, 539m. Decomposition point: 218 °C.  
 
 
  
  
Chapter 7 – Experimental  
237 
7.2 Assay and Analysis Materials and Methods 
 
All materials, except Mallard Blue (MalB) dye, which was synthesized in the DKS group 
laboratory, employed in spectroscopic assays were obtained from commercial sources 
and used without further purification unless stated. Sodium salt heparin from porcine 
intestinal mucosa with a molecular weight between 15,000 ± 2,000 Da (1 KU = 1000 
units) was obtained from Calbiochem®. Ammonium carbonate, deoxyribonucleic acid 
sodium salt from calf thymus (DNA), ethylenediaminetetraacetic acid trisodium salt 
hydrate (EDTA), ethidium bromide (EthBr), N-(2-hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid) (HEPES), human serum (from human male AB plasma), Nile Red, 
phosphate buffered saline (PBS), and Trizma® hydrochloride (Tris HCl) were obtained 
from Sigma Aldrich. 
UV/Vis absorbance was measured on a Shimadzu UV-2401PC spectrophotometer and 
fluorescence on a Hitachi F-4500 spectrofluorimeter. All MalB solutions were incubated 
at 50°C for 24 hours prior to use and stored in the dark. Unless stated, all experiments 
were performed in triplicate and data are reported as a mean value plus or minus one 
standard deviation. TEM images were obtained by an FEI Tecnai 12 BioTWIN operated 
at 120 kV. Dynamic Light Scattering (DLS) was carried out using a Zetasizer Nano 
(Malvern Instruments). The EDX system is a Thermo Ultra Dry detector and Noran 
software which produces the spectral peak graphs. The SEM is an FEI Sirion XL30. CHN 
analysis were performed with Exeter Analytical CE-440 analyser, used in conjunction 
with a Sartorius SE2 analytical balance. Isothermal Titration Calorimetry (ITC) 
experiments were conducted using a Nano ITC Technology (TA Instruments, New 
Castle, DE, USA) and performed by our collaborators in the Molecular Simulation 
Engineering (MOSE) Laboratory, Department of Engineering and Architectures (DEA), 
University of Trieste; Erik Laurini,  Paola Posocco and Sabrina Pricl.   
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Nile Red Assay183 
This assay aims to determine the critical aggregation concentration (CAC) for the binders. 
A Nile Red (2.5 mM) stock solution was made in EtOH. Solutions of binder were 
prepared at a variety of concentrations starting from (200 µM) in disposable cuvettes. 
Samples of the stock solution were diluted by PBS buffer to the required concentration in 
a 1 mL assay volume. Nile Red (1 µL) was applied to each sample to give a concentration 
of (2.5 µM). The fluorescence emission was measured using an excitation wavelength of 
550 nm. Fluorescence intensity was recorded at 635 nm. This procedure was performed 
in triplicate.  
 
Dynamic Light Scattering (DLS) 
The measurements were made of the back-scattered light fluctuations at an angle of 173° 
with the calculation of an autocorrelation function. The samples were measured at 25 °C, 
adjusted to the temperature for 1 minute prior to the measurement. The autocorrelation 
functions were analysed using the DTS v5.1 software provided by Malvern. 
Measurements were done in triplicate with 10-15 runs per single measurement and the 
calculated mean values (based on intensity and volume distribution) were used. The 
samples were measured in 10 mM Tris HCl buffer and in ultrapure water. The samples 
were measured after filtering through nylon filters (0.45µm) to remove all dust from them.  
 
Transmission Electron Microscopy (TEM) 
10 µL of compound (200 µM) in H2O was placed on a copper grid (standard) with 
Formvar and carbon support film and allowed to set for 5 minutes. A stain (1% uranyl 
acetate) was applied to the grid while wet (1% in water, pH 4.5) to allow the stain to run 
across the grid, then the majority of it was wiped off with a filter paper. The grid was left 
to rest for 20 minutes before taking the images.   
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Mallard Blue (MalB) Assay in Buffer123 
MalB (25 µM) solution was incubated at 50 °C for 24 hours (to prevent aggregation) prior 
to use and was wrapped with foil to ensure that the dye was not exposed to direct light. 2 
mL of MalB (25 µM), heparin (27 µM) and NaCl (150 mM) in Tris HCl (10 mM) was 
placed in a cuvette then titrated with binder stock solution to give a suitable charge ratio 
for the binder and heparin in the cuvette. Binder stock solution consisted of the original 
solution of MalB/Heparin/NaCl/Tris HCl stock solution, then a concentration of the 
binder, depending on the charge of the binder, was added so that, after 10 µL binder stock, 
the cuvette charge ratio (+:-) is 0.1. After each addition, the mixture in the cuvette was 
stirred (with a clean plastic pipette) to ensure total mixing and the absorbance was 
recorded at 615 nm against the baseline of the Tris HCl (10 mM). The normalization of 
the absorbance was made between two solutions, the first one was MalB (25 µM) and 
NaCl (150 mM) in Tris HCl (10 mM) and the other contained MalB (25 µM), heparin (27 
µM) and NaCl (150 mM) in Tris HCl (10 mM). This procedure was performed in 
triplicate. 
 
Mallard Blue (MalB) Assay in Human Serum123 
MalB (25 µM) solution was incubated at 50 °C for 24 hours prior to use and was wrapped 
with foil to ensure that the dye was not exposed to direct light. 14 disposable cuvettes 
were charged with 1.75 mL of MalB (28.53 µM) in Tris HCl (10 mM) and a certain 
volume of the binder stock solution to maintain a suitable charge ratio between binder 
and heparin. The binder stock solution consisted of the binder and also MalB (25 µM), 
heparin (27 µM) and Tris HCl (10 mM). Another heparin (80 µM) solution was made 
separately in human serum (100%). Each cuvette was titrated sequentially with 0.25 mL 
of the heparin-in-serum solution and was mixed fully (with a clean plastic pipette). The 
absorbance was recorded at 615 nm against the baseline of 1.75 mL Tris HCl (10 mM) 
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and 0.25 mL human serum (100%). Normalization of the absorbance was made between 
two solutions, the first is MalB (25 µM) and the second containing MalB (25 µM) and 
heparin (27 µM). This procedure was performed in triplicate. 
 
Energy dispersive X-Ray (EDX) Analysis 
The EDX system is a Thermo Ultra Dry detector and Noran software which produces the 
spectra peak graphs. The SEM is an FEI Sirion XL30. Samples were dissolved in MeOH, 
applied on metal pin stub and allowed to dry prior to analysis.   
 
Ethidium Bromide Displacement (DNA Assay)208,305 
A solution of Calf Thymus DNA (8.0 μM) was prepared in SHE buffer (2 mM HEPES, 
0.05 mM EDTA, 150mM NaCl) at pH 7.5. Ethidium bromide was diluted with SHE 
Buffer to give a final concentration of 10.14 μM. Background ethidium bromide 
fluorescence was measured at 5.07 μM. The binder stock solution, at varying 
concentration depending on the charge of the binder, was prepared in a 50:50 solution of 
the ethidium bromide and DNA solutions to give a final EthBr concentration of 5.07 μM 
and DNA at 4.0 μM with respect to one DNA base (Mr 330 gmol-1). Appropriate amounts 
of the binder solution were added to 2 ml of a stock solution containing EthBr (5.07 μM) 
and DNA (4.0 μM) to achieve the desired charge ratio (+:-). The fluorescence was 
measured on a Hitachi F-4500 spectrofluorimeter using an excitation wavelength of 540 
nm. Fluorescence intensity was recorded at 595 nm. The fluorescence values were 
normalised to a solution containing only DNA (4.0 μM) and EthBr (5.07 μM). This 
procedure was performed in triplicate.
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Isothermal Titration Calorimetry (ITC)217 
Isothermal Titration Calorimetry (ITC) experiments were carried out by Pricl and co-
workers at University of Trieste. Full details of the methodology can be found in 
reference.217 The experiments were conducted using a Nano ITC Technology (TA 
Instruments, New Castle, DE, USA). Binding conditions were optimized for each SAMul 
ligand. The thermodynamics of micellization of all SAMul molecules were investigated 
in Tris HCl/150 mM NaCl buffered solutions. The same solution conditions were 
employed to obtain the thermodynamic parameters for heparin/SAMul ligand binding, 
while for DNA binding SHE/150 mM NaCl buffered solutions were used. In the binding 
assays, DNA and heparin initial concentration in the corresponding buffered solutions 
was 30 μM. All solutions and buffers used in the experiments were degassed for 30 min 
at room temperature under stirring at 350 rpm prior to experiment. Upon filling the cell 
and syringe, stirring was turned on and each system was allowed to thermally equilibrate 
for 30 minutes. The enthalpy change caused by DNA/heparin dilution, measured under 
the same circumstances by titration buffer/NaCl solutions into the corresponding 
solutions, was found to be very small and therefore was neglected. Raw data curves were 
integrated with Microcal Origin Software, as described in the instrument manual. 
Statistics were performed on the thermodynamic parameters with a desired confidence 
interval of 95%. Each experiment was repeated in duplicate, and showed excellent 
reproducibility. 
 
Multiscale Modelling Methods217 
Multiscale modelling of self-assembly process was carried out by Pricl and co-workers at 
University of Trieste. Full details of the methodology can be found in reference.217 
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In summary, they used their well-validated multiscale molecular modelling 
procedure102,199,235-237 based on the systematic elimination of computationally expensive 
degrees of freedom while retaining implicitly their influence on the remaining degrees 
freedom.  
The outline of the general strategy of the multiscale modeling approach may be 
summarized as follows: i) explicit solvent atomistic MD calculations240,241 were 
performed on C16-DAPMA, C16-SPD, and C16-SPM and their assembly; using the 
AMBER program306 and the GAFF force field,307,308 solvated in a TIP3P309 water box; ii) 
coarse-grained DPD simulations238,239  were carried out at concentrations higher than the 
experimental CAC and the aggregates were characterized in terms of dimension and 
aggregation number; the mesoscale model parameters were calculated exploiting the 
conformational properties and energetic values obtained from MD simulation at point 
(i)306 using an explicit solvent model in which each molecule was represented as single 
force centers (beads) and solvent was treated explicitly in the presence of ions and 
counterions. Langevin dynamics were then conducted using the DPD representation of 
the system; iii) the equilibrium configurations of the self-assembled systems obtained at 
point (ii) were mapped back to the corresponding atomistic MD models, and then new 
atomistic MD simulations were conducted to calculate binding energies between each 
micelle and DNA as well as the heparin molecule.
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Abbreviations 
AIBN 2-2’-azobis(2-methylpropionitrile)  
app Apparent (NMR) 
ATIII Antithrombin III 
AuNCs Gold Nanocomposites 
AuNPs Gold Nanoparticles 
br Broad (NMR) 
Boc tert-Butyl Dicarbonate    
Boc2O di-tert-butyl dicarbonate 
CAC Critical Aggregation Concentration  
Calc Calculated 
CD3OD Deuterated Methanol 
CD Circular Dichroism 
CE50 Charge Excess at 50% Binding 
Chol Cholesterol 
C-L Cross-linking 
CMC Critical Micelle Concentration 
d Doublet (NMR) 
DAB 1,4-Diaminobutane 
DAP Diaminopropane 
DAPMA N,N-Di-(3-aminopropyl)-N-methylamine 
DCM Dichloromethane  
DCC N,N’-dicyclohexylcarbodiimide 
DCU N,N’-Dicyclohexylurea 
DLS Dynamic Light Scattering  
DNA Deoxyribonucleic Acid 
DPD Dissipative Particle Dynamics 
EC50 Effective Concentration at 50% Binding 
EDX Energy Dispersive X-Ray 
EPR Enhanced Permeability and Retention 
ESI Electrospray Ionization 
EtBr Ethidium Bromide 
Et3N Triethylamine 
EtOAc Ethyl Acetate  
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FDA Food and Drug Administration 
G1 First Generation 
GPC Gel Permeation Chromatography 
HCl(g) Gaseous Hydrogen Chloride 
HEPES N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HIV Human Immunodeficiency Virus 
HRMS High Resolution Mass Spectrometry 
HTS High-Throughput Screening 
HSA Human Serum Albumin 
Hz Hertz 
IR Infrared 
ITC Isothermal Titration Calorimetry 
IU International Unit 
J   Coupling frequency, Hz 
kDa                                                                                       1000 Dalton (Atomic mass unit)
LMWHs Low Molecular Weight Heparins 
m medium (IR) 
m                                                                                         Multiplet (NMR)
M                                               Molar Concentration 
m/z Mass/charge ratio (Mass spectrometry) 
MalB                                      Mallard Blue (Dye) 
maxAbs Maximum Absorbance 
MD Multiscale Modelling 
mg  Milligram 
MHz Megahertz 
mL Milliliter 
µM Micro Molar 
µm  Micro Millimeter  
mp Melting Point  
MS                                           Mass Spectrometry 
mV Millivolts 
MW Molecular Weight  
MWCO                                    Molecular Weight Cut-Off 
nm                                           Nanometer
NMR Nuclear Magnetic Resonance 
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NPs 
ns 
Nanoparticles  
Nano second 
PA Peptide Amphiphile 
PAMAM Poly(amidoamine) 
PBS Phosphate-buffered Saline  
PDI Poly-Dispersity Index                                                                             
PEG Poly(ethylene) glycol 
ppm                                              Parts per million (NMR) 
q Quartet (NMR) 
quint Quintet (NMR) 
Rf Retention factor 
r.t Room Temperature 
s strong (IR) 
s Singlet (NMR) 
SAMul   Self-Assembled Multivalency 
SEM                                                                                      Scanning Electron Microscopy
SPD Spermidine 
SPM Spermine 
t Triplet (NMR) 
TBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate 
TEM Transmission Electron Microscopy 
THF Tetrahydrofuran 
TLC                                                                                                                          Thin Layer Chromatography
UV Ultraviolet (spectroscopy) 
+ve    Positive charge             
Vis Visible light (spectroscopy) 
νmax   Infrared Maximum Spectra 
w weak (IR) 
Z Benzyloxy or benzyl ester protecting group 
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